haloperidol has been researched along with Anochlesia in 805 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 8.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 7.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| "Catalepsy was induced by systemic haloperidol (0." | 5.56 | Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats. ( Ihme, H; Melo-Thomas, L; Schwarting, RKW, 2020) |
| "Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics." | 5.36 | Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 5.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "Haloperidol alone did not lower body temperature, but it potentiated the body temperature lowering effect of NT77L." | 5.31 | Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. ( Boules, M; Fauq, A; Jackson, J; McCormick, D; McMahon, B; Richelson, E; Stewart, J; Warrington, L, 2001) |
| "In haloperidol-induced catalepsy in rats (1." | 5.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| "Nicotine was found to markedly potentiate haloperidol-induced hypokinesia in rats." | 5.28 | Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. ( Blythe, MM; Fogelson, HM; Klykylo, WM; Manderscheid, PZ; McConville, BJ; Norman, AB; Parker, KW; Sanberg, PR, 1989) |
| " The extract at both the doses displayed a significant reduction in postural flexion, moderate decrease in tremor, muscular rigidity and postural immobility scores but do not exhibit significant lowering of hypokinesia score in reserpine induced Parkinsonian model." | 4.12 | Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. ( Kadiri, SK; Karkar, VV; Pal Roy, S; Rao Konijeti, S, 2022) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 4.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| " effect of test drug on clonidine and haloperidol induced catalepsy, milk-induced leukocytosis and eosinophilia, mast cell stabilizing activity in mice and studies on smooth muscle preparation of guinea pig ileum (in-vitro)." | 3.88 | Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma. ( Nirmal, S; Vikhe, S, 2018) |
| " tardive dyskinesia) treatment with antipsychotics, including haloperidol, varies substantially among people." | 3.85 | Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. ( Miksys, S; Nobrega, JN; Remington, G; Tolledo, EC; Tyndale, RF; Wadji, FB, 2017) |
| " Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol." | 3.83 | Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models. ( Cheng, J; Giguere, PM; Huang, XP; Kozikowski, AP; McCorvy, JD; Pogorelov, VM; Rodriguiz, RM; Roth, BL; Schmerberg, CM; Wetsel, WC; Zhu, H, 2016) |
| " To evaluate the interactions between antipsychotics and drugs for mood disorders in modulating extrapyramidal side effects (EPS), we examined the effects of antidepressants and mood-stabilizing drugs on haloperidol (HAL)-induced bradykinesia and catalepsy in mice and rats." | 3.78 | Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. ( Imaki, J; Ohno, Y; Sato, M; Shimizu, S; Shin, N; Sugiuchi, T; Tatara, A, 2012) |
| " effect on clonidine and haloperidol induced catalepsy, milk-induced leucocytosis and eosinophilia, mast cell stabilizing activity in mice and studies on smooth muscle preparation of guinea pig ileum (in vitro)." | 3.78 | Antihistaminic and antiallergic actions of extracts of Solanum nigrum berries: possible role in the treatment of asthma. ( Bhawar, SB; Nirmal, SA; Patel, AP; Pattan, SR, 2012) |
| "We examined the effects of JP-1302 (a selective alpha2C antagonist), BRL-44408 (a selective alpha2A antagonist) and yohimbine (a non-selective alpha2 antagonist) on haloperidol-induced bradykinesia and catalepsy in mice to elucidate the role of alpha2 adrenoceptor subtypes in modifying extrapyramidal motor disorders." | 3.75 | Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. ( Imaki, J; Mae, Y; Ohno, Y; Shimizu, S, 2009) |
| "Mice were treated once with 50 or 100 mg/kg of the essential oil, intraperitoneally, 30 min before being submitted to behavioural models of: locomotor activity (open-field), catalepsy, anxiety (elevated plus maze), depression (forced swimming test and tail suspension tests) as well as apomorphine-induced stereotypy." | 3.75 | Central nervous system effects of the essential oil of the leaves of Alpinia zerumbet in mice. ( de Araújo, FY; de Moraes, MO; de Oliveira, GV; de Sousa, FC; Leal, LK; Macêdo, DS; Moura, BA; Silva, MI; Vasconcelos, SM; Viana, GS, 2009) |
| "In order to better define the role of 5-HT(1A) receptors in the modulation of extrapyramidal motor functions, we investigated the effect of 5-HT(1A) agonists on tacrine-induced tremulous jaw movements (TJM) in rats, a putative model of parkinsonian tremor." | 3.73 | In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. ( Artaiz, I; Castro, E; Del Olmo, E; Innerárity, A; Labeaga, L; Orjales, A; Pazos, A; Zazpe, A, 2006) |
| " Muscle rigidity was assessed quantitatively and objectively as increases in electromyographic (EMG) activity (muscle rigidity) in the hindlimb muscles of the rat following subcutaneous administration of haloperidol, fluphenazine and thioridazine." | 3.71 | An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. ( Crocker, AD; Hemsley, KM, 2001) |
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 3.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| " Both ASP and GLU produced a hyperthermic response in all animals, including those in which hypothermia was induced by reserpine." | 3.69 | Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats. ( Gupta, MC; Singh, J, 1997) |
| " Recent studies in mutant dystonic hamsters (dt[sz]), an animal model of idiopathic generalized dystonia, revealed antidystonic effects of both N-methyl-D-aspartate (NMDA) receptor antagonists, such as dizocilpine (MK-801), and of neuroleptics, such as haloperidol and clozapine." | 3.69 | MK-801 potentiates antidystonic effects of clozapine but not of haloperidol in mutant dystonic hamsters. ( Löscher, W; Richter, A, 1997) |
| " Tremorine-induced tremor in mice was inhibited by I-893." | 3.68 | [Pharmacological effects of the novel dopamine uptake inhibitor 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on the central nervous system]. ( Hotta, K; Mizusawa, H; Morita, S; Nagase, T; Omote, M; Sakai, K; Yamane, M, 1991) |
| " The drug does not possess an antidepressant action proper but activates the aggressive-defensive behaviour in experimental reserpine depression and reduces the provocation-induced aggressive behaviour in experimental haloperidol depression." | 3.66 | [Psychopharmacologic spectrum of melanostatin]. ( Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV, 1980) |
| "Several useful animal models for parkinsonism have been developed so far." | 2.72 | Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. ( Alves, CO; de Oliveira, AR; Magalhães, MS; Waku, I, 2021) |
| "We examined haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors after ibotenic acid lesions of the medial prefrontal cortex (MPFC), dorsal (DH), or ventral hippocampus (VH) in adult rats." | 2.68 | Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. ( Braun, AR; Jaskiw, GE; Lipska, BK; Weinberger, DR, 1995) |
| "Notably, catalepsy induced by haloperidol, a D2 antagonist, is augmented, whereas catalepsy induced by SCH23390, a D1 antagonist, was not affected in H-FABP null mice." | 2.47 | [Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain]. ( Fukunaga, K; Owada, Y; Shioda, N; Yamamoto, Y, 2011) |
| "Catalepsy was induced by systemic haloperidol (0." | 1.56 | Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats. ( Ihme, H; Melo-Thomas, L; Schwarting, RKW, 2020) |
| "Subsequently, catalepsy tests were performed again." | 1.51 | Influence of aversive stimulation on haloperidol-induced catalepsy in rats. ( Barroca, NCB; Brandão, ML; Colombo, AC; da Silva, NT; de Oliveira, AR; Guarda, MD; Reimer, AE, 2019) |
| "Haloperidol-induced catalepsy is an animal model of a psychotic disorder that may be associated with neurodegeneration and free radical damage." | 1.51 | Role of Aqueous Extract of the Wood Ear Mushroom, Auricularia polytricha (Agaricomycetes), in Avoidance of Haloperidol-lnduced Catalepsy via Oxidative Stress in Rats. ( Chinnaboina, GK; Gupta, G; Liu, X; Mishra, A; Sharma, RK; Singh, M, 2019) |
| "Treatment with fluoxetine did not affect the motor coordination caused by haloperidol." | 1.51 | The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms. ( Ahmadi, SA; Haddadi, R; Sabahi, M, 2019) |
| "Haloperidol (1 mg/kg, ip) was administered for 21 successive days to induce orofacial dyskinesia and catalepsy." | 1.48 | Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. ( Dhingra, D; Gahalain, N; Goswami, S, 2018) |
| "HP produced a full blown catalepsy, akinesia and a significant impairment in locomotion and antioxidant status." | 1.48 | Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice. ( Anoopkumar-Dukie, S; Arora, D; Grant, GD; Hall, S; Kinra, M; Mallik, SB; Mudgal, J; Nampoothiri, M; Rao, CM, 2018) |
| "Varenicline is an anti-smoking drug and has the potential to prevent neurodegeneration." | 1.48 | Haloperidol-induced parkinsonism is attenuated by varenicline in mice. ( Gupta, S; Patel, RK; Sharma, AK; Wardhan, N, 2018) |
| "Catalepsy was evaluated through the bar test, and schizophrenia-like symptoms, by means of the Open Field Test (OFT), Passive Avoidance Test (PAT), and the Forced Swimming Test (FST)." | 1.48 | Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests. ( Herrera-Ruiz, M; Jiménez-Ferrer, E; Román-Ramos, R; Santillán-Urquiza, MA; Tortoriello, J; Zamilpa, A, 2018) |
| "Recently, we described catalepsy induced in Wistar rats by somatostatin antagonist, cyclosomatostatin (cSST); this model simulates such a disease-associated abnormality as a fall in brain somatostatin levels." | 1.48 | Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation. ( Frenkel, DD; Gorev, NP; Ionov, ID; Pushinskaya, II, 2018) |
| "The ability of DAE to induce catalepsy and enhance haloperidol-induced catalepsy was also investigated in mice." | 1.46 | An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice. ( Adjei, S; Amoateng, P; Karikari, TK; Kukuia, KKE; Nyarko, AK; Osei-Safo, D, 2017) |
| "The ability of SNE to cause catalepsy in naïve mice as well as its effect on haloperidol-induced catalepsy was assessed." | 1.46 | Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis. ( Adjei, S; Amoateng, P; Bekoe, EO; Karikari, TK; Kombian, SB; Kukuia, KKE; Osei-Safo, D, 2017) |
| "THC and haloperidol markedly caused catalepsy in V1bRKO mice as well as in WT mice." | 1.46 | Role of vasopressin V1a receptor in ∆ ( Egashira, N; Iwasaki, K; Kinjo, J; Koushi, E; Mishima, K; Morimoto, S; Myose, T; Tanaka, H; Tanoue, A; Tsuchihashi, R, 2017) |
| "In addition, CBD reduced catalepsy induced by drugs with distinct pharmacological mechanisms, including the typical antipsychotic haloperidol." | 1.43 | Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. ( Del Bel, EA; Gomes, FV; Guimaraes, FS; Sonego, AB, 2016) |
| "Haloperidol can induce catalepsy and this drug effect can be conditioned as well as sensitized to contextual cues." | 1.43 | Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized cata ( Carey, RJ; Carrera, MP; Dias, FRC; Oliveira, LR; Santos, BG; Silva, JLL, 2016) |
| "Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine." | 1.42 | Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015) |
| "A significant reduction of the catalepsy response was seen in rats previously given haloperidol and receiving DBS at the IC." | 1.42 | Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients? ( Melo-Thomas, L; Thomas, U, 2015) |
| "At similar doses in a catalepsy study, the time on the bar was increased but the maximal effect was less than that seen with haloperidol." | 1.42 | Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition. ( Burdi, DF; Campbell, JE; Campbell, U; Engel, S; Hewitt, MC; Jones, PG; Lew, R; Quinton, MS, 2015) |
| "5 mg/kg) or MP-10 (3-30 mg/kg) did not produce cataleptic behavior when dosed alone, but co-administration of haloperidol with MP-10 (3 and 10 mg/kg) induced cataleptic behaviors." | 1.42 | The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents. ( Gentzel, RC; Hershey, J; Kandebo, M; Koser, AJ; Renger, JJ; Roberts, R; Smith, SM; Toolan, D; Uslaner, J, 2015) |
| "Blonanserin is a new atypical antipsychotic drug that shows high affinities to dopamine D2 and 5-HT2 receptors; however, the mechanisms underlying its atypicality are not fully understood." | 1.42 | Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin. ( Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A, 2015) |
| " Moreover, its use is less toxic and safer." | 1.42 | Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine. ( Gmiro, VE; Serdyuk, SE; Veselkina, OS, 2015) |
| " Microinjection of the preferential D(3) agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) into lobe 9 of the cerebellum significantly reduced spontaneous locomotor activity with a U-shaped dose-response curve." | 1.40 | Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats. ( Andatsu, S; Kizu, T; Miyoshi, S; Ohno, Y; Sato, M; Shimizu, S; Sugiuchi, T; Tatara, A, 2014) |
| " In order to test the hypothesis that the differential blockade of the muscarinic receptor subtypes would influence their potency and efficacy to prevent EPS, here we tested four anticholinergics with varying order of affinities for the muscarinic receptor subtypes, and compared their dose-response curves to inhibit haloperidol-induced catalepsy in male rats." | 1.40 | The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes. ( Alvarez-Cervera, FJ; Bata-García, JL; Erosa-Rivero, HB; Góngora-Alfaro, JL; Heredia-López, FJ, 2014) |
| "Haloperidol induced catalepsy was determined using the classic bar test and a new MED Associates Catalepsy Test Chamber instrument." | 1.40 | Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. ( Ablordeppey, SY; Bricker, B; Sampson, D, 2014) |
| "Resistance to catalepsy in PRS rats did not depend on reductions in blood or striatal levels, as compared with unstressed control rats." | 1.39 | Early life stress causes refractoriness to haloperidol-induced catalepsy. ( Battaglia, G; Bucci, D; Consolazione, M; Lionetto, L; Maccari, S; Mairesse, J; Marrocco, J; Morley-Fletcher, S; Nicoletti, F; Ravasi, L; Simmaco, M, 2013) |
| " To test this hypothesis in a rodent model, the A2A receptor antagonists SCH 412348 (3 mg/kg), vipadenant (10 mg/kg), caffeine (30 mg/kg), or istradefylline (3 mg/kg) were chronically (19-22 days) administered to Sprague Dawley rats, and dyskinetic behaviors were scored across this chronic dosing paradigm." | 1.39 | A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. ( Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E, 2013) |
| "Haloperidol is a dopamine D2 receptor antagonist that induces catalepsy when systemically administered to rodents." | 1.39 | Dopaminergic mechanisms underlying catalepsy, fear and anxiety: do they interact? ( Brandão, ML; Colombo, AC; de Oliveira, AR; Reimer, AE, 2013) |
| "Catalepsy was evaluated by positioning both forepaws of rats on an elevated horizontal wooden bar and recording the time that the animal maintained this position." | 1.39 | Modulation of haloperidol-induced catalepsy in rats by GABAergic neural substrate in the inferior colliculus. ( Medeiros, P; Melo-Thomas, L; Tostes, JG, 2013) |
| "Nicotine did not induce catalepsy on its own." | 1.39 | Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome. ( Boye, SM, 2013) |
| "Catalepsy was measured using the bar test." | 1.39 | Somatostatin antagonist induces catalepsy in the aged rat. ( Ionov, ID; Pushinskaya, II, 2013) |
| "In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine." | 1.39 | Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. ( Acuña-Lizama, MM; Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL, 2013) |
| " Both acute and chronic administration of enalapril/losartan produced an increase in the duration of haloperidol induced catalepsy at the highest dose (20 mg/kg)." | 1.38 | Co-administration of haloperidol and drugs affecting the angiotensin pathway: effect on the extrapyramidal system. ( Gopalakrishna, HN; Nair, V; Pai, MR; Pemminati, S; Shreyasi, C; Swati, B, 2012) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "Significant catalepsy sensitization was not observed in rats repeatedly tested with SCH 23390." | 1.38 | Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors. ( Banasikowski, TJ; Beninger, RJ, 2012) |
| "Both haloperidol and nicotine treatment decreased the transporter and α6β2* nAChRs (the asterisk indicates the possible presence of other nicotinic subunits in the receptor complex) when given alone, with no further decline with combined drug treatment." | 1.38 | Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. ( Bordia, T; McIntosh, JM; Quik, M, 2012) |
| "Sertraline (10 mg/kg ip) was injected either acutely, or over 5 days of repeated treatment." | 1.38 | Effects of sertraline on experimental mouse models of psychosis. ( Bilge, U; Erol, K, 2012) |
| "Rats treated with haloperidol or haloperidol plus NGB 2904 or nafadotride developed catalepsy sensitization with repeated conditioning." | 1.38 | Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904. ( Banasikowski, TJ; Beninger, RJ, 2012) |
| " Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic compounds." | 1.38 | Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments. ( Enzensperger, C; Fleck, C; Lehmann, J; Mueller, FK; Robaa, D; Schulze, M; Siol, O, 2012) |
| "JNJ-37822681 induced catalepsy and inhibited avoidance behavior, but with a specificity margin relative to apomorphine antagonism that was larger than that obtained for haloperidol and similar to that obtained for olanzapine." | 1.38 | Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. ( Atack, J; Cik, M; De Bruyn, M; Hendrickx, H; Langlois, X; Lavreysen, H; Macdonald, G; Megens, A; Peeters, L; te Riele, P; Vermeire, J; Wouters, R, 2012) |
| "Histamine was also found to damage the dopaminergic neurons in rat substantia nigra." | 1.38 | Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA. ( Ionov, ID; Severtsev, NN, 2012) |
| "Catalepsy was measured using the bar test." | 1.38 | Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat. ( Ionov, ID; Severtsev, NN, 2012) |
| "The process of catalepsy sensitization incorporates different learning stages." | 1.37 | The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization. ( Kulak, A; Riedinger, K; Schmidt, WJ; von Ameln-Mayerhofer, A, 2011) |
| "Rats treated with haloperidol at doses of 0." | 1.37 | Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats. ( Haleem, DJ; Shireen, E, 2011) |
| "The drug-induced catalepsy was strongly attenuated, but not abolished, in M(4) knockout mice as compared to wild-type controls." | 1.37 | Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. ( Dencker, D; Fink-Jensen, A; Schmidt, LS; Schülein, C; Wess, J; Woldbye, DP; Wörtwein, G, 2011) |
| "Here we used the animal models of extrapyramidal disorders cited above, which were performed in two distinct experiments: orofacial dyskinesia (OD)/catalepsy induced by acute reserpine and subchronic haloperidol after (experiment 1) and before (experiment 2) oral treatment with pecan shell aqueous extract (AE), a natural and promissory antioxidant." | 1.37 | Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract. ( Barcelos, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Dias, VT; Dolci, GS; Pase, CS; Reckziegel, P; Segat, HJ; Trevizol, F, 2011) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "Blonanserin is a novel antipsychotic agent that preferentially interacts with dopamine D(2) and 5-HT(2A) receptors." | 1.36 | Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. ( Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A, 2010) |
| "Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0." | 1.36 | Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy. ( Brandão, ML; Coimbra, NC; Ferrari, EA; Francisco, A; Maisonnette, SS; Medeiros, P; Mello, RO; Melo, LL; Santos, P, 2010) |
| "Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics." | 1.36 | Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010) |
| "Haloperidol induced severe catalepsy at 40 min after intramuscular injection." | 1.35 | Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. ( Arai, H; Iwashita, A; Matsuoka, N; Matsuya, T; Mihara, K; Mihara, T; Miyoshi, S; Murakami, Y; Nishimura, S; Noda, A, 2008) |
| " In contrast, acute or chronic administration of MPEP (mGlu5 receptor antagonist) has no anticataleptic action." | 1.35 | Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. ( Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N, 2008) |
| "No changes in haloperidol-induced catalepsy or MK-801-induced locomotion were seen following PD." | 1.35 | Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding. ( Brown, AS; Butler, PD; Keegan, D; Palmer, AA; Rotrosen, J; Siska, LD; Susser, E, 2008) |
| "Haloperidol treatment significantly induced the catalepsy as observed from increased descent time measured in the bar test." | 1.35 | Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. ( Alam, MM; Anwer, T; Azam, F; Barodia, SK, 2009) |
| " Here, we examined the effects of acute and repeated dosing with two antipsychotics, haloperidol and clozapine, and Delta(9)-tetrahydrocannabinol [Experiments 1 and 2, respectively] in adolescent rats of both sexes that differed in shipping status (i." | 1.35 | To breed or not to breed? Empirical evaluation of drug effects in adolescent rats. ( Evans, RL; Wiley, JL, 2009) |
| "Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)." | 1.35 | Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009) |
| "Simulation results show that catalepsy sensitization, and its context dependency, can be explained by "NoGo" learning via simulated D2 receptor antagonism in striatopallidal neurons, leading to increasingly slowed response latencies." | 1.35 | A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal. ( Frank, MJ; Riedinger, K; Schmidt, WJ; von Ameln-Mayerhofer, A; Wiecki, TV, 2009) |
| "Catalepsy was monitored on an inclined surface." | 1.35 | Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex. ( Ahmed, S; Batool, F; Haleem, DJ, 2009) |
| " This study was planned to investigate changes in striatal levels of norepinephrine, dopamine and serotonin after acute and chronic administration of classical neuroleptics (haloperidol and chlorpromazine)." | 1.35 | In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2009) |
| "Haloperidol (HAL) is a widely used neuroleptic drug for the treatment of acute and chronic psychosis." | 1.35 | Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. ( Himabindhu, G; Thaakur, S, 2009) |
| "Treatment with caffeine significantly increased locomotion reduced by haloperidol, but not at all doses tested." | 1.35 | Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. ( Goode, T; Harris, A; Trevitt, J; Vallance, C, 2009) |
| "In the rat, akinetic catalepsy induced by a dopamine D2 receptor antagonist (haloperidol 5mg/kg) can model human catalepsy." | 1.35 | Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control. ( Clark, CA; Sacrey, LA; Whishaw, IQ, 2009) |
| "Caffeine-treated rats also had higher catalepsy latency scores compared with control rats (P<0." | 1.35 | Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine. ( Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL; Heredia-López, FJ; Moo-Puc, RE; Pineda, JC; Villanueva-Toledo, JR, 2009) |
| "Catalepsy was induced with haloperidol (1 mg/kg) i." | 1.35 | Effect of Withania somnifera root extract on haloperidol-induced catalepsy in albino mice. ( Arjuman, A; Gopalakrishna, HN; Nair, V; Nandini, M, 2008) |
| "Aripiprazole is an atypical antipsychotic that acts as a partial agonist at the dopamine D(2) receptor." | 1.35 | Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. ( Guimarães, FS; Leite, JV; Moreira, FA, 2008) |
| " In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A2A receptor versus the human A2A receptor." | 1.35 | Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. ( Castro-Palomino, JC; Chen, Y; Crespo, MI; Díaz, JL; Gross, RS; Gual, S; Joswig, T; Lanier, MC; Lechner, SM; Lin, E; Malany, S; Markison, S; Moorjani, M; O'Brien, Z; Prat, M; Rueter, JK; Santos, M; Saunders, J; Slee, DH; Wen, J; Williams, JP; Zhang, X, 2008) |
| "Metoclopramide is a strong postsynaptic dopamine D(2) receptor blocker with no antipsychotic potency." | 1.35 | Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. ( Agovic, MS; Banerjee, SP; Lidsky, TI; Yablonsky-Alter, E, 2008) |
| "Rats treated with haloperidol at a dose of 1 mg/kg exhibited impaired motor coordination and a decrease in exploratory activity." | 1.34 | Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| "ACP-103 also attenuated catalepsy produced by haloperidol or risperidone." | 1.34 | ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. ( Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I, 2007) |
| "At a dose of 0." | 1.34 | Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists. ( Acher, FC; Amalric, M; Bertrand, HO; Brabet, I; Gaven, F; Goudet, C; Lopez, S; Marino, MJ; Neyton, J; Oueslati, N; Pin, JP; Sibille, P; Valenti, O, 2007) |
| " The study also investigated the probably occurring side effects (measuring cataleptic activity and motor coordination) following single and chronic administration of CBZ compared to haloperidol (HAL, CAS 52-86-8), a conventional antipsychotic." | 1.34 | Some behavioural effects of carbamazepine - comparison with haloperidol. ( Czubak, A; Glowacka, D; Kus, K; Matschay, A; Nowakowska, E, 2007) |
| "significantly inhibited catalepsy induced by haloperidol; had no effect at 1." | 1.34 | The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. ( Gyertyán, I; Sághy, K, 2007) |
| "Because catalepsy is thought to be a good predictor of extrapyramidal symptoms in humans, treatment with orexin-1 antagonists might decrease the occurrence or severity of antipsychotic treatment-emergent extrapyramidal symptoms in humans." | 1.34 | The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. ( Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK, 2007) |
| "Apomorphine stereotypy was not potentiated or antagonised by pretreatment with 7." | 1.34 | Effects of dextromethorphan on dopamine dependent behaviours in rats. ( Balsara, JJ; Gaikwad, RV; Gaonkar, RK; Jadhav, JH; Jadhav, SA; Thorat, VM, 2007) |
| "The degree of catalepsy (cataleptic score) was measured as the time the animal maintained an imposed posture." | 1.34 | Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice. ( Arjuman, A; Chakradhar Rao, U; Dorababu, P; Gopalakrishna, HN; Mohan, L; Nair, V, 2007) |
| "Mild catalepsy was observed at 30 mg/kg, being more pronounced at 50 mg/kg and 100 mg/kg." | 1.33 | Atypical antipsychotic profile of flunarizine in animal models. ( Dall'Igna, OP; de Oliveira, RV; Fett, P; Gomes, MW; Lara, DR; Mantese, CE; Schuh, J; Souza, DO; Tort, AB, 2005) |
| "Vitamin C enhanced the catalepsy produced by NOS inhibitors and Hal." | 1.33 | Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice. ( Del Bel, EA; Lazzarini, M; Salum, C, 2005) |
| "MTEP (3 and 5 mg/kg i." | 1.33 | MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S, 2005) |
| "Haloperidol and GHB produced catalepsy in control and diabetic rats; haloperidol was less potent in diabetic rats (D(50)=0." | 1.33 | Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy. ( France, CP; Koek, W; Sevak, RJ, 2005) |
| "Injection of haloperidol during catalepsy modeling decreased the content of NO in rat cerebral cortex." | 1.33 | Modulating role of NO in haloperidol-induced catalepsy. ( Bashkatova, VG; Mikoyan, VD; Narkevich, VB, 2005) |
| " However, limited peptide stability and oral bioavailability have prevented these compounds from being developed as relevant pharmaceuticals." | 1.33 | Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. ( Dix, TA; Hadden, MK; Kokko, KP; Mazella, J; Orwig, KS, 2005) |
| "Since the catalepsy test has predictive value regarding extrapyramidal effects, the possibility of pharmacological interactions between haloperidol and Ginkgo biloba extracts should be further investigated in clinical studies." | 1.33 | Ginkgo biloba leaf extract (EGb 761) enhances catalepsy induced by haloperidol and L-nitroarginine in mice. ( Del Bel, EA; Fontana, L; Oliveira, RM; Souza, AS, 2005) |
| "Fluoxetine (1-25 mg/kg) also inhibited catalepsy, although the effect was not dose-dependent; no differences were observed between males and females (5 mg/kg, 180 min: males, 185 +/- 14 vs 712 +/- 14 s in C; females, 169 +/- 10 vs 710 +/- 19 s in C)." | 1.33 | Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. ( Bonikovski, V; Futuro-Neto, HA; Pires, JG, 2005) |
| "Haloperidol and risperidone induced catalepsy at doses producing >80% D2RO, while aripiprazole despite higher D2RO (>90%) induced no catalepsy." | 1.33 | Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. ( Fletcher, PJ; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE, 2006) |
| "Haloperidol induced catalepsy and muscle rigidity in the control mice, but these responses were significantly reduced in Fyn-deficient mice." | 1.33 | Fyn is required for haloperidol-induced catalepsy in mice. ( Hattori, K; Isosaka, T; Iyo, M; Kohsaka, S; Maekawa, M; Sato, T; Uchino, S; Yagi, T; Yuasa, S, 2006) |
| "Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism." | 1.33 | Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. ( Kulkarni, SK; Kumar, A, 2006) |
| "Haloperidol is a high potency typical neuroleptic used in the treatment of schizophrenia but produces muscles related side effects commonly known as EPS." | 1.33 | Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol. ( Ahmed, SW; Ali, O; Haleem, DJ; Kamil, N; Obaid, R; Saify, ZS, 2005) |
| "The prolongation of haloperidol-induced catalepsy with nitric oxide synthase inhibitors was not reversed by L-arginine." | 1.33 | The effect of nitric oxide on fentanyl and haloperidol-induced catalepsy in mice. ( Erkent, U; Ilhan, M; Iskit, AB; Onur, R, 2006) |
| "Papaverine is found to inhibit conditioned avoidance responding in rats and mice and to inhibit PCP- and amphetamine-stimulated locomotor activity in rats." | 1.33 | Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. ( Chambers, L; Chapin, DS; Harms, JF; Lebel, LA; McCarthy, SA; Menniti, FS; Schmidt, CJ; Shrikhande, A; Siuciak, JA; Wong, S, 2006) |
| "Catalepsy was induced by haloperidol (2 mg/kg p." | 1.33 | Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. ( Akhtar, M; Ali, A; Pillai, KK; Uma Devi, P; Vohora, D, 2006) |
| " Limited oral bioavailability of AC-90179 likely reflects rapid metabolism rather than poor absorption." | 1.32 | Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist. ( Andersson, CM; Bradley, SR; Brann, MR; Davis, RE; Hacksell, U; Harvey, SC; Kold, H; Makhay, M; Son, T; Spalding, TA; Tolf, BR; Vanover, KE; Veinbergs, I; Weiner, DM, 2004) |
| "Catalepsy was induced with haloperidol (1 mg/kg, ip) and measured at 30-min intervals by means of a bar test." | 1.32 | Gender-related differences in the effects of nitric oxide donors on neuroleptic-induced catalepsy in mice. ( Bonikovski, V; Costa, PG; Futuro Neto, HA; Pires, JG; Saraiva, FP, 2003) |
| "In both experiments, intensification of catalepsy was very stable and was observed 18 days later in haloperidol-treated rats and 101 days later in lesioned animals." | 1.32 | Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. ( Klein, A; Schmidt, WJ, 2003) |
| "Catalepsy was induced by a subcutaneous (s." | 1.32 | The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms. ( Garavaglia, C; Invernizzi, RW; Samanin, R, 2003) |
| "At the time of peak hyperalgesia, WIN55,212-2 (1-30mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0." | 1.32 | A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. ( Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL, 2003) |
| "NMDA-induced convulsions were effectively prevented by both mono- and dications, while only dications were effective against kainate convulsions." | 1.32 | The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. ( Gmiro, VE; Gorbunova, LV; Lukomskaya, NY; Rukoyatkina, NI, 2003) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "THP inhibited catalepsy intensity with an ED(50) of 0." | 1.32 | Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. ( Alvarez-Cervera, FJ; Arankowsky-Sandoval, G; Góngora-Alfaro, JL; Heredia-López, F; Moo-Puc, RE; Pineda, JC, 2003) |
| "The effect on rat catalepsy induced by Delta9-tetrahydrocannabinol (Delta9-THC) in association with haloperidol (HP) or clozapine (CLOZ) administration was investigated." | 1.32 | Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. ( Casti, P; Casu, G; Marchese, G; Pani, L; Ruiu, S; Saba, P; Sanna, A, 2003) |
| " Thus, for example, NT69L after five daily injections at a fixed dosage was as effective at reversing cocaine-induced hyperactivity as after the first injection." | 1.32 | Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. ( Boules, M; Fauq, A; McCormick, D; McMahon, B; Richelson, E; Stewart, J; Wang, R; Warrington, L; Yerbury, S, 2003) |
| "Catalepsy is a model for Parkinson's disease." | 1.32 | Burst activity of spiny projection neurons in the striatum encodes superimposed muscle tetani in cataleptic rats. ( Frank, ST; Schmidt, WJ, 2003) |
| "KCH-1110 did not induce catalepsy in mice, but at much higher doses only a slight catalepsy response was shown." | 1.32 | Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110. ( Cho, H; Cho, YS; Choi, KI; Jeong, D; Jung, JY; Jung, SH; Kim, GD; Koh, HY; Kong, JY; Lee, S; Pae, AN; Park, WK; Yun, CW, 2003) |
| "In a parallel cohort, catalepsy was measured using the bar test." | 1.32 | Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat. ( Bongiovanni, R; Jaskiw, GE, 2004) |
| "Haloperidol-induced increase of striatal enkephalin mRNA is totally abolished in NGFI-B KO mice whereas the increase of neurotensin mRNA expression is reduced by 50%." | 1.32 | The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. ( Beaudry, G; Ethier, I; Lévesque, D; Milbrandt, J; Rouillard, C; St-Hilaire, M, 2004) |
| "An intensification of catalepsy has been observed upon repeated testing in rats with permanent neurodegeneration of substantia nigra." | 1.32 | Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "In conclusion, sensitization of catalepsy is represented by striatal cellular activity as indicated by increases in spike-frequency of spiny I neurons." | 1.32 | Increase of spiny I activity in striatum after development of context-dependent sensitization of catalepsy in rats. ( Frank, ST; Schmidt, WJ, 2004) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| ", CP-101,606) might be useful drugs for the treatment of extrapyramidal side effects (EPS) associated with the chronic use of typical antipsychotics such as haloperidol." | 1.32 | Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. ( Hashimoto, K; Hattori, K; Iyo, M; Yanahashi, S; Yuasa, S, 2004) |
| "Haloperidol treatment in mice induced a strong cataleptic state within 1 h of injection, reaching a maximal plateau after 2 h and lasting for 4 h." | 1.32 | Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. ( Kulkarni, SK; Naidu, PS, 2004) |
| "In contrast, MS-377 did not affect the catalepsy induction by these drugs." | 1.31 | Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors. ( Horikomi, K; Karasawa, J; Takagi, K; Takahashi, S, 2002) |
| "Furthermore, catalepsy was also tested after administration of each of these drugs." | 1.31 | Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats. ( Ferger, B; Fischer, DA; Kuschinsky, K, 2002) |
| "Both drugs inhibited catalepsy induced by the dopamine D1-like receptor antagonist R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390), the dopamine D2-like receptor antagonist raclopride and by haloperidol, findings in agreement with a dopaminergic effect of cyclooxygenase inhibitors." | 1.31 | Cyclooxygenase inhibitor modulation of dopamine-related behaviours. ( Brooks, RJ; Fletcher, PJ; Kalasinsky, KS; Lee, M; Ross, BM; Seeman, M; Turenne, SD; Vorce, SP, 2002) |
| "Catalepsy was induced by the classical antipsychotic haloperidol (0." | 1.31 | 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. ( Colpaert, FC; Koek, W; Prinssen, EP, 2002) |
| "The degree of haloperidol-induced catalepsy was thus proportional to the level of striatal dopamine D(2) receptor expression (0." | 1.31 | Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. ( Boulay, D; Depoortere, R; Oblin, A; Perrault, G; Sanger, DJ; Schoemaker, H, 2000) |
| "Catalepsy, a symptom of Parkinson's disease and related disorders can be produced in rats and other laboratory animals by the blockade of nigrostriatal dopamine using dopaminergic antagonists such as haloperidol." | 1.31 | Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats. ( Field, EF; Pellis, SM; Whishaw, IQ, 2000) |
| "Haloperidol catalepsy consolidated without any additional learning and could be retrieved up to two weeks later by placing the animals in the test box." | 1.31 | Haloperidol catalepsy consolidation in the rat as a model of neuromodulatory integration. ( Bazyan, AS; Getsova, VM; Orlova, NV, 2000) |
| "Nicotine has been reported to potentiate the cataleptic effect of the dopamine receptor antagonist haloperidol in rats." | 1.31 | Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms. ( Boye, SM; Clarke, PB, 2000) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 1.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "Haloperidol-pretreated animals showed markedly impaired active avoidance, deficits which were improved by 2." | 1.31 | Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance. ( Feldon, J; Murphy, CA, 2000) |
| "For haloperidol-induced catalepsy, significant QTLs were detected on chromosome 14 (two different QTLs) in the CxLP intercross, and chromosomes 1 and 9 in the B6xD2 intercross." | 1.31 | Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs. ( Cipp, L; Demarest, K; Hitzemann, R; Koyner, J; McCaughran, J; Patel, N; Rasmussen, E, 2000) |
| "Except for reserpine, catalepsy scores were significantly lower in A2AR KO mice than in A2AR WT mice following low doses of these cataleptogenic agents." | 1.31 | Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. ( Costentin, J; El Yacoubi, M; Ledent, C; Parmentier, M; Vaugeois, JM, 2001) |
| "Using the CAR and the catalepsy (CAT) tests as indices for antipsychotic activity and extrapyramidal side effect (EPS) liability, respectively, the effects of the selective 5-HT(2A) receptor antagonist MDL 100,907 in combination with the DA D(2) receptor antagonists haloperidol or raclopride were studied in rats." | 1.31 | Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. ( Browning, JL; Hicks, PB; Wadenberg, MG; Young, KA, 2001) |
| "However, we found that catalepsy, which is thought to reflect the EPS of typical APDs, is unaffected in NT-null mutant mice, suggesting that NT does not contribute to the generation of EPS." | 1.31 | Neurotensin-deficient mice show altered responses to antipsychotic drugs. ( Carraway, RE; Deitemeyer, N; Deutch, AY; Dobner, PR; Fadel, J, 2001) |
| " The findings indicated that, on day 1 to day 6, a greater development of tolerance was seen in the group of mice treated at 9:00 AM, and catalepsy behavior exhibited a significant difference between the two dosing times (P < 0." | 1.31 | Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice. ( Higuchi, S; Ohdo, S; Viyoch, J; Yukawa, E, 2001) |
| " In addition, the C57BL/6 strain exhibited a greater degree of sensitization to repeated dosing than did the other 2 strains." | 1.31 | Haloperiodol-induced microcatalepsy differs in CD-1, BALB/c, and C57BL/6 mice. ( Fowler, SC; Vorontsova, E; Zarcone, TJ, 2001) |
| "The muscle rigidity was measured as an increased resistance of a hind leg to passive extension and flexion at the ankle joint." | 1.31 | Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wierońska, J; Wolfarth, S, 2001) |
| "Haloperidol alone did not lower body temperature, but it potentiated the body temperature lowering effect of NT77L." | 1.31 | Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. ( Boules, M; Fauq, A; Jackson, J; McCormick, D; McMahon, B; Richelson, E; Stewart, J; Warrington, L, 2001) |
| "Catalepsy was induced in rats by acute treatment with haloperidol (1 mg/kg), and catalepsy was scored for the next 4 h." | 1.31 | Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. ( Kulkarni, SK; Naidu, PS, 2001) |
| "HAL-induced catalepsy, while reduced by the systemic administration of the 5-HT(1A) agonist 8-OH-DPAT (0." | 1.31 | Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role. ( Cervo, L; De Deurwaerdère, P; Spampinato, U; Stinus, L, 2002) |
| "Compound 28 induced catalepsy at 10 times higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7." | 1.30 | Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. ( Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y, 1998) |
| "Induction of catalepsy and inhibition of stereotypies weaker than standards, along with a lower increase in serum prolactin levels, were indicative of a potential atypical profile for this compound." | 1.30 | 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). ( Agut, J; Anglada, L; Bolós, J; De la Fuente, N; Gubert, S; Ortiz, JA; Planas, JM; Príncep, M; Sacristán, A, 1998) |
| "Antagonism of haloperidol catalepsy by 10 mg/kg verapamil is also explained on the basis of presynaptic D2 DA autoreceptor induced blockade by 10 mg/kg verapamil whereas potentiation of haloperidol catalepsy by 20 mg/kg verapamil is explained on the basis of its calcium channel blocking activity." | 1.30 | EFFECTS OF VERAPAMIL ON DOPAMINE DEPENDENT BEHAVIOURS IN RATS. ( Balsara, JJ; Gaonkar, RK; Malekar, AR, 1999) |
| "In this study, both catalepsy and changes in extracellular levels of striatal dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) induced by the typical neuroleptic haloperidol (HAL) were simultaneously assessed, using intracerebral microdialysis in freely moving rats, in the presence of either the 5-HT1A agonist 8-OH-DPAT or the 5-HT2A/C antagonist ritanserin." | 1.30 | 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. ( Bonhomme, N; De Deurwaerdère, P; Le Moal, M; Lucas, G; Spampinato, U, 1997) |
| "Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia." | 1.30 | The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats. ( Kikuchi, T; Morita, S; Nakai, M; Tottori, K; Uwahodo, Y, 1997) |
| "On day 1, the catalepsy scores at 3 hr revealed no significant difference between nutritional groups, but at 6 hr undernourished rats responded significantly less to chlorpromazine or haloperidol." | 1.30 | Undernutrition during suckling changes the sensitivity to haloperidol and chlorpromazine in two behavioural measures in weaning rats. ( Kleinpaul, ER; Rocha, JB; Rocha, LK; Santos, JE, 1997) |
| "Haloperidol-treated rats had higher bolus counts than vehicle-treated rats, and this increase was significantly reversed by the lipophilic but not the hydrophilic beta-antagonists." | 1.30 | The effects of beta-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia. ( Sachdev, PS; Saharov, T, 1997) |
| "When treated with haloperidol, RIIbeta mutant mice fail to induce either c-fos or neurotensin mRNA and the acute cataleptic response is blocked." | 1.30 | Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. ( Adams, MR; Brandon, EP; Chartoff, EH; Dorsa, DM; Idzerda, RL; McKnight, GS, 1997) |
| "In haloperidol-induced catalepsy in rats (1." | 1.30 | Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. ( Cohen, S; Levy, R; Speiser, Z, 1998) |
| "By contrast, catalepsy induced by a single injection of haloperidol lasted only approximately 2 days, and tolerance developed to its effects after long-term treatment." | 1.30 | D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors. ( Davidkova, G; Morabito, M; Weiss, B; Zhang, SP; Zhou, LW, 1998) |
| "In contrast, haloperidol catalepsy was not affected by the SCH23390 pretreatment." | 1.30 | Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration. ( Akimoto, T; Mizuki, Y; Suetsugi, M; Ushijima, I; Yamada, M, 1998) |
| "Nemonapride induced catalepsy in both cross-legged position and bar tests at low, but not at high doses." | 1.30 | The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties. ( Kleven, MS; Koek, W; Prinssen, EP, 1998) |
| ", 30 min) were administered to rats for 4 weeks in a between-groups dosing design." | 1.30 | Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not. ( Fowler, SC; Liou, JR, 1998) |
| "Catalepsy was defined as rats remaining immobile over a horizontal metal bar for at least 30 s, 90 min after dosing." | 1.30 | Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. ( Blackburn, TP; Holland, V; Kettle, A; Reavill, C; Riley, G, 1999) |
| "Haloperidol-induced catalepsy was inhibited by the Merz glycine site antagonists MRZ 2/570, MRZ 2/571 and MRZ 2/576 but not by another antagonist L-701,324 or the glycine site partial agonists ACPC and D-CS." | 1.30 | GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. ( Danysz, W; Karcz-Kubicha, M; Lorenz, B, 1999) |
| "Nicotine was microinjected directly into the striatum or pontine reticular formation of rats and its cataleptogenic effects were studied when given alone or in combination with systemical injections of haloperidol." | 1.30 | Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats. ( Elazar, Z; Paz, M, 1999) |
| "2." | 1.30 | Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice. ( Amorim, SC; Costa, PG; Futuro-Neto, HA; Pires, JG; Ribeiro, CA; Saraiva, FP, 1999) |
| " The catalepsy-reversal action of the diethylglycine-substituted peptidomimetic 5 was examined further and found to exhibit a U-shaped dose-response effect with an optimal dose of 1 microg/kg." | 1.30 | Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats. ( Buckley, AT; Costain, WJ; Evans, MC; Johnson, RL; Mishra, RK, 1999) |
| "Prominent catalepsy, otherwise consistently seen in the mice treated with haloperidol (0." | 1.30 | Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. ( Buljat, G; Dodig, G; Jelovac, N; Marovic, A; Miklic, P; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rucman, R; Seiwerth, S; Sikiric, P; Turkovic, B, 1999) |
| "7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature." | 1.30 | Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice. ( Brust, P; Gupta, CN; Parimoo, P; Raghavan, SA; Rangisetty, JB; Sridhar, N; Srinivas, P; Subramanian, AR; Veeranjaneyulu, A, 1999) |
| "This "injection-conditioned catalepsy" was also observed after repeated treatment with the dopamine D2 antagonists, haloperidol and metoclopramide." | 1.30 | Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice. ( Chinen, CC; Frussa-Filho, R, 1999) |
| "Catalepsy was tested 30, 60, 90, 120, and 180 min." | 1.30 | Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation. ( Andrews, JS; Drinkenburg, WH; Keith, AB; Sahgal, A, 1999) |
| "These results suggest that the pontine catalepsy produced by microinjections of carbachol in PRF is generated independently of the dopaminergic cataleptogenic mechanism in basal ganglia." | 1.29 | The striatal dopaminergic catalepsy mechanism is not necessary for the expression of pontine catalepsy produced by carbachol injections into the pontine reticular formation. ( Elazar, Z; Paz, M; Peleg, N; Ring, G, 1995) |
| "The potentiation of the haloperidol catalepsy was antagonized by imipramine which displayed antiglutamatergic and antimuscarinic properties." | 1.29 | [Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy]. ( Vamvakidès, A, 1995) |
| "0 mg/kg induced a significant leftward displacement of the control dose-response curve constructed for apomorphine (0." | 1.29 | Effect of manipulation of the GABA system on dopamine-related behaviors. ( Palermo-Neto, J; Sandoval, MR, 1995) |
| "Haloperidol (0." | 1.29 | [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats]. ( Minematsu, N, 1995) |
| "However, the severity of the catalepsy score following the third through seventh injections of haloperidol strongly correlated with the concurrent number of VCMs." | 1.29 | Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. ( Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ, 1995) |
| "Bemesetron significantly reduced catalepsy at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0." | 1.29 | Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice. ( Futuro-Neto, HA; Pires, JG; Silva, SR, 1995) |
| "The differential induction of catalepsy-associated behavior or scratching is believed to be related to, respectively, pre- and postsynaptic activity of quinpirole on dopamine D2/D3 receptors." | 1.29 | K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys. ( Barrett, JE; Rosenzweig-Lipson, S, 1995) |
| "The score of catalepsy was significantly low 120 min after administration of RIS as compared to HPD." | 1.29 | [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol]. ( Hayakawa, H; Kawai, K; Kikumoto, O; Motohashi, N; Okamoto, Y; Yamawaki, S; Yokota, N, 1993) |
| "A pharmacodynamic interactional study with omeprazole was undertaken in rats." | 1.29 | Pharmacodynamic interactions of omeprazole with CNS active drugs in rats. ( Chakrabarti, A; Chandrashekhar, SM; Garg, SK, 1995) |
| "Both haloperidol and clozapine treatment reduced the weight gain of the rats." | 1.29 | Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. ( Koch, T; Korf, J; Sebens, JB; Ter Horst, GJ, 1995) |
| "SCH23390 catalepsy had a rapid onset but a short duration, whereas haloperidol catalepsy had a slower onset and longer duration." | 1.29 | Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. ( Mizuki, Y; Ushijima, I; Yamada, M, 1995) |
| " Mice and rats were given A5 intraperitoneally at three different dosage levels." | 1.29 | The influence of antineoplaston A5 on the central dopaminergic structures. ( Burzynski, SR; Chodkowska, A; Feldo, M; Juszkiewicz, M; Kleinrok, Z; Majewska, B, 1994) |
| "In the catalepsy test, felbamate antagonized dopamine D2 receptor- but not D1 receptor-induced akinesia." | 1.29 | Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats. ( Kretschmer, BD, 1994) |
| "Pretreatment with carbaryl failed to affect apomorphine-induced stereotypes." | 1.29 | Effects of carbaryl on some dopaminergic behaviors in rats. ( Reis, M; Rigon, AR; Takahashi, RN, 1994) |
| "However, the incidence of catalepsy induced by haloperidol (0." | 1.29 | Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats. ( Araki, Y; Furuno, K; Gomita, Y; Suemaru, K, 1993) |
| "Haloperidol-induced (1 mg/kg, i." | 1.29 | Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. ( Lipska, BK; Weinberger, DR, 1993) |
| "Haloperidol was also associated with a transient (30 min) increase in dorsolateral striatum acetylcholine release in the chronically treated rats." | 1.29 | Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. ( Beck, O; O'Connor, WT; Osborne, PG; Ungerstedt, U, 1994) |
| "These findings suggest that, while the catalepsy resulting from DA receptor blockade by haloperidol originates mainly from the VM, the expression of this phenomenon depends on an intact glutamatergic transmission within the dorsorostral CP." | 1.29 | Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. ( Kawano, K; Miyagishi, T; Ono, T; Yoshida, Y, 1994) |
| "Haloperidol-treated rats showed an increase of DA, DOPAC, and HVA overflow in the PFC and the NAC-C." | 1.29 | Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. ( Baptista, T; Fernandez, R; Hernandez, L; Murzi, E; Tucci, S, 1994) |
| "Therefore, the THC-induced catalepsy model may be useful for distinguishing between both classes of NMDA receptor antagonists." | 1.29 | Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. ( Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T; Yamamoto, I, 1994) |
| "KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i." | 1.29 | KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. ( Kanda, T; Nakamura, J; Shimada, J; Shiozaki, S; Suzuki, F, 1994) |
| "Remoxipride induced immediate catalepsy after high i." | 1.29 | Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. ( Lundström, J; Nilsson, LB; Ogren, SO, 1993) |
| "Nicotine potentiated the catalepsy produced by haloperidol." | 1.29 | Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms. ( Cahill, DW; el-Etri, MM; Emerich, DF; Norman, AB; Sanberg, PR; Shipley, MT; Zanol, MD, 1993) |
| "haloperidol) can induce catalepsy in rodents." | 1.29 | Effects of the 5-HT receptor antagonists cyanopindolol, ICI 169,369, cisapride and granisetron on neuroleptic-induced catalepsy in mice. ( Futuro-Neto, HA; Pires, JG; Ramage, AG; Silva, SR, 1993) |
| "Catalepsy was measured by recording the time the animal remained with its forepaws placed over a rod 6 cm above the bench." | 1.29 | NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. ( Awere, S; Blackman, A; Leander, JD; Moore, NA, 1993) |
| " Animals that were lesioned and treated with haloperidol chronically had longer durations of catalepsy at the first two dose-response determinations." | 1.29 | Partial 6-hydroxydopamine-induced lesions and haloperidol-induced catalepsy. ( Fisher, H; Johnson, SK; Wagner, GC, 1993) |
| "Haloperidol catalepsy was measured by the method of Costall and Nylor." | 1.29 | The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. ( Burzynski, SR; Chodkowska, A; Juszkiewicz, M; Kleinrok, Z; Mlynarczyk, M, 1995) |
| "Naloxone treatment had little effect on VCMs but increased catalepsy scores in both haloperidol and vehicle treated groups." | 1.29 | Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. ( Egan, MF; Ferguson, JN; Hyde, TM, 1995) |
| "Heritability for the catalepsy response was 0." | 1.29 | Mapping the genes for haloperidol-induced catalepsy. ( Cipp, L; Dains, K; Gatley, J; Hitzemann, B; Hitzemann, R; Kanes, S; Rasmussen, E; Sanderson, S; Silverman, M, 1996) |
| "4." | 1.29 | Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. ( Andersen, HL; Kilpatrick, IC, 1996) |
| "Further, when the HAL (1 mg/kg) catalepsy score was maximal (at 120 min), the rats were subjected to cold stress (3 degrees C for 10 min) or treated with NA, AD (2 micrograms/kg, i." | 1.29 | Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. ( Chopde, CT; Hote, MS; Mandhane, SN; Muthal, AV, 1995) |
| "However, haloperidol catalepsy was decreased only 7 days, then reversed 14 days and gradually increased 21 days after the last injection of a 15- or 21-day pretreatment course of cocaine." | 1.29 | Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice. ( Mizuki, Y; Ushijima, I; Yamada, M, 1995) |
| "In haloperidol-treated rats hypersensitivity of the dopaminergic system developed at the end of 2 weeks' administration, as evidenced by depression of dopamine metabolism." | 1.29 | Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. ( Antkiewicz-Michaluk, L; Karolewicz, B; Michaluk, J; Vetulani, J, 1996) |
| "The lack of catalepsy of clozapine, therefore, cannot be addressed primarily to clozapine's agonistic activity at 5-HT1A receptors." | 1.29 | 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. ( Bartoszyk, GD; Roos, C; Ziegler, H, 1996) |
| "All these drugs reduced the onset of catalepsy, significantly increased the cataleptic score and delayed the onset and inhibited the Methamphetamine-induced stereotypy." | 1.29 | Effect of pre-treatment of some calcium channel blockers on catalepsy and stereotypic behaviour in rats. ( Belorkar, NR; Khanzode, SD; Kharkar, VT; Mahakalkar, SM; Manekar, MS, 1996) |
| " The compound was essentially inactive in binding to dopamine D2 receptors and its chronic administration to rats did not result in dopamine receptor supersensitivity." | 1.28 | Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents. ( Bernstein, E; Dextraze, P; Eison, MS; Lobeck, WG; New, JS; Taylor, DP; Temple, DL; Yevich, JP; Yocca, FD, 1992) |
| "The ED50 of delta 9-THC for catalepsy in experimentally naive rats was not different from that in rats trained with the drug discrimination procedure, indicating that the cataleptogenic effect was not appreciably attenuated by long-term exposure to low doses of delta 9-THC." | 1.28 | Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat. ( Gold, LH; Martin, BR; Prescott, WR, 1992) |
| "Catalepsy was measured by the bar test." | 1.28 | Effects of age and isolation on the evolution of catalepsy during chronic haloperidol treatment. ( Frussa-Filho, R; Otoboni, JR; Palermo-Neto, J; Uema, FT, 1992) |
| "During the induction of catalepsy, the intensity was the strongest at 4." | 1.28 | Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. ( Fujiwara, H, 1992) |
| "Both neuroleptics consistently produced catalepsy throughout the treatment period, although HAL was generally more cataleptogenic than RAC." | 1.28 | Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. ( Chapman, MA; Meshul, CK; See, RE, 1992) |
| "The incidence of haloperidol-induced catalepsy was investigated in mice whose postsynaptic dopamine (DA) receptors in the striatum had been upregulated by denervation with 6-hydroxydopamine (6-OHDA)." | 1.28 | Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice. ( Iwata, S; Izumi, K; Nomoto, M, 1992) |
| "The catalepsy was significantly decreased by IP atropine." | 1.28 | Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats. ( Bolioli, B; Castelló, ME; Dajas, F, 1992) |
| "Nicotine alone did not produce catalepsy or any significant changes in locomotion." | 1.28 | Nicotine potentiates the behavioral effects of haloperidol. ( Emerich, DF; Norman, AB; Sanberg, PR, 1991) |
| "morphine was also markedly enhanced in ADX lactating animals." | 1.28 | Prolactin response to morphine in intact and adrenalectomized lactating rats. ( Bartha, L; Fekete, MI; Kiem, DT; Makara, GB; Nagy, G, 1991) |
| "Severe vomiting was evoked by Apo in dogs, but not by Eph even when lethal dose (20 mg." | 1.28 | [Comparison of central stimulating effects between ephedrine and apomorphine]. ( Li, BH; Li, Q, 1991) |
| "Whether inducing catalepsy in the rat by an intraperitoneal injection of haloperidol (0." | 1.28 | The effect of theophylline and immobilization stress on haloperidol-induced catalepsy and on metabolism in the striatum and hippocampus, studied with lactography. ( Dijk, S; Korf, J; Krugers, HJ, 1991) |
| "Nicotine alone did not produce catalepsy." | 1.28 | Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. ( Emerich, DF; McConville, BJ; Norman, AB; Sanberg, PR; Zanol, MD, 1991) |
| "Haloperidol, which was used as a reference compound for classical DA antagonists, showed clear activity in all four models at low doses (0." | 1.28 | The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437. ( Bohus, BG; Horn, AS; Tepper, PG; Timmerman, W, 1990) |
| "It is concluded that (1) the catalepsy induced by systemic administration of haloperidol seems to result from the action of this drug on both the ventro-rostral striatum and the nucleus accumbens, (2) both D1 and D2 dopamine receptors in the ventro-rostral striatum are involved in the cataleptogenic action of neuroleptics, and (3) in the nucleus accumbens, only D1 dopamine receptors seem to play an important role in this phenomenon." | 1.28 | Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy. ( Karcz, M; Ossowska, K; Wardas, J; Wolfarth, S, 1990) |
| "Homovanillic acid was measured in the striatum and the prefrontal cortex on the 2nd day." | 1.28 | The enhancement of the hypomotility induced by small doses of haloperidol in the phase of dopaminergic supersensitivity in mice. ( Abe, E; Fujiwara, H; Itoh, T; Kohori, I; Masuda, Y; Murai, S; Saito, H, 1991) |
| "SG treatment alone did not induce catalepsy." | 1.28 | Influences of diterpene sclareol glycol on some dopamine related behavior. ( Georgieva, JV, 1991) |
| "Pretreatment with clomipramine alone caused a potentiation of neuroleptic-induced catalepsy." | 1.28 | Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice. ( Futuro-Neto, HA; Pires, JG; Silva, SR, 1990) |
| "Pretreatment with yohimbine (1." | 1.28 | Effects of yohimbine on dopamine dependent behaviours in rats and mice. ( Balsara, JJ; Bapat, TR; Bende, MM; Chandorkar, AG, 1990) |
| "4." | 1.28 | Influences of estrogen and/or progesterone on some dopamine related behavior in rats. ( Dorce, VA; Palermo-Neto, J, 1990) |
| " The extract was also able to produce a rightward displacement of the apomorphine dose-response curve for stereotyped behavior and decrease the maximum response possible." | 1.28 | Effects of a Palicourea marcgravii leaf extract on some dopamine-related behaviors of rats. ( de Souza-Spinosa, H; Górniak, SL; Palermo-Neto, J, 1990) |
| "4." | 1.28 | Effects of dihydroergotoxine on some dopamine-related behaviors in rats. ( Flório, JC; Palermo-Neto, J, 1990) |
| "Catalepsy-sensitive Fisher rats and catalepsy-resistant Brown Norway rats were treated for 14 days with haloperidol at a dose of either 1 mg/kg or 5 mg/kg daily." | 1.28 | Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. ( Kane, JM; Kinon, BJ, 1989) |
| "The degree of catalepsy was assessed 30 and 60 min after application of drugs by placing the rat on a horizontal bar, on a podium and on a vertical grid." | 1.28 | Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. ( Bubser, M; Schmidt, WJ, 1989) |
| "Stereotypy and catalepsy methods were used in order to clarify the role of the central dopaminergic (DA-ergic) transmitter mechanisms for the individual differences." | 1.28 | Significance of the cerebral dopaminergic neurotransmission for the individual differences in learning and memory (experiments on rats). ( Kamburova, T; Kehayov, R; Markovska, V, 1989) |
| "The incidence of catalepsy, evaluated with the forelimbs or hindlimbs placed on a standard horizontal bar, increased in three successive tests in mice injected with haloperidol." | 1.28 | Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice. ( Fukuda, T; Iwata, S; Izumi, K; Shimizu, T, 1989) |
| "Nicotine was found to markedly potentiate haloperidol-induced hypokinesia in rats." | 1.28 | Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. ( Blythe, MM; Fogelson, HM; Klykylo, WM; Manderscheid, PZ; McConville, BJ; Norman, AB; Parker, KW; Sanberg, PR, 1989) |
| " This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics." | 1.28 | [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man]. ( Vamvakides, A, 1989) |
| "The dose of 3 necessary to produce catalepsy in rats is much greater than that required for activity in behavioral tests predictive of antipsychotic efficacy, for example the suppression of high base line medial forebrain bundle self-stimulation in rats." | 1.27 | Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8- triazaspiro[4.5]decan-4-ones as potential antipsychotic agents. ( Butler, DE; Coughenour, LL; DeWald, HA; Downs, DA; Lewis, EP; Lobbestael, SJ; Pattison, IC; Poschel, BP; Tecle, H; Wise, LD, 1985) |
| " The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy." | 1.27 | Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents. ( Catt, JD; Eison, MS; Lobeck, WG; Minielli, JL; New, JS; Riblet, LA; Smith, DW; Taylor, DP; Temple, DL; Yevich, JP, 1986) |
| "Only buspirone (1." | 1.27 | Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. ( McDonald, CC; McMillen, BA, 1983) |
| "At doses known to elicit catalepsy in rats, haloperidol (1." | 1.27 | Cataleptogenic potency of the antipsychotic drugs is inversely correlated with neuronal activity in the amygdaloid complex of the rat. ( Alloway, KD; Bashore, TR; Gelman, J; Rebec, GV, 1983) |
| "Benzhydramine antagonized the catalepsy induced by analgesics (particularly by codeine)." | 1.27 | The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol. ( Langwiński, R; Malec, D, 1983) |
| "Remoxipride was shown to be a selective dopamine D2 receptor antagonist since it displaced [3H]spiperone (IC50 = 1570 nM) but not [3H]flupentixol (IC50 greater than 100 000 nM) in rat striatum, and did not inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100 000 nM)." | 1.27 | Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. ( Angeby, K; Florvall, L; Hall, H; Köhler, C; Lindbom, LO; Magnusson, O; Ogren, SO, 1984) |
| "Unlike apomorphine, Ro 15-1788 reversed catalepsy induced by haloperidol (0." | 1.27 | [Effect of an imidazobenzodiazepine (RO 15-1788) on aggressive behavior in mice]. ( Allikmets, LKh; Maĭmets, MO; Nurk, AM; Riago, LK; Vasar, EE, 1984) |
| "The 'pinch-induced' model of catalepsy in the mouse was disrupted by atropine sulfate (4 mg/kg IP), confirming an earlier finding, and also by the antinicotinic mecamylamine (4 mg/kg)." | 1.27 | Cholinergic-dopaminergic interactions in experimental catalepsy. ( Klemm, WR, 1983) |
| " An experimental study of the long-term administrations of haloperidol revealed the formation of adaptation to the drug which can be overcome by a zigzag-like sharp elevation of the dosage followed by rapid reduction to the baseline level." | 1.27 | [Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)]. ( Allikmets, LKh; Avrutskiĭ, GIa; Beliakov, AV; Neduva, AA; Zharkovskiĭ, AM, 1984) |
| "2-Br-LIS produced catalepsy in mice (ED50 3." | 1.27 | Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride. ( Kehr, W; Sauer, G; Wachtel, H, 1983) |
| "Haloperidol catalepsy was characterized by increases in frequency, intensity, and duration of simultaneous tonic cocontractions in antagonistic flexor and extensor muscles of the limbs." | 1.27 | Morphine versus haloperidol catalepsy in the rat: an electromyographic analysis of postural support mechanisms. ( De Ryck, M; Teitelbaum, P, 1983) |
| "Though catalepsy is one of the primary features classically associated with morphine injections in animals, several investigators have suggested that morphine may not produce true catalepsy." | 1.27 | Morphine may not produce true catalepsy. ( Feigenbaum, JJ; Klawans, HL; Moon, BH; Yanai, J, 1983) |
| "Haloperidol catalepsy was increased only by ivc histamine." | 1.27 | Is the brain histamine involved in cataleptogenic action of analgesics and haloperidol? ( Langwiński, R; Malec, D, 1983) |
| "The neurochemical background of clinical experiences that the patients receiving high dosage haloperidol showed no extrapyramidal side effects was investigated by using rats." | 1.27 | [High dosage haloperidol reduces cataleptic response with increased noradrenaline metabolism in the rat brain areas]. ( Takashima, M; Toru, M, 1983) |
| "Apomorphine was always injected 30 min before the rabbits were killed." | 1.27 | Alterations in apomorphine concentration in spinal cord and brain follow the time course of catalepsies induced by different treatments. ( Harasiewicz, A; Kolasiewicz, W; Melzacka, M; Wolfarth, S, 1983) |
| "HB-7 and HB-2 weakened haloperidol catalepsy, compared with PB and DPH." | 1.27 | Study of the participation of the dopaminergic transmission system in the effects of two newly synthesized barbiturates. ( Getova, D; Markovska, V, 1988) |
| "For the inhibition of catalepsy CCK-8-NS was the more active as it decreased catalepsy scores even 120 min after administration." | 1.27 | Inhibition of haloperidol-induced catalepsy by cholecystokinin octapeptides after central administration to rats. ( Kádár, T; Kovács, K; Penke, B; Telegdy, G, 1985) |
| "SCH 23390 produced catalepsy in all three tests with ED50 (mg/kg s." | 1.27 | Catalepsy induced by SCH 23390 in rats. ( Di Chiara, G; Morelli, M, 1985) |
| "But molindone was cataleptogenic, albeit less potent than haloperidol." | 1.27 | Neuroleptic-induced catalepsy: a D2 blockade phenomenon? ( Klemm, WR, 1985) |
| " Catalepsy was inhibited in an inverted U-shape dose-response relationship with the maximal effect of each peptide occurring at 1." | 1.27 | Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats. ( Hara, C; Kastin, AJ, 1986) |
| "Catalepsy was tested by the standard bar test 30 min after intraperitoneal treatment of HAL." | 1.27 | Potentiation of haloperidol-induced catalepsy by beta-adrenoceptor antagonists in mice. ( Hara, C; Ogawa, N, 1986) |
| "When the catalepsy score was almost maximal (60 s, measured by the bar-test), the rats were handled, exposed to cold (3 degrees C) or immobilized." | 1.27 | Transient supression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla. ( Korf, J; Yntema, OP, 1987) |
| "The NT-induced catalepsy was inhibited by pretreatment with atropine, trihexyphenidyl or biperiden (each drug, 0." | 1.27 | Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice. ( Furukawa, T; Shibata, K; Yamada, K, 1987) |
| "Similarly, catalepsy induced by (-)-sulpiride (40 mg/kg, i." | 1.27 | Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats. ( Wambebe, C, 1987) |
| "Morphine-induced catalepsy was enhanced by fenfluramine and attenuated by metergoline, whereas neither fenfluramine nor metergoline had any effect on haloperidol-induced catalepsy." | 1.27 | Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. ( Berendsen, HH; Broekkamp, CL; Oosterloo, SK; van Delft, AM, 1988) |
| "Haloperidol 10 mg/kg s." | 1.27 | Possible function of alpha 1-adrenoceptors in the CNS in anaesthetized and conscious animals. ( Kobinger, W; Pichler, L, 1985) |
| "3) Amantadine was equipotent to imipramine in suppressing haloperidol-induced catalepsy in rats, but L-DOPA was without effect." | 1.27 | [Behavioral pharmacology of amantadine with special references to the effect on abnormal behavior in mice and rats]. ( Fujiwara, M; Kiyota, Y; Ohta, H; Sakurai, Y; Shibata, S; Shimazoe, T; Ueki, S, 1985) |
| "With regard to the haloperidol-induced catalepsy as measured by means of the bar test, a similar distribution of effective and ineffective injection sites was observed; however, higher doses of haloperidol (1." | 1.27 | Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. ( Cools, A; Ellenbroek, B; Jaspers, R; Schwarz, M; Sontag, KH, 1985) |
| "The haloperidol catalepsy was strongly inhibited by administration of picrotoxin to the Vm while the morphine catalepsy remained unchanged after picrotoxin." | 1.27 | Thalamus as a relay station for catalepsy and rigidity. ( Kolasiewicz, W; Ossowska, K; Wolfarth, S, 1985) |
| "All rats were tested for catalepsy and at the end of the last catalepsy test, striatal DOPAC, HVA and ACh were determined." | 1.27 | Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. ( de Graaf, CJ; Korf, J, 1986) |
| "When haloperidol was given concurrently with the infusion of dopamine, spontaneous locomotor activity was markedly increased after the infusion for a period of at least 7 weeks: this long-term change was antagonised by ketotifen (1 mg/kg/24 hr), given during the period of treatment with dopamine/haloperidol or by a single acute injection of ketotifen (0." | 1.27 | Ketotifen can antagonise changes in sensitivity of cerebral dopamine receptors: behavioural correlates in rodent and primate. ( Barnes, JC; Barnes, NJ; Barnes, NM; Costall, B; Domeney, AM; Naylor, RJ, 1987) |
| "Theophylline was shown to induce a dose-dependent inhibition of this catalepsy." | 1.27 | Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis. ( Casas, M; Ferre, S; Guix, T; Jane, F, 1988) |
| "Bicuculline (50 ng) abolished the catalepsy evoked by muscimol (25 ng)." | 1.27 | Evidence for the independent role of GABA synapses of the zona incerta-lateral hypothalamic region in haloperidol-induced catalepsy. ( Ossowska, K; Wardas, J; Wolfarth, S, 1988) |
| "Haloperidol induced catalepsy with a continuous dose-response between 0 or 0." | 1.27 | Dose-catalepsy response to haloperidol in rat: effects of strain and sex. ( Baldessarini, RJ; Campbell, A; Cremens, MC, 1988) |
| "This observed catalepsy could be blocked with prior administration of indomethacin, a prostaglandin synthesis inhibitor." | 1.27 | Radiation-induced increases in sensitivity of cataleptic behavior to haloperidol: possible involvement of prostaglandins. ( Dalton, TK; Hunt, WA; Joseph, JA; Kandasamy, SB; Stevens, S, 1988) |
| "The effect of haloperidol on catalepsy was enhanced following the GP lesion." | 1.27 | Dopamine dependent behaviours in rats with bilateral ibotenic acid-induced lesions of the globus pallidus. ( Avdelidis, D; Spyraki, C, 1986) |
| "Catecholamine-depletion-induced catalepsy isolates and leaves intact an aggregate of allied reflexes (e." | 1.27 | Pharmacological subtraction of the sensory controls over grasping in rats. ( de la Cruz, F; O'Brien, DP; Pellis, SM; Pellis, VC; Teitelbaum, P, 1987) |
| "However, catalepsy was observed in both restrained and freely moving rats." | 1.27 | Apomorphine and haloperidol effects on striatal 3H-dopamine release in anesthetized, awake restrained and freely moving rats. ( Besson, MJ; Danguir, J; Girault, JA; Glowinski, J; Savaki, HE; Spampinato, U, 1986) |
| "The chronic administration of haloperidol (HAL), domperidone (DOM), or sulpiride (SUL) increased the density of striatal dopamine (DA) receptors in intact but not in hypophysectomized (Hypox) male rats." | 1.27 | Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists. ( Hruska, RE, 1986) |
| "In rats, MCP produced catalepsy and inhibited apomorphine-induced stereotypy, locomotor activity, and rotational behavior." | 1.27 | Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide. ( Fahn, S; Hassan, MN; Higgins, D; Kuhn, C; Reches, A, 1986) |
| "Minaprine is a new psychotropic drug which has recently proved to be effective in the treatment of various depressive states." | 1.27 | Minaprine, a new drug with antidepressant properties. ( Bizière, K; Garattini, S; Kan, JP; Mandel, P; Roncucci, R; Worms, P, 1985) |
| "Haloperidol-treated rats show brisk righting, bracing, and clinging reflexes, effects suggesting that motor subsystems subserving static postural support are dominant over those involved in more phasic locomotor and orienting movements." | 1.27 | Forelimb placing and hopping reflexes in haloperidol- and morphine-treated cataleptic rats. ( Wolgin, DL, 1985) |
| "Apomorphine alone produced catalepsy at low doses." | 1.27 | Experimental catalepsy is both enhanced and disrupted by apomorphine. ( Klemm, WR, 1985) |
| "Haloperidol-induced (0." | 1.27 | [Minute rhythms of haloperidol catalepsy in rats]. ( Arushanian, EB; Popova, AP, 1986) |
| " injection of HAL (as in the acutely treated animals) after chronic administration of HAL for 3 weeks." | 1.27 | Reduced metabolic response of the rat brain to haloperidol after chronic treatment. ( Larson, DM; Pizzolato, G; Rapoport, SI; Soncrant, TT, 1985) |
| "Furthermore, the catalepsy induced by CCK-8-SE was of short duration." | 1.27 | Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice. ( Borda, L; Kádár, T; Kovács, K; Penke, B; Telegdy, G, 1985) |
| "In haloperidol-treated rats, bracing, i." | 1.27 | Fractionation of the cataleptic bracing response in rats. ( Chen, YC; Pellis, SM; Teitelbaum, P, 1985) |
| "Diminution of catalepsy was explained by a decrease of the blocking effect of the neuroleptic on the dopamine system." | 1.27 | [Adaptation to neuroleptic preparations and several ways of combatting it (experimental study)]. ( Beliakov, AV; Matvienko, OA; Neduva, AA; Zharkovskiĭ, AM, 1985) |
| "The behavioral effect (catalepsy) of HAL was less in old than in young rats." | 1.27 | Reduced metabolic response of the aged rat brain to haloperidol. ( Holloway, HW; Pizzolato, G; Rapoport, SI; Soncrant, TT, 1985) |
| "Prior to the induction of catalepsy and after recovery from it, mice display the entire range of typical apomorphine-induced behavior including sniffing, climbing, gnawing, and licking." | 1.27 | Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice. ( Randall, PK; Yurek, DM, 1985) |
| "The pharmacokinetic behaviour of haloperidol (0." | 1.27 | Pharmacokinetics and effects of haloperidol in the isolated mouse. ( Baumann, GH; Zetler, G, 1985) |
| "DD-3480 exhibited catalepsy-inducing effects in a dose-dependent manner at oral doses of 2." | 1.26 | Behavioral pharmacologic studies in the monkey with DD-3480. ( Chen, PC; Matsuda, H; Nishimori, T; Shibuya, T, 1982) |
| "and s." | 1.26 | Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. ( Chase, TN; Cohen, SL; Knight, M; Tamminga, CA, 1982) |
| "Buspirone is a novel psychotropic drug with clear anxiolytic activity in man." | 1.26 | Notes on buspirone's mechanisms of action. ( Caccia, S; Garattini, S; Mennini, T, 1982) |
| "Thus, catalepsy is a robust endogenously regulated circadian response that is only slowly influenced by altered lighting conditions which dissociate this rhythm of neuroleptic response from that of spontaneous general arousal." | 1.26 | Circadian changes in behavioral effects of haloperidol in rats. ( Baldessarini, RJ; Campbell, A, 1982) |
| "Thus, catalepsy was maximal at about 4:00 p." | 1.26 | Circadian changes in the destruction and effects of haloperidol in the rat. ( Baldessarini, RJ; Campbell, A; Cohen, BM; Herschel, M; Madsen, JR; Sommer, B, 1982) |
| "Domperidone induced a weak catalepsy in decompressed rats, but failed to induce any catalepsy in control rats." | 1.26 | Changes in blood-brain barrier permeability to drugs in decompressed rats. ( Kaakkola, S; Laitinen, LA; Lehtosalo, J, 1982) |
| "Haloperidol-induced catalepsy in rats is reduced by low dose baclofen and is potentiated by high dose baclofen." | 1.26 | Biphasic dose-response effect of baclofen on haloperidol catalepsy in the rat. ( Richardson, AK; Richardson, JS, 1982) |
| "This is referred to as catalepsy." | 1.26 | Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. ( Sanberg, PR, 1980) |
| "The potentiation of haloperidol-induced catalepsy by GABA mimetics is also observed with dipropylacetate, delta-aminovaleric acid and gamma-acetylenic GABA." | 1.26 | Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. ( Lloyd, KG; Worms, P, 1980) |
| "Quipazine-treated animals required more elicitation attempts before displaying TI." | 1.26 | Tonic immobility in domestic fowl: anticataleptic effects of quipazine. ( Wallnau, LB, 1980) |
| "haloperidol-treated rats (1, 2." | 1.26 | Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms. ( De Ryck, M; Schallert, T; Teitelbaum, P, 1980) |
| "Both haloperidol and morphine produced catalepsy when injected into the reticular formation." | 1.26 | Involvement of caudate nucleus, amygdala or reticular formation in neuroleptic and narcotic catalepsy. ( Broekkamp, CL; Dunstan, R; Lloyd, KG, 1981) |
| "Haloperidol-induced catalepsy was potentiated in DSP-4 treated rats, while arecoline-induced catalepsy was attenuated." | 1.26 | Alterations in drug induced catalepsy and post-decapitation convulsions following brain and spinal cord depletion of norepinephrine by the neurotoxin DSP-4. ( Asin, KE; Fibiger, HC; Wirtshafter, D, 1982) |
| "Haloperidol-induced catalepsy was also examined." | 1.26 | Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. ( Erzin-Waters, C; Muller, P; Seeman, P, 1976) |
| "Gabaculine also induced catalepsy of medium intensity and potentiated the effect of haloperidol 24h after injection, when GABA was increased in the globus pallidus as well as in the substantia nigra." | 1.26 | Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines. ( Kamioka, T; Matsui, Y, 1978) |
| "YM-08050 induced catalepsy only at much higher doses than to exhibit the inhibitory activities." | 1.26 | Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050). ( Maeno, H; Sano, K; Usuda, S, 1979) |
| " SHPGE2, PGE2, and C did not cause catalepsy and did not show statistically significant dose-response antagonism of rotational behavior at less than toxic doses." | 1.26 | Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat. ( Bloss, JL; Singer, GH, 1978) |
| "It did not, however, affect haloperidol catalepsy at any of the four doses tested." | 1.26 | Noradrenergic influences on catalepsy. ( Fibiger, HC; Mason, ST; Roberts, DC, 1978) |
| "Pretreatment with quipazine, a serotonin agonist, and clomipramine, a selective serotonin neuronal uptake blocker, was found to potentiate the cataleptic effect of haloperidol in a dose-dependent manner in rats." | 1.26 | Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. ( Balsara, JJ; Chandorkar, AG; Jadhav, JH, 1979) |
| "Haloperidol catalepsy can be countered by electrical stimulation of the lateral hypothalamus (LH) and, to a lesser extent, the reticular formation (RH)." | 1.26 | Movement induced in cataleptic rats: differential effects produced by electrical stimulation of the lateral hypothalamus, substantia nigra, and reticular formation. ( Mickley, GA; Teitelbaum, H, 1978) |
| "or 1." | 1.26 | Tolerance of haloperidol catalepsy. ( Ezrin-Waters, C; Seeman, P, 1977) |
| "2." | 1.26 | The interaction of clonidine with dopamine-dependent behaviour in rodents. ( Jenner, PG; Marsden, CD; Pycock, CJ, 1977) |
| "Sulpiride was administered orally and intraventricularly, and the effects of sulpiride were compared to those of haloperidol and chlorpromazine administered through the same routes." | 1.26 | Dopamine receptor blocking activity of sulpiride in the central nervous system. ( Honda, F; Kato, R; Noguchi, H; Satoh, H; Satoh, Y; Shimomura, K; Uchida, S, 1977) |
| "Mecamylamine pretreatment reduced the morphine- and haloperidol-induced elevation of striatal HVA concentrations." | 1.26 | Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol. ( Ahtee, L; Kaakkola, S, 1978) |
| "On the other hand, the catalepsy produced by intranigral picrotoxin was much more sensitive to apomorphine and was disrupted by systemic scopolamine administration." | 1.26 | Evidence that a nigral gabaergic--cholinergic balance controls posture. ( De Montis, GM; Olianas, MC; Scheel-Krüger, J; Serra, G; Tagliamonte, A, 1979) |
| "It is proposed that the decrement in catalepsy occurring between 10 and 15 days of age is related to increased dopaminergic activity in the neostriatum." | 1.26 | Dopaminergic antagonism and catalepsy in the developing rat. ( Baez, LA; Burt, DK; Granneman, J; Shanklin, C, 1979) |
| "Our results suggest that akinesia and catalepsy, induced in rats by haloperidol might be, at least in part, due to a decrease in sensitivity of alpha-motoneurones to proprioceptive stimuli." | 1.26 | Effect of haloperidol on reflex activation of rat alpha-motoneurones. A possible explanation for akinesia and catalepsy? ( Kuschinsky, K; Langer, J; Seeber, U; Sontag, KH, 1979) |
| "Pretreatment with haloperidol significantly depressed the accumulation of apomorphine in the caudate nucleus and hippocampus, but not in the cerebellum." | 1.26 | Accumulation of apomorphine in caudate nucleus and hippocampus of the rabbit. ( Melzacka, M; Rurak, A; Smiałowski, A; Vetulani, J, 1979) |
| "When morphine was injected 4 h after AMT, a mutual potentiation of the two drugs on hypokinesia and catalepsy was observed, although previous biochemical measurements had shown no effect of morphine on CA depletion under these conditions." | 1.26 | AMT catalepsy and hypokinesia: interaction with morphine and cocaine. ( Ayhan, H; Papeschi, R; Theiss, P, 1976) |
| "The combination quickly caused a strong catalepsy." | 1.25 | On a prime role for newly synthesized dopamine in striatal function. ( Dorris, RL; Shore, PA, 1975) |
| "Maprotiline was more potent than anitriptyline and imipramine in antagonizing haloperidol-induced catalepsy as well as in suppressing muricide induced by either olfactory bulbectomy or delta-9-tetrahydrocannabinol in rats." | 1.25 | [Behavior pharmacology of maprotiline, a new antidepressant]. ( Fujiwara, M; Ibii, N; Inoue, K; Kataoka, Y; Ueki, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 296 (36.77) | 18.7374 |
| 1990's | 203 (25.22) | 18.2507 |
| 2000's | 168 (20.87) | 29.6817 |
| 2010's | 126 (15.65) | 24.3611 |
| 2020's | 12 (1.49) | 2.80 |
| Authors | Studies |
|---|---|
| Voith, K | 1 |
| Bruderlein, FT | 1 |
| Humber, LG | 1 |
| Sato, M | 3 |
| Arimoto, M | 1 |
| Ueno, K | 1 |
| Kojima, H | 1 |
| Yamasaki, T | 1 |
| Sakurai, T | 1 |
| Kasahara, A | 1 |
| Nagai, Y | 1 |
| Irie, A | 1 |
| Masuda, Y | 3 |
| Oka, M | 1 |
| Uno, H | 1 |
| Yevich, JP | 2 |
| New, JS | 2 |
| Lobeck, WG | 2 |
| Dextraze, P | 1 |
| Bernstein, E | 1 |
| Taylor, DP | 2 |
| Yocca, FD | 1 |
| Eison, MS | 2 |
| Temple, DL | 2 |
| Hrib, NJ | 1 |
| Jurcak, JG | 1 |
| Huger, FP | 1 |
| Errico, CL | 1 |
| Dunn, RW | 2 |
| Cascio, G | 1 |
| Manghisi, E | 1 |
| Fregnan, G | 1 |
| Wise, LD | 2 |
| Pattison, IC | 2 |
| Butler, DE | 2 |
| DeWald, HA | 2 |
| Lewis, EP | 2 |
| Lobbestael, SJ | 2 |
| Tecle, H | 1 |
| Coughenour, LL | 2 |
| Downs, DA | 1 |
| Poschel, BP | 2 |
| Smith, DW | 1 |
| Catt, JD | 1 |
| Minielli, JL | 1 |
| Riblet, LA | 1 |
| Henning, R | 1 |
| Lattrell, R | 1 |
| Gerhards, HJ | 1 |
| Leven, M | 1 |
| Chakrabarti, JK | 2 |
| Horsman, L | 2 |
| Hotten, TM | 1 |
| Pullar, IA | 2 |
| Tupper, DE | 2 |
| Wright, FC | 2 |
| Fairhurst, J | 1 |
| Gutteridge, NJ | 1 |
| Smith, CW | 1 |
| Steggles, DJ | 1 |
| Iwanami, S | 1 |
| Takashima, M | 3 |
| Hirata, Y | 1 |
| Hasegawa, O | 1 |
| Usuda, S | 2 |
| Florvall, L | 2 |
| Ogren, SO | 5 |
| Norman, MH | 1 |
| Rigdon, GC | 1 |
| Navas, F | 1 |
| Cooper, BR | 1 |
| Howard, HR | 1 |
| Lowe, JA | 1 |
| Seeger, TF | 1 |
| Seymour, PA | 1 |
| Zorn, SH | 1 |
| Maloney, PR | 1 |
| Ewing, FE | 1 |
| Newman, ME | 1 |
| Schmidt, AW | 2 |
| Furman, JS | 1 |
| Robinson, GL | 1 |
| Jackson, E | 1 |
| Johnson, C | 1 |
| Morrone, J | 1 |
| Bolós, J | 2 |
| Gubert, S | 2 |
| Anglada, L | 2 |
| Planas, JM | 2 |
| Burgarolas, C | 1 |
| Castelló, JM | 1 |
| Sacristán, A | 2 |
| Ortiz, JA | 2 |
| Oshiro, Y | 1 |
| Sato, S | 1 |
| Kurahashi, N | 1 |
| Tanaka, T | 1 |
| Kikuchi, T | 3 |
| Tottori, K | 3 |
| Uwahodo, Y | 3 |
| Nishi, T | 1 |
| Reitz, AB | 1 |
| Baxter, EW | 1 |
| Codd, EE | 1 |
| Davis, CB | 1 |
| Jordan, AD | 1 |
| Maryanoff, BE | 1 |
| Maryanoff, CA | 1 |
| McDonnell, ME | 1 |
| Powell, ET | 1 |
| Renzi, MJ | 1 |
| Schott, MR | 1 |
| Scott, MK | 1 |
| Shank, RP | 1 |
| Vaught, JL | 1 |
| Taverne, T | 1 |
| Diouf, O | 1 |
| Depreux, P | 1 |
| Poupaert, JH | 1 |
| Lesieur, D | 1 |
| Guardiola-Lemaître, B | 1 |
| Renard, P | 1 |
| Rettori, MC | 1 |
| Caignard, DH | 1 |
| Pfeiffer, B | 1 |
| Agut, J | 1 |
| Príncep, M | 1 |
| De la Fuente, N | 1 |
| Liao, Y | 1 |
| Venhuis, BJ | 1 |
| Rodenhuis, N | 1 |
| Timmerman, W | 2 |
| Wikström, H | 1 |
| Meier, E | 1 |
| Bartoszyk, GD | 2 |
| Böttcher, H | 1 |
| Seyfried, CA | 1 |
| Sundell, S | 1 |
| Raviña, E | 2 |
| Negreira, J | 1 |
| Cid, J | 1 |
| Masaguer, CF | 2 |
| Rosa, E | 1 |
| Rivas, ME | 2 |
| Fontenla, JA | 2 |
| Loza, MI | 2 |
| Tristán, H | 1 |
| Cadavid, MI | 2 |
| Sanz, F | 1 |
| Lozoya, E | 1 |
| Carotti, A | 1 |
| Carrieri, A | 1 |
| Birch, AM | 1 |
| Bradley, PA | 1 |
| Gill, JC | 1 |
| Kerrigan, F | 1 |
| Needham, PL | 1 |
| Casariego, I | 1 |
| Montenegro, GY | 1 |
| Enguix, MJ | 1 |
| Villazon, M | 1 |
| Demontis, GC | 1 |
| Campiani, G | 3 |
| Butini, S | 3 |
| Gemma, S | 3 |
| Nacci, V | 3 |
| Fattorusso, C | 3 |
| Catalanotti, B | 3 |
| Giorgi, G | 1 |
| Cagnotto, A | 3 |
| Goegan, M | 1 |
| Mennini, T | 4 |
| Minetti, P | 4 |
| Di Cesare, MA | 3 |
| Mastroianni, D | 2 |
| Scafetta, N | 2 |
| Galletti, B | 2 |
| Stasi, MA | 4 |
| Castorina, M | 2 |
| Pacifici, L | 2 |
| Ghirardi, O | 3 |
| Tinti, O | 3 |
| Carminati, P | 3 |
| Zhao, H | 1 |
| He, X | 1 |
| Thurkauf, A | 1 |
| Hoffman, D | 1 |
| Kieltyka, A | 1 |
| Brodbeck, R | 1 |
| Primus, R | 1 |
| Wasley, JW | 1 |
| Liégeois, JF | 1 |
| Eyrolles, L | 1 |
| Ellenbroek, BA | 1 |
| Lejeune, C | 1 |
| Carato, P | 1 |
| Bruhwyler, J | 1 |
| Géczy, J | 1 |
| Damas, J | 1 |
| Delarge, J | 1 |
| Sikazwe, DM | 2 |
| Li, S | 2 |
| Lyles-Eggleston, M | 2 |
| Ablordeppey, SY | 4 |
| Morelli, E | 1 |
| Mereghetti, I | 2 |
| Carli, M | 1 |
| Vertechy, M | 2 |
| Di Serio, S | 3 |
| Altundas, R | 1 |
| Xia, J | 1 |
| Fan, P | 1 |
| Yang, Q | 1 |
| Zhang, W | 1 |
| Zhu, X | 1 |
| Vanase-Frawley, M | 1 |
| Shrihkande, A | 1 |
| Villalobos, A | 1 |
| Borne, RF | 1 |
| Vanover, KE | 2 |
| Harvey, SC | 1 |
| Son, T | 1 |
| Bradley, SR | 2 |
| Kold, H | 1 |
| Makhay, M | 1 |
| Veinbergs, I | 2 |
| Spalding, TA | 1 |
| Weiner, DM | 1 |
| Andersson, CM | 1 |
| Tolf, BR | 1 |
| Brann, MR | 2 |
| Hacksell, U | 2 |
| Davis, RE | 2 |
| Trotta, F | 1 |
| Fiorini, I | 1 |
| Azam, F | 3 |
| Alkskas, IA | 1 |
| Ahmed, MA | 1 |
| Kołaczkowski, M | 1 |
| Marcinkowska, M | 1 |
| Bucki, A | 1 |
| Pawłowski, M | 1 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 1 |
| Siwek, A | 1 |
| Wasik, A | 1 |
| Wesołowska, A | 1 |
| Mierzejewski, P | 2 |
| Bienkowski, P | 1 |
| Sampson, D | 2 |
| Bricker, B | 2 |
| Zhu, XY | 1 |
| Peprah, K | 1 |
| Lamango, NS | 1 |
| Setola, V | 1 |
| Roth, BL | 2 |
| Cheng, J | 1 |
| Giguere, PM | 1 |
| Schmerberg, CM | 1 |
| Pogorelov, VM | 1 |
| Rodriguiz, RM | 1 |
| Huang, XP | 1 |
| Zhu, H | 1 |
| McCorvy, JD | 1 |
| Wetsel, WC | 1 |
| Kozikowski, AP | 1 |
| Pal Roy, S | 1 |
| Kadiri, SK | 1 |
| Karkar, VV | 1 |
| Rao Konijeti, S | 1 |
| Romero-Fernandez, W | 1 |
| Taura, JJ | 1 |
| Crans, RAJ | 1 |
| Lopez-Cano, M | 1 |
| Fores-Pons, R | 1 |
| Narváez, M | 1 |
| Carlsson, J | 1 |
| Ciruela, F | 1 |
| Fuxe, K | 2 |
| Borroto-Escuela, DO | 1 |
| De la Casa, LG | 1 |
| Cintado, MA | 1 |
| González-Tirado, G | 1 |
| Cárcel, L | 1 |
| Reakkamnuan, C | 1 |
| Kumarnsit, E | 1 |
| Cheaha, D | 1 |
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Nurmaganbetov, ZS | 1 |
| Arystan, LI | 1 |
| Muldaeva, GM | 1 |
| Haydargalieva, LS | 1 |
| Adekenov, SM | 1 |
| Kiselev, AV | 1 |
| Vedenkin, AS | 1 |
| Stovbun, IS | 1 |
| Sergienko, VI | 1 |
| Kalinina, TS | 1 |
| Natfji, AA | 1 |
| Nikitin, DO | 1 |
| Semina, II | 2 |
| Moustafine, RI | 1 |
| Khutoryanskiy, VV | 1 |
| Lin, H | 1 |
| Stephens, GJ | 1 |
| Watson, KA | 1 |
| Osborn, HMI | 1 |
| Greco, F | 1 |
| Łażewska, D | 1 |
| Olejarz-Maciej, A | 1 |
| Reiner, D | 1 |
| Kaleta, M | 1 |
| Latacz, G | 1 |
| Zygmunt, M | 1 |
| Doroz-Płonka, A | 1 |
| Karcz, T | 1 |
| Frank, A | 1 |
| Stark, H | 1 |
| Kieć-Kononowicz, K | 1 |
| Parambi, DGT | 1 |
| Saleem, U | 1 |
| Shah, MA | 1 |
| Anwar, F | 2 |
| Ahmad, B | 1 |
| Manzar, A | 1 |
| Itzaz, A | 1 |
| Harilal, S | 1 |
| Uddin, MS | 1 |
| Kim, H | 1 |
| Mathew, B | 1 |
| Zemba Cilic, A | 1 |
| Zemba, M | 1 |
| Cilic, M | 1 |
| Balenovic, I | 1 |
| Strbe, S | 1 |
| Ilic, S | 1 |
| Vukojevic, J | 1 |
| Zoricic, Z | 1 |
| Filipcic, I | 1 |
| Kokot, A | 1 |
| Drmic, D | 1 |
| Blagaic, AB | 1 |
| Tvrdeic, A | 1 |
| Seiwerth, S | 2 |
| Sikiric, P | 2 |
| Ramírez-Jarquín, UN | 1 |
| Shahani, N | 1 |
| Pryor, W | 1 |
| Usiello, A | 2 |
| Subramaniam, S | 1 |
| Ihme, H | 1 |
| Schwarting, RKW | 2 |
| Melo-Thomas, L | 8 |
| Kent, CN | 1 |
| Fulton, MG | 1 |
| Stillwell, KJ | 1 |
| Dickerson, JW | 2 |
| Loch, MT | 2 |
| Rodriguez, AL | 2 |
| Blobaum, AL | 4 |
| Boutaud, O | 1 |
| Rook, JL | 1 |
| Niswender, CM | 7 |
| Conn, PJ | 7 |
| Lindsley, CW | 6 |
| Waku, I | 1 |
| Magalhães, MS | 1 |
| Alves, CO | 1 |
| de Oliveira, AR | 3 |
| Kumari, N | 1 |
| Agrawal, S | 1 |
| Luthra, PM | 3 |
| Miksys, S | 1 |
| Wadji, FB | 1 |
| Tolledo, EC | 1 |
| Remington, G | 1 |
| Nobrega, JN | 4 |
| Tyndale, RF | 1 |
| Zergiebel, S | 1 |
| Fleck, C | 2 |
| Arndt, HD | 1 |
| Enzensperger, C | 2 |
| Seeling, A | 1 |
| Dhingra, D | 1 |
| Goswami, S | 1 |
| Gahalain, N | 1 |
| Amoateng, P | 2 |
| Adjei, S | 2 |
| Osei-Safo, D | 2 |
| Kukuia, KKE | 2 |
| Karikari, TK | 2 |
| Nyarko, AK | 1 |
| Bekoe, EO | 1 |
| Kombian, SB | 1 |
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Egashira, N | 1 |
| Koushi, E | 1 |
| Myose, T | 1 |
| Tanoue, A | 1 |
| Mishima, K | 3 |
| Tsuchihashi, R | 1 |
| Kinjo, J | 1 |
| Tanaka, H | 1 |
| Morimoto, S | 1 |
| Iwasaki, K | 1 |
| Tonelli, LC | 3 |
| Wöhr, M | 2 |
| Schwarting, R | 2 |
| Vikhe, S | 1 |
| Nirmal, S | 1 |
| Engelhardt, KA | 1 |
| Marchetta, P | 1 |
| Suzuki, K | 1 |
| Harada, A | 1 |
| Suzuki, H | 1 |
| Capuani, C | 1 |
| Ugolini, A | 1 |
| Corsi, M | 1 |
| Kimura, H | 1 |
| Arora, D | 1 |
| Mudgal, J | 1 |
| Nampoothiri, M | 1 |
| Mallik, SB | 1 |
| Kinra, M | 1 |
| Hall, S | 1 |
| Anoopkumar-Dukie, S | 1 |
| Grant, GD | 1 |
| Rao, CM | 1 |
| Sharma, AK | 2 |
| Gupta, S | 1 |
| Patel, RK | 1 |
| Wardhan, N | 1 |
| Prieto, SG | 1 |
| Silva, JCS | 1 |
| de Lima, MO | 1 |
| Almeida, MC | 1 |
| Echeverry, MB | 1 |
| Santillán-Urquiza, MA | 1 |
| Herrera-Ruiz, M | 1 |
| Zamilpa, A | 1 |
| Jiménez-Ferrer, E | 1 |
| Román-Ramos, R | 1 |
| Tortoriello, J | 1 |
| Ionov, ID | 4 |
| Pushinskaya, II | 2 |
| Gorev, NP | 1 |
| Frenkel, DD | 1 |
| Kumbol, VW | 1 |
| Abotsi, WKM | 1 |
| Ekuadzi, E | 1 |
| Woode, E | 1 |
| Barroca, NCB | 1 |
| Guarda, MD | 1 |
| da Silva, NT | 1 |
| Colombo, AC | 2 |
| Reimer, AE | 2 |
| Brandão, ML | 4 |
| Liu, X | 2 |
| Sharma, RK | 1 |
| Mishra, A | 1 |
| Chinnaboina, GK | 1 |
| Gupta, G | 4 |
| Singh, M | 1 |
| Ahmadi, SA | 1 |
| Sabahi, M | 1 |
| Haddadi, R | 1 |
| Ufartes, R | 1 |
| Schneider, T | 1 |
| Mortensen, LS | 1 |
| de Juan Romero, C | 1 |
| Hentrich, K | 1 |
| Knoetgen, H | 1 |
| Beilinson, V | 1 |
| Moebius, W | 1 |
| Tarabykin, V | 1 |
| Alves, F | 1 |
| Pardo, LA | 1 |
| Rawlins, JN | 1 |
| Stuehmer, W | 1 |
| Marrocco, J | 1 |
| Mairesse, J | 1 |
| Bucci, D | 2 |
| Lionetto, L | 1 |
| Battaglia, G | 2 |
| Consolazione, M | 1 |
| Ravasi, L | 1 |
| Simmaco, M | 1 |
| Morley-Fletcher, S | 1 |
| Maccari, S | 1 |
| Nicoletti, F | 5 |
| Singh, R | 1 |
| David, SR | 1 |
| Verma, RK | 1 |
| Jones, N | 1 |
| Bleickardt, C | 1 |
| Mullins, D | 1 |
| Parker, E | 1 |
| Hodgson, R | 1 |
| Wang, H | 1 |
| Chen, XY | 1 |
| Chen, WF | 1 |
| Xue, Y | 2 |
| Wei, L | 2 |
| Chen, L | 3 |
| Tostes, JG | 1 |
| Medeiros, P | 4 |
| Prus, AJ | 2 |
| Hillhouse, TM | 1 |
| LaCrosse, AL | 1 |
| Shimizu, S | 7 |
| Tatara, A | 4 |
| Sugiuchi, T | 2 |
| Miyoshi, S | 2 |
| Andatsu, S | 1 |
| Kizu, T | 1 |
| Ohno, Y | 7 |
| Muthuraju, S | 1 |
| Nobre, MJ | 1 |
| Saito, VM | 1 |
| Konieczny, J | 5 |
| Lenda, T | 1 |
| Magaji, MG | 1 |
| Mohammed, M | 1 |
| Magaji, RA | 1 |
| Musa, AM | 1 |
| Abdu-Aguye, I | 1 |
| Hussaini, IM | 1 |
| Erosa-Rivero, HB | 1 |
| Bata-García, JL | 3 |
| Alvarez-Cervera, FJ | 4 |
| Heredia-López, FJ | 2 |
| Góngora-Alfaro, JL | 5 |
| Piazza, J | 1 |
| Hoare, T | 1 |
| Molinaro, L | 1 |
| Terpstra, K | 1 |
| Bhandari, J | 1 |
| Selvaganapathy, PR | 1 |
| Gupta, B | 1 |
| Mishra, RK | 3 |
| Viana, MB | 1 |
| Barbosa-Silva, RC | 1 |
| Lewitus, GM | 1 |
| Pribiag, H | 1 |
| Duseja, R | 1 |
| St-Hilaire, M | 2 |
| Stellwagen, D | 1 |
| Zheng, J | 1 |
| Yang, Z | 1 |
| Li, X | 1 |
| Li, L | 1 |
| Ma, H | 1 |
| Wang, M | 1 |
| Zhang, H | 2 |
| Zhen, X | 1 |
| Zhang, X | 5 |
| Moshiri, M | 1 |
| Mohammadpour, AH | 1 |
| Vahabzadeh, M | 1 |
| Etemad, L | 1 |
| Memar, B | 1 |
| Hosseinzadeh, H | 1 |
| Kasture, SB | 2 |
| Gaikar, M | 1 |
| Kasture, V | 2 |
| Arote, S | 1 |
| Salve, B | 1 |
| Rosas, M | 1 |
| Cotti, E | 1 |
| Acquas, E | 1 |
| Morris, LC | 1 |
| Nance, KD | 1 |
| Gentry, PR | 1 |
| Days, EL | 1 |
| Weaver, CD | 2 |
| Thompson, AD | 4 |
| Jones, CK | 6 |
| Locuson, CW | 1 |
| Morrison, RD | 2 |
| Daniels, JS | 4 |
| Niswender, KD | 1 |
| Thomas, U | 1 |
| Lilienthal, H | 1 |
| Korkalainen, M | 1 |
| Andersson, PL | 1 |
| Viluksela, M | 1 |
| Alatorre, A | 1 |
| Oviedo-Chávez, A | 1 |
| Villalobos, N | 1 |
| Ríos, A | 1 |
| Barrientos, R | 1 |
| Querejeta, E | 1 |
| Cannella, M | 1 |
| Motolese, M | 1 |
| Molinaro, G | 1 |
| Gradini, R | 1 |
| Bruno, V | 1 |
| Iderberg, H | 2 |
| Maslava, N | 1 |
| Bubser, M | 7 |
| Hopkins, CR | 4 |
| Cenci, MA | 3 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Pace, S | 1 |
| Borsini, F | 1 |
| Jones, PG | 1 |
| Hewitt, MC | 1 |
| Campbell, JE | 1 |
| Quinton, MS | 1 |
| Engel, S | 1 |
| Lew, R | 1 |
| Campbell, U | 1 |
| Burdi, DF | 1 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Kleven, MS | 5 |
| Koek, W | 6 |
| Bardin, L | 1 |
| Depoortère, R | 3 |
| Newman-Tancredi, A | 3 |
| Gentzel, RC | 1 |
| Toolan, D | 1 |
| Roberts, R | 1 |
| Koser, AJ | 1 |
| Kandebo, M | 1 |
| Hershey, J | 1 |
| Renger, JJ | 1 |
| Uslaner, J | 1 |
| Smith, SM | 1 |
| Masui, A | 1 |
| Tamura, M | 1 |
| Minamimoto, S | 1 |
| Mizuguchi, Y | 1 |
| Ochiai, M | 1 |
| Mizobe, Y | 1 |
| Jain, NS | 2 |
| Tandi, L | 1 |
| Verma, L | 1 |
| Robinson, SJ | 1 |
| Petzer, JP | 1 |
| Terre'Blanche, G | 1 |
| Petzer, A | 1 |
| van der Walt, MM | 1 |
| Bergh, JJ | 1 |
| Lourens, AC | 1 |
| Maurice, N | 1 |
| Deltheil, T | 1 |
| Melon, C | 2 |
| Degos, B | 1 |
| Mourre, C | 1 |
| Amalric, M | 7 |
| Kerkerian-Le Goff, L | 2 |
| Gmiro, VE | 5 |
| Serdyuk, SE | 2 |
| Veselkina, OS | 1 |
| Fegade, HA | 1 |
| Umathe, SN | 2 |
| Malekar, AR | 1 |
| Balsara, JJ | 8 |
| Gaonkar, RK | 3 |
| Sonego, AB | 1 |
| Gomes, FV | 1 |
| Del Bel, EA | 4 |
| Guimaraes, FS | 3 |
| Oliveira, LR | 1 |
| Dias, FRC | 1 |
| Santos, BG | 1 |
| Silva, JLL | 1 |
| Carey, RJ | 1 |
| Carrera, MP | 1 |
| Lin, X | 1 |
| Thompson Gray, A | 1 |
| Engers, DW | 3 |
| Javitch, JA | 1 |
| de Freitas, RL | 1 |
| Silva, MO | 1 |
| Coimbra, NC | 2 |
| Rajput, SK | 1 |
| Meena, CL | 1 |
| Pant, AB | 1 |
| Jain, R | 1 |
| Sharma, SS | 1 |
| Kronbauer, M | 1 |
| Metz, VG | 1 |
| Roversi, K | 1 |
| Dias, VT | 2 |
| de David Antoniazzi, CT | 1 |
| da Silva Barcelos, RC | 1 |
| Burger, ME | 3 |
| Madhu, A | 1 |
| Arali, B | 1 |
| Chellappan, DK | 1 |
| Dua, K | 1 |
| Hitzemann, R | 8 |
| Malmanger, B | 2 |
| Belknap, J | 1 |
| Darakjian, P | 2 |
| McWeeney, S | 2 |
| Mihara, T | 1 |
| Noda, A | 1 |
| Arai, H | 1 |
| Mihara, K | 1 |
| Iwashita, A | 1 |
| Murakami, Y | 1 |
| Matsuya, T | 1 |
| Nishimura, S | 1 |
| Matsuoka, N | 2 |
| Imaki, J | 5 |
| Ishihara, S | 1 |
| Sofue, N | 1 |
| Sasa, M | 1 |
| Kawai, Y | 1 |
| Varty, GB | 1 |
| Hodgson, RA | 1 |
| Pond, AJ | 1 |
| Grzelak, ME | 1 |
| Parker, EM | 1 |
| Hunter, JC | 1 |
| Lopez, S | 4 |
| Turle-Lorenzo, N | 2 |
| Johnston, TH | 1 |
| Brotchie, JM | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Jackson, J | 2 |
| Young, CK | 1 |
| Hu, B | 2 |
| Bland, BH | 1 |
| Chang, PY | 1 |
| Chuang, CH | 1 |
| Chen, JC | 1 |
| Tung, CS | 1 |
| Palmer, AA | 1 |
| Brown, AS | 1 |
| Keegan, D | 1 |
| Siska, LD | 1 |
| Susser, E | 1 |
| Rotrosen, J | 1 |
| Butler, PD | 1 |
| Barodia, SK | 3 |
| Anwer, T | 1 |
| Alam, MM | 1 |
| Tellew, JE | 3 |
| Luo, Z | 2 |
| Moorjani, M | 4 |
| Lin, E | 4 |
| Lanier, MC | 4 |
| Chen, Y | 4 |
| Williams, JP | 4 |
| Saunders, J | 4 |
| Lechner, SM | 4 |
| Markison, S | 4 |
| Joswig, T | 4 |
| Petroski, R | 2 |
| Piercey, J | 2 |
| Kargo, W | 2 |
| Malany, S | 4 |
| Santos, M | 4 |
| Gross, RS | 4 |
| Wen, J | 3 |
| Jalali, K | 2 |
| O'Brien, Z | 3 |
| Stotz, CE | 1 |
| Crespo, MI | 4 |
| Díaz, JL | 4 |
| Slee, DH | 4 |
| Jadhav, SA | 2 |
| Gaikwad, RV | 2 |
| Thorat, VM | 2 |
| Gursale, SC | 1 |
| Wiley, JL | 1 |
| Evans, RL | 1 |
| Grauer, SM | 1 |
| Graf, R | 1 |
| Navarra, R | 1 |
| Sung, A | 1 |
| Logue, SF | 1 |
| Stack, G | 1 |
| Huselton, C | 1 |
| Liu, Z | 1 |
| Comery, TA | 1 |
| Marquis, KL | 1 |
| Rosenzweig-Lipson, S | 3 |
| Neustadt, BR | 1 |
| Liu, H | 1 |
| Hao, J | 1 |
| Greenlee, WJ | 1 |
| Stamford, AW | 1 |
| Foster, C | 1 |
| Arik, L | 1 |
| Lachowicz, J | 1 |
| Bertorelli, R | 1 |
| Fredduzzi, S | 1 |
| Varty, G | 1 |
| Cohen-Williams, M | 1 |
| Ng, K | 1 |
| Zhao, M | 1 |
| Madan, A | 1 |
| Voronina, TA | 1 |
| Belopolskaya, MV | 1 |
| Kheyfets, IA | 1 |
| Dugina, JL | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Raghubir, R | 1 |
| Wiecki, TV | 1 |
| Riedinger, K | 2 |
| von Ameln-Mayerhofer, A | 2 |
| Schmidt, WJ | 18 |
| Frank, MJ | 1 |
| Batool, F | 2 |
| Ahmed, S | 2 |
| Haleem, DJ | 6 |
| Kulkarni, SK | 7 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Kowalska, M | 1 |
| Kamińska, K | 1 |
| Wanjari, MM | 1 |
| Manna, SS | 1 |
| Kasture, S | 3 |
| Barhate, S | 1 |
| Mohan, M | 1 |
| Ballero, M | 1 |
| Sanna, C | 1 |
| Maxia, A | 3 |
| Mae, Y | 1 |
| Thaakur, S | 1 |
| Himabindhu, G | 1 |
| Trevitt, J | 1 |
| Vallance, C | 1 |
| Harris, A | 1 |
| Goode, T | 1 |
| Auclair, AL | 1 |
| Barret-Grévoz, C | 2 |
| Barreto, M | 1 |
| Beurrier, C | 1 |
| Révy, D | 1 |
| Selvam, C | 1 |
| Goudet, C | 2 |
| Lhérondel, M | 1 |
| Gubellini, P | 2 |
| Kerkerian-LeGoff, L | 1 |
| Acher, F | 1 |
| Pin, JP | 2 |
| Clark, CA | 1 |
| Sacrey, LA | 1 |
| Whishaw, IQ | 2 |
| Barcelos, RC | 2 |
| Benvegnú, DM | 2 |
| Boufleur, N | 2 |
| Reckziegel, P | 2 |
| Müller, LG | 1 |
| Pase, C | 1 |
| Emanuelli, T | 1 |
| Moo-Puc, RE | 2 |
| Villanueva-Toledo, JR | 1 |
| Pineda, JC | 2 |
| de Araújo, FY | 1 |
| Silva, MI | 1 |
| Moura, BA | 1 |
| de Oliveira, GV | 1 |
| Leal, LK | 1 |
| Vasconcelos, SM | 1 |
| Viana, GS | 1 |
| de Moraes, MO | 1 |
| de Sousa, FC | 1 |
| Macêdo, DS | 1 |
| Greco, B | 1 |
| van der Putten, H | 1 |
| Flor, PJ | 1 |
| Shioda, N | 2 |
| Yamamoto, Y | 2 |
| Watanabe, M | 1 |
| Binas, B | 1 |
| Owada, Y | 2 |
| Fukunaga, K | 2 |
| Ferger, B | 2 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Kirsten, TB | 1 |
| Taricano, M | 1 |
| Flório, JC | 2 |
| Palermo-Neto, J | 6 |
| Bernardi, MM | 1 |
| Mishra, CB | 1 |
| Prakash, A | 1 |
| Senthil Kumar, JB | 1 |
| Brown, AR | 1 |
| Kolb, B | 1 |
| Teskey, GC | 1 |
| Okano, M | 1 |
| Okumura, T | 1 |
| Melo, LL | 1 |
| Santos, P | 1 |
| Mello, RO | 1 |
| Ferrari, EA | 1 |
| Maisonnette, SS | 1 |
| Francisco, A | 1 |
| Shah, AH | 1 |
| Ahmed, SD | 1 |
| Saify, ZS | 2 |
| Bateup, HS | 1 |
| Santini, E | 1 |
| Shen, W | 1 |
| Birnbaum, S | 1 |
| Valjent, E | 1 |
| Surmeier, DJ | 1 |
| Fisone, G | 1 |
| Nestler, EJ | 1 |
| Greengard, P | 1 |
| Wadenberg, ML | 4 |
| Fjällström, AK | 1 |
| Federley, M | 1 |
| Persson, P | 1 |
| Stenqvist, P | 1 |
| González-Lugo, OE | 1 |
| Ceballos-Huerta, F | 1 |
| Jiménez-Capdeville, ME | 1 |
| Arankowsky-Sandoval, G | 2 |
| Koener, B | 1 |
| Goursaud, S | 1 |
| Van De Stadt, M | 1 |
| Calas, AG | 1 |
| Jeanjean, AP | 1 |
| Maloteaux, JM | 2 |
| Hermans, E | 2 |
| Kulak, A | 1 |
| Shireen, E | 2 |
| Creed-Carson, M | 1 |
| Oraha, A | 1 |
| Fink-Jensen, A | 1 |
| Schmidt, LS | 1 |
| Dencker, D | 1 |
| Schülein, C | 1 |
| Wess, J | 1 |
| Wörtwein, G | 1 |
| Woldbye, DP | 1 |
| Holly, EN | 1 |
| Ebrecht, B | 1 |
| Trevizol, F | 1 |
| Pase, CS | 1 |
| Segat, HJ | 1 |
| Dolci, GS | 1 |
| Olczak, M | 1 |
| Duszczyk, M | 1 |
| Meyza, K | 1 |
| Majewska, MD | 1 |
| Pawar, A | 1 |
| Kasture, A | 1 |
| Foddis, C | 2 |
| Frau, MA | 2 |
| McFarlane, HG | 1 |
| Steele, J | 1 |
| Vinion, K | 1 |
| Bongiovanni, R | 2 |
| Double, M | 1 |
| Jaskiw, GE | 4 |
| Field, JR | 1 |
| Lindsley, SR | 1 |
| Zhou, Y | 2 |
| Gogliotti, RD | 1 |
| Jadhav, S | 2 |
| Zamorano, R | 1 |
| Bogenpohl, J | 1 |
| Smith, Y | 1 |
| Morrison, R | 1 |
| Iancu, OD | 1 |
| Walter, NA | 2 |
| Jardemark, K | 1 |
| Marcus, MM | 1 |
| Malmerfelt, A | 1 |
| Shahid, M | 1 |
| Svensson, TH | 2 |
| Pemminati, S | 1 |
| Swati, B | 1 |
| Shreyasi, C | 1 |
| Gopalakrishna, HN | 3 |
| Nair, V | 3 |
| Pai, MR | 1 |
| Bridges, TM | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Banasikowski, TJ | 2 |
| Beninger, RJ | 3 |
| Bordia, T | 1 |
| McIntosh, JM | 1 |
| Quik, M | 1 |
| Bilge, U | 1 |
| Erol, K | 1 |
| Lancioni, MC | 1 |
| Mahmood, D | 1 |
| Khanam, R | 1 |
| Pillai, KK | 2 |
| Akhtar, M | 2 |
| Kazmi, I | 1 |
| Afzal, M | 1 |
| Rahman, M | 1 |
| Saleem, S | 1 |
| Ashraf, MS | 1 |
| Khusroo, MJ | 1 |
| Nazeer, K | 1 |
| Mujeeb, M | 1 |
| Ahmed, Z | 1 |
| Povarnina, PY | 1 |
| Gudasheva, TA | 1 |
| Vorontsova, ON | 1 |
| Bondarenko, NA | 1 |
| Seredenin, SB | 1 |
| Schulze, M | 1 |
| Siol, O | 1 |
| Robaa, D | 1 |
| Mueller, FK | 1 |
| Lehmann, J | 1 |
| Langlois, X | 1 |
| Megens, A | 1 |
| Lavreysen, H | 1 |
| Atack, J | 1 |
| Cik, M | 1 |
| te Riele, P | 1 |
| Peeters, L | 1 |
| Wouters, R | 1 |
| Vermeire, J | 1 |
| Hendrickx, H | 1 |
| Macdonald, G | 1 |
| De Bruyn, M | 1 |
| Bennouar, KE | 1 |
| Uberti, MA | 1 |
| Bacolod, MD | 1 |
| Jimenez, HN | 1 |
| Cajina, M | 1 |
| Doller, D | 1 |
| Severtsev, NN | 2 |
| Shin, N | 1 |
| Johnson, KA | 1 |
| Tantawy, MN | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Nirmal, SA | 1 |
| Patel, AP | 1 |
| Bhawar, SB | 1 |
| Pattan, SR | 1 |
| Prasad, MV | 1 |
| Thangavel, N | 1 |
| Shrivastava, AK | 1 |
| Mohan, G | 1 |
| Goldstein, N | 1 |
| Goldstein, R | 1 |
| Terterov, D | 1 |
| Kamensky, AA | 1 |
| Kovalev, GI | 1 |
| Zolotarev, YA | 1 |
| Avakyan, GN | 1 |
| Terterov, S | 1 |
| Baturin, VA | 2 |
| Manvelian, ÉA | 1 |
| Bulgakova, MD | 1 |
| Frau, R | 1 |
| Pillolla, G | 1 |
| Bini, V | 1 |
| Tambaro, S | 2 |
| Devoto, P | 1 |
| Bortolato, M | 1 |
| Boye, SM | 2 |
| Acuña-Lizama, MM | 1 |
| Shi, L | 1 |
| Bian, X | 1 |
| Qu, Z | 1 |
| Ma, Z | 1 |
| Wang, K | 1 |
| Jiang, H | 1 |
| Xie, J | 1 |
| Oganesian, GA | 3 |
| Aristakesian, EA | 1 |
| Romanova, IV | 1 |
| Vataev, SI | 2 |
| Kuzik, VV | 1 |
| Chintawar, SD | 1 |
| Somani, RS | 1 |
| Kasture, VS | 1 |
| Karasawa, J | 1 |
| Takahashi, S | 2 |
| Takagi, K | 2 |
| Horikomi, K | 2 |
| Pillot, C | 1 |
| Ortiz, J | 1 |
| Héron, A | 1 |
| Ridray, S | 1 |
| Schwartz, JC | 2 |
| Arrang, JM | 2 |
| Fischer, DA | 1 |
| Kuschinsky, K | 4 |
| Ross, BM | 1 |
| Brooks, RJ | 1 |
| Lee, M | 1 |
| Kalasinsky, KS | 1 |
| Vorce, SP | 1 |
| Seeman, M | 1 |
| Fletcher, PJ | 2 |
| Turenne, SD | 1 |
| Fregoso-Aguilar, T | 1 |
| Urióstegui, T | 1 |
| Zamudio, S | 1 |
| De la Cruz, F | 3 |
| Mayerhofer, A | 2 |
| Meyer, A | 1 |
| Kovar, KA | 2 |
| Suzuki, Y | 1 |
| Funakoshi, T | 1 |
| Chaki, S | 1 |
| Kawashima, N | 1 |
| Ogawa, S | 1 |
| Kumagai, T | 1 |
| Nakazato, A | 1 |
| Komurasaki, T | 1 |
| Okuyama, S | 1 |
| Naidu, PS | 3 |
| Esaki, T | 1 |
| Itoh, Y | 1 |
| Shimoji, K | 1 |
| Cook, M | 1 |
| Jehle, J | 1 |
| Sokoloff, L | 1 |
| Prinssen, EP | 3 |
| Colpaert, FC | 2 |
| Vorel, SR | 1 |
| Ashby, CR | 1 |
| Paul, M | 1 |
| Hayes, R | 1 |
| Hagan, JJ | 1 |
| Middlemiss, DN | 1 |
| Stemp, G | 1 |
| Gardner, EL | 1 |
| Pires, JG | 7 |
| Costa, PG | 2 |
| Saraiva, FP | 2 |
| Bonikovski, V | 2 |
| Futuro Neto, HA | 1 |
| Klein, A | 1 |
| Invernizzi, RW | 2 |
| Garavaglia, C | 1 |
| Samanin, R | 2 |
| Garris, PA | 1 |
| Budygin, EA | 1 |
| Phillips, PE | 1 |
| Venton, BJ | 1 |
| Robinson, DL | 1 |
| Bergstrom, BP | 1 |
| Rebec, GV | 3 |
| Wightman, RM | 1 |
| Karasawa, H | 1 |
| Taketo, MM | 1 |
| Matsui, M | 1 |
| Kehl, LJ | 1 |
| Hamamoto, DT | 1 |
| Wacnik, PW | 1 |
| Croft, DL | 1 |
| Norsted, BD | 1 |
| Wilcox, GL | 1 |
| Simone, DA | 1 |
| Rukoyatkina, NI | 1 |
| Gorbunova, LV | 3 |
| Lukomskaya, NY | 1 |
| Srinivasan, J | 2 |
| Banjaw, MY | 1 |
| Wardas, J | 4 |
| Pietraszek, M | 3 |
| Dziedzicka-Wasylewska, M | 1 |
| Nakai, S | 1 |
| Hirose, T | 1 |
| Imaoka, T | 1 |
| Okazaki, H | 1 |
| Miwa, T | 2 |
| Nakai, M | 2 |
| Yamada, S | 1 |
| Dunn, B | 1 |
| Burris, KD | 1 |
| Molinoff, PB | 1 |
| Altar, CA | 1 |
| Heredia-López, F | 1 |
| Darbaky, Y | 1 |
| Forni, C | 1 |
| Baunez, C | 1 |
| Marchese, G | 3 |
| Casti, P | 3 |
| Ruiu, S | 3 |
| Saba, P | 1 |
| Sanna, A | 1 |
| Casu, G | 2 |
| Pani, L | 3 |
| BOISSIER, JR | 2 |
| SIMON, P | 2 |
| Boules, M | 3 |
| McMahon, B | 2 |
| Wang, R | 1 |
| Warrington, L | 2 |
| Stewart, J | 2 |
| Yerbury, S | 1 |
| Fauq, A | 3 |
| McCormick, D | 2 |
| Richelson, E | 3 |
| Singh, KP | 1 |
| Sanyal, AK | 1 |
| Frank, ST | 2 |
| Park, WK | 1 |
| Jeong, D | 1 |
| Yun, CW | 1 |
| Lee, S | 1 |
| Cho, H | 1 |
| Kim, GD | 1 |
| Koh, HY | 1 |
| Pae, AN | 1 |
| Cho, YS | 1 |
| Choi, KI | 1 |
| Jung, JY | 1 |
| Jung, SH | 1 |
| Kong, JY | 1 |
| Ethier, I | 1 |
| Beaudry, G | 1 |
| Milbrandt, J | 1 |
| Rouillard, C | 1 |
| Lévesque, D | 1 |
| Sevak, RJ | 2 |
| France, CP | 2 |
| Bartholini, F | 1 |
| Casu, MA | 1 |
| Congeddu, E | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Mutoh, S | 1 |
| Levant, B | 1 |
| Radel, JD | 1 |
| Carlson, SE | 1 |
| Yanahashi, S | 1 |
| Hashimoto, K | 1 |
| Hattori, K | 2 |
| Yuasa, S | 2 |
| Iyo, M | 2 |
| Tort, AB | 2 |
| Dall'Igna, OP | 2 |
| de Oliveira, RV | 1 |
| Mantese, CE | 1 |
| Fett, P | 1 |
| Gomes, MW | 1 |
| Schuh, J | 1 |
| Souza, DO | 2 |
| Lara, DR | 3 |
| Assié, MB | 1 |
| Cosi, C | 1 |
| Dagaev, SG | 1 |
| Fil'ko, OA | 1 |
| Kubarskaya, LG | 1 |
| Khrabrova, AV | 1 |
| Mukovskii, LA | 1 |
| Glukhova, RI | 1 |
| Sanotskii, VI | 1 |
| Dolgo-Saburov, VB | 1 |
| Nakazono, M | 1 |
| Hasegawa, S | 1 |
| Yamamoto, T | 1 |
| Zaitsu, K | 1 |
| Haleem, MA | 2 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Lazzarini, M | 1 |
| Salum, C | 1 |
| Santos, KC | 1 |
| Santos, CA | 1 |
| de Oliveira, RM | 1 |
| Ossowska, K | 7 |
| Wolfarth, S | 8 |
| Pilc, A | 3 |
| Narkevich, VB | 2 |
| Mikoyan, VD | 1 |
| Bashkatova, VG | 1 |
| Hadden, MK | 1 |
| Orwig, KS | 1 |
| Kokko, KP | 1 |
| Mazella, J | 1 |
| Dix, TA | 1 |
| Fontana, L | 1 |
| Souza, AS | 1 |
| Oliveira, RM | 1 |
| Futuro-Neto, HA | 6 |
| Natesan, S | 2 |
| Reckless, GE | 2 |
| Kapur, S | 3 |
| Uchino, S | 1 |
| Isosaka, T | 1 |
| Maekawa, M | 1 |
| Sato, T | 1 |
| Kohsaka, S | 1 |
| Yagi, T | 1 |
| Kumar, A | 1 |
| Ali, O | 1 |
| Kamil, N | 1 |
| Obaid, R | 1 |
| Ahmed, SW | 1 |
| Erkent, U | 1 |
| Iskit, AB | 1 |
| Onur, R | 1 |
| Ilhan, M | 1 |
| Dekundy, A | 1 |
| Schaefer, D | 1 |
| Danysz, W | 3 |
| Zazpe, A | 1 |
| Artaiz, I | 1 |
| Innerárity, A | 1 |
| Del Olmo, E | 1 |
| Castro, E | 1 |
| Labeaga, L | 1 |
| Pazos, A | 1 |
| Orjales, A | 1 |
| Kuter, K | 1 |
| Wiker, C | 1 |
| Siuciak, JA | 1 |
| Chapin, DS | 1 |
| Harms, JF | 1 |
| Lebel, LA | 1 |
| McCarthy, SA | 1 |
| Chambers, L | 1 |
| Shrikhande, A | 1 |
| Wong, S | 1 |
| Menniti, FS | 2 |
| Schmidt, CJ | 1 |
| Uma Devi, P | 1 |
| Ali, A | 1 |
| Vohora, D | 1 |
| Kim, HS | 1 |
| Song, M | 1 |
| Yumkham, S | 1 |
| Choi, JH | 1 |
| Lee, T | 1 |
| Kwon, J | 1 |
| Lee, SJ | 1 |
| Kim, JI | 1 |
| Lee, KW | 1 |
| Han, PL | 1 |
| Shin, SW | 1 |
| Baik, JH | 2 |
| Kim, YS | 1 |
| Ryu, SH | 1 |
| Suh, PG | 1 |
| Kanes, SJ | 2 |
| Tokarczyk, J | 1 |
| Siegel, SJ | 1 |
| Bilker, W | 1 |
| Abel, T | 1 |
| Kelly, MP | 1 |
| Barlow, KB | 1 |
| Samad, N | 1 |
| Gardell, LR | 1 |
| Pounds, L | 1 |
| Johnson, RW | 1 |
| Barido, R | 1 |
| Anderson, GT | 1 |
| Dyssegaard, A | 1 |
| Brunmark, P | 1 |
| Tabatabaei, A | 1 |
| Bonhaus, DW | 1 |
| Sibille, P | 1 |
| Brabet, I | 1 |
| Valenti, O | 1 |
| Oueslati, N | 1 |
| Gaven, F | 1 |
| Bertrand, HO | 1 |
| Neyton, J | 1 |
| Marino, MJ | 2 |
| Acher, FC | 1 |
| Nowakowska, E | 1 |
| Kus, K | 1 |
| Czubak, A | 1 |
| Glowacka, D | 1 |
| Matschay, A | 1 |
| Gyertyán, I | 1 |
| Sághy, K | 1 |
| Rasmussen, K | 1 |
| Hsu, MA | 1 |
| Noone, S | 1 |
| Johnson, BG | 1 |
| Thompson, LK | 1 |
| Hemrick-Luecke, SK | 1 |
| Hofstetter, JR | 1 |
| Hitzemann, RJ | 3 |
| Belknap, JK | 1 |
| McWeeney, SK | 1 |
| Mayeda, AR | 1 |
| Jadhav, JH | 4 |
| Arjuman, A | 2 |
| Nandini, M | 1 |
| Lee, J | 1 |
| Rushlow, WJ | 1 |
| Rajakumar, N | 1 |
| Leite, JV | 1 |
| Moreira, FA | 1 |
| Dorababu, P | 1 |
| Chakradhar Rao, U | 1 |
| Mohan, L | 1 |
| Rueter, JK | 2 |
| Castro-Palomino, JC | 2 |
| Prat, M | 2 |
| Gual, S | 2 |
| Perez-Costas, E | 1 |
| Guidetti, P | 1 |
| Melendez-Ferro, M | 1 |
| Kelley, JJ | 1 |
| Roberts, RC | 1 |
| Pissios, P | 1 |
| Frank, L | 1 |
| Kennedy, AR | 1 |
| Porter, DR | 1 |
| Marino, FE | 1 |
| Liu, FF | 1 |
| Pothos, EN | 1 |
| Maratos-Flier, E | 1 |
| Owolabi, AR | 1 |
| Akanmu, MA | 1 |
| Ukponmwan, OE | 1 |
| Agovic, MS | 1 |
| Yablonsky-Alter, E | 2 |
| Lidsky, TI | 2 |
| Banerjee, SP | 2 |
| Stille, G | 3 |
| Zetterström, T | 1 |
| Sharp, T | 1 |
| Ungerstedt, U | 3 |
| Georgiev, VP | 1 |
| Klousha, VE | 1 |
| Petkov, VD | 2 |
| Markovska, VL | 1 |
| Svirskis, SV | 1 |
| Mountsinietse, RK | 1 |
| Anouans, ZE | 1 |
| Zetler, G | 8 |
| Reavill, C | 3 |
| Jenner, P | 2 |
| Marsden, CD | 3 |
| Val'dman, AV | 1 |
| Kozlovskaia, MM | 1 |
| Klusha, VE | 1 |
| Svirskis, ShV | 1 |
| Lloyd, KG | 8 |
| Worms, P | 8 |
| McMillen, BA | 5 |
| German, DC | 1 |
| Sanghere, MK | 1 |
| Warnack, W | 1 |
| Shore, PA | 2 |
| Bekemeier, H | 1 |
| Krause, E | 1 |
| Chiu, S | 1 |
| Paulose, CS | 1 |
| Dawbarn, D | 1 |
| Pycock, C | 2 |
| Bhargava, HN | 1 |
| Arnt, J | 2 |
| Christensen, AV | 1 |
| Hyttel, J | 1 |
| Barghon, R | 1 |
| Protais, P | 1 |
| Colboc, O | 1 |
| Costentin, J | 2 |
| Shibuya, T | 1 |
| Nishimori, T | 1 |
| Matsuda, H | 1 |
| Chen, PC | 1 |
| Cohen, SL | 1 |
| Knight, M | 1 |
| Tamminga, CA | 1 |
| Chase, TN | 2 |
| Garattini, S | 2 |
| Caccia, S | 1 |
| Bianchetti, G | 1 |
| Morselli, PL | 1 |
| McDonald, CC | 1 |
| Costall, B | 12 |
| Dannenburg, WN | 1 |
| Johnson, DN | 1 |
| Naylor, RJ | 12 |
| Gelman, J | 1 |
| Alloway, KD | 2 |
| Bashore, TR | 1 |
| Malec, D | 2 |
| Langwiński, R | 2 |
| Hall, H | 1 |
| Köhler, C | 2 |
| Magnusson, O | 2 |
| Lindbom, LO | 1 |
| Angeby, K | 1 |
| Bacopoulos, NG | 1 |
| Vasar, EE | 1 |
| Maĭmets, MO | 1 |
| Riago, LK | 1 |
| Nurk, AM | 3 |
| Allikmets, LKh | 3 |
| Vekshina, NL | 1 |
| Stanishevskaia, AS | 1 |
| Speciale, C | 1 |
| Ferrara, N | 1 |
| Sortino, MA | 1 |
| Giammona, G | 3 |
| Bernardini, R | 2 |
| De Simone, D | 3 |
| Marano, P | 1 |
| Mjörndal, T | 1 |
| Persson, SA | 1 |
| Klemm, WR | 4 |
| Crocker, AD | 2 |
| Overstreet, DH | 2 |
| Nandal, NV | 1 |
| Burte, NP | 1 |
| Chandorkar, AG | 4 |
| Sanberg, PR | 12 |
| Pevsner, J | 2 |
| Coyle, JT | 2 |
| Roussinov, K | 1 |
| Georgiev, V | 1 |
| Petkov, V | 1 |
| Lazarova, M | 1 |
| Petkova, B | 2 |
| Shopova, S | 1 |
| Markovska, V | 3 |
| Getova, D | 2 |
| Draganova, S | 1 |
| Xu, J | 1 |
| Jin, GZ | 2 |
| Yu, LP | 1 |
| Liu, XJ | 1 |
| Wang, XL | 1 |
| Hong, GX | 1 |
| Avrutskiĭ, GIa | 1 |
| Neduva, AA | 2 |
| Zharkovskiĭ, AM | 4 |
| Beliakov, AV | 2 |
| Pizzolato, G | 3 |
| Soncrant, TT | 3 |
| Rapoport, SI | 3 |
| Hartgraves, SL | 1 |
| Kelly, PH | 1 |
| McKeon, TW | 1 |
| Lorden, JF | 1 |
| Oltmans, GA | 1 |
| Beales, M | 1 |
| Walkley, SU | 1 |
| Matvienko, OA | 2 |
| Vamvakidès, A | 5 |
| Kelly, ME | 1 |
| Wachtel, H | 2 |
| Kehr, W | 1 |
| Sauer, G | 1 |
| De Ryck, M | 2 |
| Teitelbaum, P | 9 |
| Clementi, G | 2 |
| Patti, F | 3 |
| Prato, A | 2 |
| De Giorgio, RM | 1 |
| Scapagnini, U | 2 |
| Rampello, L | 1 |
| Reggio, A | 2 |
| Gallitto, G | 1 |
| Feigenbaum, JJ | 1 |
| Yanai, J | 1 |
| Moon, BH | 1 |
| Klawans, HL | 1 |
| Toru, M | 2 |
| Spear, LP | 2 |
| Shalaby, IA | 2 |
| Brick, J | 1 |
| Campbell, A | 5 |
| Baldessarini, RJ | 5 |
| Dorow, R | 1 |
| Kolasiewicz, W | 2 |
| Harasiewicz, A | 1 |
| Melzacka, M | 2 |
| Turski, W | 1 |
| Czuczwar, SJ | 1 |
| Turski, L | 2 |
| Kleinrok, Z | 7 |
| Herschel, M | 2 |
| Sommer, B | 1 |
| Madsen, JR | 1 |
| Cohen, BM | 2 |
| Poulos, CX | 1 |
| Hinson, R | 1 |
| Kaakkola, S | 3 |
| Lehtosalo, J | 1 |
| Laitinen, LA | 1 |
| Richardson, JS | 1 |
| Richardson, AK | 1 |
| Murai, S | 2 |
| Itoh, T | 2 |
| Kolasa, K | 2 |
| Rajtar, G | 1 |
| Morelli, M | 2 |
| Porceddu, ML | 1 |
| Imperato, A | 1 |
| Di Chiara, G | 2 |
| Banning, JW | 1 |
| Uretsky, NJ | 1 |
| Patil, PN | 1 |
| Beal, JL | 1 |
| Wallnau, LB | 2 |
| Schallert, T | 3 |
| Scatton, B | 1 |
| Zivkovic, B | 1 |
| Dedek, J | 1 |
| Dunstan, R | 1 |
| Broekkamp, CL | 4 |
| Shipley, JE | 1 |
| Rowland, N | 1 |
| Antelman, SM | 4 |
| Buggy, J | 1 |
| Edwards, DJ | 4 |
| Shapiro, AP | 1 |
| Bordash, GD | 1 |
| Corso, P | 1 |
| Myslobodsky, MS | 1 |
| Mintz, M | 1 |
| Kajiyama, H | 1 |
| Nomura, Y | 1 |
| Pisa, M | 1 |
| Fibiger, HC | 3 |
| Condorelli, DF | 1 |
| Maccagnano, C | 1 |
| Panico, AM | 1 |
| Tigano, G | 1 |
| Jones, DL | 1 |
| Berg, SL | 1 |
| Dorris, RL | 4 |
| Dill, RE | 2 |
| Di Paolo, T | 1 |
| Poyet, P | 1 |
| Labrie, F | 1 |
| Saller, CF | 1 |
| Kopin, IJ | 1 |
| Ikeda, H | 2 |
| Zarkovsky, AM | 1 |
| Rägo, LK | 1 |
| Allikmets, LH | 1 |
| Yamada, K | 3 |
| Furukawa, T | 3 |
| Bowers, MB | 1 |
| Rozitis, A | 1 |
| Asin, KE | 3 |
| Wirtshafter, D | 2 |
| Fujii, T | 1 |
| Elazar, Z | 4 |
| Peleg, N | 1 |
| Paz, M | 4 |
| Ring, G | 1 |
| Verma, A | 2 |
| Borlongan, CV | 2 |
| Martinez, R | 1 |
| Shytle, RD | 2 |
| Freeman, TB | 1 |
| Cahill, DW | 4 |
| Henderson, MG | 1 |
| Titkov, ES | 2 |
| Karmanova, IG | 1 |
| Sandoval, MR | 1 |
| Schneider, JS | 1 |
| Zuck, LG | 1 |
| Minematsu, N | 1 |
| Consolo, S | 1 |
| Costi, P | 1 |
| Zecca, L | 1 |
| Hyde, TM | 2 |
| Egan, MF | 2 |
| Wing, LL | 1 |
| Wyatt, RJ | 1 |
| Weinberger, DR | 3 |
| Kleinman, JE | 1 |
| Silva, SR | 4 |
| Delfs, JM | 1 |
| Anegawa, NJ | 1 |
| Chesselet, MF | 1 |
| Barrett, JE | 1 |
| Corbett, R | 1 |
| Hartman, H | 1 |
| Kerman, LL | 1 |
| Woods, AT | 1 |
| Strupczewski, JT | 1 |
| Helsley, GC | 1 |
| Conway, PC | 1 |
| Kikumoto, O | 1 |
| Okamoto, Y | 1 |
| Hayakawa, H | 1 |
| Yokota, N | 1 |
| Kawai, K | 1 |
| Motohashi, N | 1 |
| Yamawaki, S | 1 |
| Chandrashekhar, SM | 1 |
| Chakrabarti, A | 2 |
| Garg, SK | 1 |
| Sebens, JB | 1 |
| Koch, T | 1 |
| Ter Horst, GJ | 1 |
| Korf, J | 5 |
| Ushijima, I | 6 |
| Mizuki, Y | 6 |
| Yamada, M | 5 |
| Juszkiewicz, M | 2 |
| Chodkowska, A | 2 |
| Burzynski, SR | 2 |
| Feldo, M | 1 |
| Majewska, B | 1 |
| Kretschmer, BD | 5 |
| Jørgensen, HA | 1 |
| Andreassen, OA | 1 |
| Hole, K | 1 |
| Winterscheid, B | 1 |
| Kinoshita, H | 2 |
| Hasegawa, T | 2 |
| Katsumata, Y | 1 |
| Kameyama, T | 3 |
| Yamamoto, I | 2 |
| Nabeshima, T | 3 |
| Nazarova, GA | 1 |
| Zolotov, NN | 1 |
| Pozdnev, VF | 1 |
| Raevskiĭ, KS | 2 |
| Rigon, AR | 1 |
| Reis, M | 1 |
| Takahashi, RN | 2 |
| Hitzemann, BA | 1 |
| Suemaru, K | 1 |
| Gomita, Y | 1 |
| Furuno, K | 1 |
| Araki, Y | 1 |
| Lipska, BK | 2 |
| Zadow, B | 2 |
| Osborne, PG | 2 |
| O'Connor, WT | 2 |
| Beck, O | 1 |
| Yoshida, Y | 2 |
| Ono, T | 2 |
| Kawano, K | 1 |
| Miyagishi, T | 2 |
| Hauber, W | 4 |
| Waldenmeier, MT | 1 |
| Tucci, S | 1 |
| Fernandez, R | 1 |
| Baptista, T | 1 |
| Murzi, E | 1 |
| Hernandez, L | 1 |
| Himori, N | 2 |
| Krisch, I | 1 |
| Bole-Vunduk, B | 1 |
| Pepelnak, M | 1 |
| Lavric, B | 1 |
| Ocvirk, A | 1 |
| Budihna, MV | 1 |
| Sket, D | 1 |
| Hitzemann, B | 2 |
| Dains, K | 3 |
| Kanes, S | 2 |
| Rosén, L | 1 |
| Bergman, J | 1 |
| Kanda, T | 1 |
| Shiozaki, S | 1 |
| Shimada, J | 1 |
| Suzuki, F | 1 |
| Nakamura, J | 1 |
| Subarnas, A | 1 |
| Tadano, T | 1 |
| Oshima, Y | 3 |
| Kisara, K | 1 |
| Ohizumi, Y | 1 |
| Andersen, R | 1 |
| Lundström, J | 1 |
| Nilsson, LB | 1 |
| Tanaka, Y | 1 |
| Kurasawa, M | 1 |
| Akaike, N | 1 |
| Verhagen-Kamerbeek, WD | 1 |
| Hazemeijer, I | 1 |
| Lakke, JP | 1 |
| Conceição, IM | 1 |
| Frussa-Filho, R | 3 |
| Emerich, DF | 3 |
| el-Etri, MM | 1 |
| Shipley, MT | 1 |
| Zanol, MD | 2 |
| Norman, AB | 5 |
| Ramage, AG | 1 |
| Moore, NA | 1 |
| Blackman, A | 1 |
| Awere, S | 1 |
| Leander, JD | 1 |
| Arushanian, EB | 5 |
| Ovanesov, KB | 2 |
| Popov, AV | 2 |
| Popova, AP | 5 |
| Shchetinin, EV | 2 |
| Neal-Beliveau, BS | 1 |
| Joyce, JN | 1 |
| Lucki, I | 1 |
| Hussain, G | 1 |
| Meltzer, HY | 2 |
| Meyer, ME | 1 |
| Cottrell, GA | 1 |
| Van Hartesveldt, C | 1 |
| Johnson, SK | 1 |
| Fisher, H | 1 |
| Wagner, GC | 1 |
| Marin, C | 1 |
| Parashos, SA | 1 |
| Kapitzoglou-Logothetis, V | 1 |
| Peppe, A | 1 |
| Mlynarczyk, M | 1 |
| Ferguson, JN | 1 |
| Braun, AR | 1 |
| Ishizumi, K | 1 |
| Kojima, A | 1 |
| Antoku, F | 1 |
| Saji, I | 1 |
| Yoshigi, M | 1 |
| Cipp, L | 3 |
| Gatley, J | 1 |
| Rasmussen, E | 3 |
| Sanderson, S | 1 |
| Silverman, M | 1 |
| Andersen, HL | 1 |
| Kilpatrick, IC | 2 |
| Chopde, CT | 3 |
| Hote, MS | 1 |
| Mandhane, SN | 3 |
| Muthal, AV | 1 |
| Gaĭnetdinov, RR | 1 |
| Münkle, M | 1 |
| Patacchioli, FR | 1 |
| Di Grezia, R | 1 |
| Angelucci, L | 1 |
| Karolewicz, B | 1 |
| Antkiewicz-Michaluk, L | 2 |
| Michaluk, J | 2 |
| Vetulani, J | 3 |
| McAllister, KH | 1 |
| Miwa, H | 1 |
| Fuwa, T | 1 |
| Yokochi, M | 1 |
| Nishi, K | 1 |
| Mizuno, Y | 1 |
| Braszko, JJ | 1 |
| Winnicka, MM | 1 |
| Wiśniewski, K | 2 |
| Roos, C | 1 |
| Ziegler, H | 1 |
| Baĭchurina, AZ | 1 |
| Garaev, RS | 1 |
| Matsuno, K | 1 |
| Senda, T | 1 |
| Kobayashi, T | 3 |
| Okamoto, K | 1 |
| Nakata, K | 1 |
| Mita, S | 1 |
| Khanzode, SD | 1 |
| Mahakalkar, SM | 1 |
| Belorkar, NR | 1 |
| Kharkar, VT | 1 |
| Manekar, MS | 1 |
| Millan, MJ | 1 |
| Gressier, H | 1 |
| Brocco, M | 1 |
| Maj, J | 4 |
| Rogóz, Z | 2 |
| Skuza, G | 2 |
| Kołodziejczyk, K | 1 |
| Singh, J | 1 |
| Gupta, MC | 1 |
| Fdez Espejo, E | 1 |
| Gil, E | 1 |
| Lucas, G | 1 |
| Bonhomme, N | 1 |
| De Deurwaerdère, P | 2 |
| Le Moal, M | 1 |
| Spampinato, U | 3 |
| Morita, S | 2 |
| Ghosh, AK | 1 |
| Kawano, M | 1 |
| Kaneyuki, H | 1 |
| Suetsugi, M | 3 |
| Usami, K | 2 |
| Hirano, H | 1 |
| Aloe, L | 1 |
| Iannitelli, A | 1 |
| Bersani, G | 1 |
| Alleva, E | 1 |
| Angelucci, F | 1 |
| Maselli, P | 1 |
| Manni, L | 1 |
| Kaur, S | 1 |
| Ozer, H | 1 |
| Starr, M | 1 |
| Takeshita, M | 2 |
| Miura, M | 1 |
| Hongo, T | 1 |
| Ohkubo, T | 1 |
| Sugawara, K | 1 |
| Kosaka, K | 1 |
| Takeshita, Y | 1 |
| Araki, T | 3 |
| Rocha, JB | 1 |
| Santos, JE | 1 |
| Rocha, LK | 1 |
| Kleinpaul, ER | 1 |
| Sachdev, PS | 1 |
| Saharov, T | 1 |
| Adams, MR | 1 |
| Brandon, EP | 1 |
| Chartoff, EH | 2 |
| Idzerda, RL | 1 |
| Dorsa, DM | 3 |
| McKnight, GS | 1 |
| Richter, A | 1 |
| Löscher, W | 1 |
| McCaughran, J | 2 |
| Mahjubi, E | 1 |
| Decena, E | 1 |
| Itoyama, Y | 2 |
| Ohta, T | 1 |
| Zalewska, A | 1 |
| Krzaścik, P | 1 |
| Kostowski, W | 4 |
| Berendsen, HH | 2 |
| Pinder, RM | 1 |
| Speiser, Z | 1 |
| Levy, R | 1 |
| Cohen, S | 1 |
| Khisti, RT | 1 |
| Sun, YJ | 1 |
| Suzuki, M | 1 |
| Kurachi, T | 1 |
| Murata, M | 1 |
| Kurachi, M | 1 |
| Costa-Campos, L | 1 |
| Nunes, DS | 1 |
| Elisabetsky, E | 1 |
| Davidkova, G | 1 |
| Zhou, LW | 1 |
| Morabito, M | 1 |
| Zhang, SP | 1 |
| Weiss, B | 1 |
| Akimoto, T | 1 |
| Kratzer, U | 1 |
| Fowler, SC | 2 |
| Liou, JR | 1 |
| Bourson, A | 1 |
| Boess, FG | 1 |
| Bös, M | 1 |
| Sleight, AJ | 1 |
| Morisset, S | 1 |
| Sahm, UG | 1 |
| Traiffort, E | 1 |
| Tardivel-Lacombe, J | 1 |
| Johnson, SA | 1 |
| Luu, NT | 1 |
| Herbst, TA | 1 |
| Knapp, R | 1 |
| Lutz, D | 1 |
| Arai, A | 1 |
| Rogers, GA | 1 |
| Lynch, G | 1 |
| Kettle, A | 1 |
| Holland, V | 1 |
| Riley, G | 1 |
| Blackburn, TP | 1 |
| Karcz-Kubicha, M | 1 |
| Lorenz, B | 1 |
| Young, KA | 2 |
| Richter, JT | 1 |
| Hicks, PB | 3 |
| Ward, RP | 2 |
| Schulze, G | 1 |
| Coper, H | 1 |
| Amorim, SC | 1 |
| Ribeiro, CA | 1 |
| Young, CD | 1 |
| Deutch, AY | 2 |
| Shapovalova, VO | 1 |
| Mykhaĭlov, VS | 1 |
| Shapovalov, VV | 1 |
| Costain, WJ | 1 |
| Buckley, AT | 1 |
| Evans, MC | 1 |
| Johnson, RL | 1 |
| Sonehara, K | 1 |
| Mita, N | 1 |
| Nagase, H | 1 |
| Iizuka, K | 1 |
| Sakai, K | 2 |
| Jelovac, N | 1 |
| Rucman, R | 1 |
| Petek, M | 1 |
| Marovic, A | 1 |
| Perovic, D | 1 |
| Mise, S | 1 |
| Turkovic, B | 1 |
| Dodig, G | 1 |
| Miklic, P | 1 |
| Buljat, G | 1 |
| Prkacin, I | 1 |
| Caronti, B | 1 |
| Passarelli, F | 1 |
| Calderaro, C | 1 |
| Palladini, G | 1 |
| Pontieri, FE | 1 |
| Tzschentke, TM | 1 |
| Srinivas, P | 1 |
| Subramanian, AR | 1 |
| Brust, P | 1 |
| Raghavan, SA | 1 |
| Rangisetty, JB | 1 |
| Gupta, CN | 1 |
| Sridhar, N | 1 |
| Veeranjaneyulu, A | 1 |
| Parimoo, P | 1 |
| Chinen, CC | 1 |
| Geurts, M | 1 |
| Nöldner, M | 1 |
| Chatterjee, SS | 1 |
| Cusack, B | 1 |
| Tyler, BM | 1 |
| McCormick, DJ | 1 |
| Boulay, D | 1 |
| Oblin, A | 1 |
| Sanger, DJ | 1 |
| Schoemaker, H | 1 |
| Perrault, G | 1 |
| Sieklucka-Dziuba, M | 2 |
| Gustaw, K | 1 |
| Dziuba, J | 2 |
| Patyra, H | 1 |
| Field, EF | 1 |
| Pellis, SM | 7 |
| Patel, NV | 1 |
| Wittmann, M | 1 |
| Rouse, ST | 1 |
| Awad, H | 1 |
| Levey, AI | 1 |
| Drinkenburg, WH | 1 |
| Keith, AB | 1 |
| Sahgal, A | 1 |
| Andrews, JS | 1 |
| Steece-Collier, K | 1 |
| Chambers, LK | 1 |
| Jaw-Tsai, SS | 1 |
| Greenamyre, JT | 1 |
| Sawada, Y | 1 |
| Nasu, R | 1 |
| Matsuo, H | 1 |
| Ohtani, H | 1 |
| Joca, SR | 1 |
| Skalisz, LL | 1 |
| Beijamini, V | 1 |
| Vital, MA | 1 |
| Andreatini, R | 1 |
| Bazyan, AS | 1 |
| Getsova, VM | 1 |
| Orlova, NV | 1 |
| Rukoiatkina, NI | 2 |
| Lukomskaia, NIa | 2 |
| Romańska, I | 1 |
| Papla, I | 1 |
| Wang, Y | 1 |
| Xu, R | 1 |
| Sasaoka, T | 1 |
| Tonegawa, S | 1 |
| Kung, MP | 1 |
| Sankoorikal, EB | 1 |
| Rougé-Pont, F | 1 |
| Picetti, R | 1 |
| Dierich, A | 1 |
| LeMeur, M | 1 |
| Piazza, PV | 1 |
| Borrelli, E | 1 |
| Clarke, PB | 1 |
| Murphy, CA | 1 |
| Feldon, J | 1 |
| Betancur, C | 1 |
| Lépée-Lorgeoux, I | 1 |
| Cazillis, M | 1 |
| Accili, D | 1 |
| Fuchs, S | 1 |
| Rostène, W | 1 |
| Aoki, T | 1 |
| Watanabe, Y | 1 |
| Demarest, K | 1 |
| Koyner, J | 1 |
| Patel, N | 1 |
| Chen, JF | 1 |
| Moratalla, R | 1 |
| Impagnatiello, F | 1 |
| Grandy, DK | 1 |
| Cuellar, B | 1 |
| Rubinstein, M | 1 |
| Beilstein, MA | 1 |
| Hackett, E | 1 |
| Fink, JS | 1 |
| Low, MJ | 1 |
| Ongini, E | 1 |
| Schwarzschild, MA | 1 |
| El Yacoubi, M | 1 |
| Ledent, C | 1 |
| Parmentier, M | 1 |
| Vaugeois, JM | 1 |
| Mizutani, H | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Mizugaki, M | 1 |
| Wadenberg, MG | 1 |
| Browning, JL | 1 |
| Hemsley, KM | 1 |
| Dobner, PR | 1 |
| Fadel, J | 1 |
| Deitemeyer, N | 1 |
| Carraway, RE | 1 |
| Viyoch, J | 1 |
| Ohdo, S | 1 |
| Yukawa, E | 1 |
| Higuchi, S | 1 |
| Zarcone, TJ | 1 |
| Vorontsova, E | 1 |
| Wierońska, J | 1 |
| Hashimoto, H | 1 |
| Shintani, N | 1 |
| Tanaka, K | 1 |
| Mori, W | 1 |
| Hirose, M | 1 |
| Matsuda, T | 1 |
| Sakaue, M | 1 |
| Miyazaki, J | 1 |
| Niwa, H | 1 |
| Tashiro, F | 1 |
| Yamamoto, K | 1 |
| Koga, K | 1 |
| Tomimoto, S | 1 |
| Kunugi, A | 1 |
| Suetake, S | 1 |
| Baba, A | 1 |
| Newman, MB | 1 |
| Manresa, JJ | 1 |
| Potts, SE | 1 |
| Alvarez, F | 1 |
| Kansal, DK | 1 |
| Cervo, L | 2 |
| Stinus, L | 1 |
| McClelland, RA | 1 |
| VanderSpek, SC | 1 |
| Baker, G | 1 |
| Nobrega, J | 1 |
| Zipursky, RB | 1 |
| Seeman, P | 4 |
| Erzin-Waters, C | 1 |
| Muller, P | 1 |
| Cheney, DL | 1 |
| Zsilla, G | 1 |
| Costa, E | 1 |
| Shibuya, M | 1 |
| Davidson, L | 1 |
| Hornykiewicz, O | 1 |
| Elliott, PN | 1 |
| Clow, A | 1 |
| Al-Shabibi, UM | 1 |
| Doggett, NS | 1 |
| Matsui, Y | 2 |
| Kamioka, T | 1 |
| Dessaigne, S | 1 |
| Scotto, AM | 1 |
| Guigues, M | 1 |
| Sano, K | 1 |
| Maeno, H | 1 |
| Pedigo, NW | 1 |
| Ling, NC | 1 |
| Ragan, P | 1 |
| Reisine, TD | 1 |
| Yamamura, HI | 1 |
| Bloss, JL | 1 |
| Singer, GH | 1 |
| Hui, SC | 2 |
| Metcalf, G | 1 |
| Moleman, P | 1 |
| Versluis, DJ | 1 |
| Bruinvels, J | 1 |
| Mason, ST | 1 |
| Roberts, DC | 1 |
| Deguchi, T | 1 |
| Bantutova, I | 1 |
| Brown, J | 1 |
| Handley, SL | 3 |
| Lal, H | 3 |
| Gianutsos, G | 1 |
| Puri, SK | 2 |
| Pieri, M | 1 |
| Schaffner, R | 1 |
| Pieri, L | 1 |
| Da Prada, M | 1 |
| Haefely, W | 1 |
| Mickley, GA | 1 |
| Teitelbaum, H | 1 |
| Ezrin-Waters, C | 2 |
| Kuczenski, R | 1 |
| Schmidt, D | 1 |
| Leith, N | 1 |
| Pycock, CJ | 2 |
| Jenner, PG | 1 |
| Massotti, M | 1 |
| Höllt, V | 1 |
| Czlonkowski, A | 3 |
| Herz, A | 1 |
| Honda, F | 1 |
| Satoh, Y | 1 |
| Shimomura, K | 1 |
| Satoh, H | 1 |
| Noguchi, H | 1 |
| Uchida, S | 1 |
| Kato, R | 1 |
| Ahtee, L | 1 |
| Ahlenius, S | 3 |
| Van Loon, GR | 1 |
| Kim, C | 1 |
| Cerbo, R | 1 |
| Carchedi, F | 1 |
| Casacchia, M | 1 |
| Meco, G | 1 |
| Kocur, J | 1 |
| Czarnecka, E | 1 |
| Kaminska, A | 1 |
| Wejman, I | 1 |
| De Montis, GM | 1 |
| Olianas, MC | 1 |
| Serra, G | 1 |
| Tagliamonte, A | 1 |
| Scheel-Krüger, J | 1 |
| Baez, LA | 1 |
| Burt, DK | 1 |
| Granneman, J | 1 |
| Shanklin, C | 1 |
| Epstein, PN | 1 |
| Altshuler, HL | 1 |
| Green, AR | 1 |
| Bloomfield, MR | 1 |
| Atterwill, CK | 2 |
| Costain, DW | 1 |
| Haglund, L | 1 |
| Angeby, T | 1 |
| Carter, CJ | 1 |
| Otter, MIa | 2 |
| Waldmeier, PC | 1 |
| Delini-Stula, AA | 1 |
| Willigens, MT | 2 |
| Langer, J | 1 |
| Seeber, U | 1 |
| Sontag, KH | 3 |
| Smiałowski, A | 1 |
| Rurak, A | 1 |
| Brand, U | 1 |
| Dittmann, EC | 1 |
| Menge, HG | 1 |
| Ito, K | 1 |
| Nurimoto, S | 1 |
| Shintomi, K | 2 |
| Kowa, Y | 1 |
| Yamamura, M | 1 |
| Ishida, R | 1 |
| Papeschi, R | 1 |
| Theiss, P | 1 |
| Ayhan, H | 1 |
| Uspenskiĭ, AE | 1 |
| Korobov, NV | 1 |
| Freye, E | 1 |
| Setler, P | 1 |
| Sarau, H | 1 |
| McKenzie, G | 1 |
| Stanley, ME | 1 |
| Glick, SD | 1 |
| Kääriäinen, I | 1 |
| Honma, T | 2 |
| Fukushima, H | 1 |
| Gajewska, S | 1 |
| Bidzinski, A | 1 |
| Hauptman, M | 1 |
| Ariyanayagam, AD | 1 |
| Binet, P | 1 |
| Miocque, M | 1 |
| Roux, M | 1 |
| Rinjard, P | 1 |
| Ueki, S | 4 |
| Fujiwara, M | 4 |
| Inoue, K | 1 |
| Kataoka, Y | 2 |
| Ibii, N | 1 |
| Janssen, PA | 5 |
| Niemegeers, CJ | 6 |
| Schellekens, KH | 2 |
| Lenaerts, FM | 2 |
| Wauquier, A | 2 |
| Prescott, WR | 1 |
| Gold, LH | 1 |
| Martin, BR | 1 |
| Otoboni, JR | 1 |
| Uema, FT | 1 |
| Volz, TL | 1 |
| Volz, L | 1 |
| Fujiwara, H | 2 |
| See, RE | 1 |
| Chapman, MA | 1 |
| Meshul, CK | 1 |
| Kaneko, M | 1 |
| Sato, K | 1 |
| Horikoshi, R | 1 |
| Yaginuma, M | 1 |
| Yaginuma, N | 1 |
| Shiragata, M | 1 |
| Kumashiro, H | 1 |
| Ono, N | 2 |
| Abiru, T | 2 |
| Sugiyama, K | 1 |
| Kamiya, H | 2 |
| Iwata, S | 2 |
| Izumi, K | 2 |
| Nomoto, M | 1 |
| Castelló, ME | 1 |
| Bolioli, B | 1 |
| Dajas, F | 1 |
| Kocan, D | 3 |
| Knopf, S | 3 |
| Caggiula, AR | 2 |
| Sagratella, S | 1 |
| Scotti de Carolis, A | 1 |
| Pèzzola, A | 1 |
| Popoli, P | 1 |
| Kizu, A | 1 |
| Fukushima, R | 1 |
| Häfner, H | 1 |
| Behrens, S | 1 |
| De Vry, J | 1 |
| Gattaz, WF | 1 |
| Schmidt, C | 1 |
| Gobaille, S | 1 |
| Hechler, V | 1 |
| Schmitt, M | 1 |
| Bourguignon, JJ | 1 |
| Maitre, M | 1 |
| Iakimovskiĭ, AF | 1 |
| Kiem, DT | 1 |
| Fekete, MI | 1 |
| Bartha, L | 1 |
| Nagy, G | 1 |
| Makara, GB | 1 |
| Meyer, D | 1 |
| Barry, H | 1 |
| Li, Q | 1 |
| Li, BH | 1 |
| Bier-Langing, CM | 1 |
| Zahniser, NR | 1 |
| Nagase, T | 1 |
| Hotta, K | 1 |
| Yamane, M | 1 |
| Omote, M | 1 |
| Mizusawa, H | 1 |
| Dijk, S | 1 |
| Krugers, HJ | 1 |
| McConville, BJ | 2 |
| Gonzalez, LP | 1 |
| Czachura, JF | 1 |
| Brewer, KW | 1 |
| Essig, EC | 1 |
| Lannes, B | 1 |
| Micheletti, G | 1 |
| Warter, JM | 1 |
| Kempf, E | 1 |
| Di Scala, G | 1 |
| Rao, KV | 2 |
| Puri, VN | 2 |
| el-Sawaf, HA | 1 |
| De Graaf, JS | 1 |
| van Delft, AM | 2 |
| Tepper, PG | 1 |
| Bohus, BG | 1 |
| Horn, AS | 1 |
| Karcz, M | 1 |
| Ganchrow, D | 1 |
| Rabinowitz, R | 1 |
| Paz, Z | 1 |
| Korczyn, AD | 1 |
| Scott, SM | 2 |
| Williams, HL | 1 |
| Saito, H | 1 |
| Abe, E | 1 |
| Kohori, I | 1 |
| Georgieva, JV | 1 |
| Kop, PB | 1 |
| Muley, MP | 1 |
| Mehta, AK | 1 |
| Ticku, MK | 1 |
| Barnes, DE | 1 |
| Robinson, B | 1 |
| Csernansky, JG | 1 |
| Bellows, EP | 1 |
| Bende, MM | 1 |
| Bapat, TR | 1 |
| Dorce, VA | 1 |
| Górniak, SL | 1 |
| de Souza-Spinosa, H | 1 |
| Ferré, S | 2 |
| Guix, T | 2 |
| Prat, G | 1 |
| Jane, F | 2 |
| Casas, M | 2 |
| Kinon, BJ | 1 |
| Kane, JM | 1 |
| Kerkman, DJ | 1 |
| Ackerman, M | 1 |
| Artman, LD | 1 |
| MacKenzie, RG | 1 |
| Johnson, MC | 1 |
| Bednarz, L | 1 |
| Montana, W | 1 |
| Stampfli, H | 1 |
| Kebabian, JW | 1 |
| Al-Khatib, IM | 1 |
| Weihmuller, FB | 1 |
| Hadjiconstantinou, M | 1 |
| Bruno, JP | 1 |
| Neff, NH | 1 |
| Kehayov, R | 1 |
| Kamburova, T | 1 |
| Lappalainen, J | 1 |
| Hietala, J | 1 |
| Syvälahti, E | 1 |
| Shimizu, T | 1 |
| Fukuda, T | 1 |
| Morrissey, TK | 1 |
| Pellis, VC | 3 |
| Brown, CG | 1 |
| Conybeare, G | 1 |
| Holland, CW | 1 |
| Jones, CA | 1 |
| Fogelson, HM | 1 |
| Manderscheid, PZ | 1 |
| Parker, KW | 1 |
| Blythe, MM | 1 |
| Klykylo, WM | 1 |
| Gao, XK | 1 |
| Song, B | 1 |
| Nordin, IC | 1 |
| Kádár, T | 2 |
| Penke, B | 2 |
| Kovács, K | 2 |
| Telegdy, G | 2 |
| Brus, R | 1 |
| Krzemiński, T | 1 |
| Juraszczyk, Z | 1 |
| Kurocok, A | 1 |
| Continsouza-Blanc, D | 1 |
| Hara, C | 2 |
| Kastin, AJ | 1 |
| Chen, YC | 3 |
| Sirkin, DW | 1 |
| Potegal, M | 1 |
| Kalda, EI | 1 |
| Erik, IuP | 1 |
| Ogawa, N | 1 |
| Yntema, OP | 1 |
| Shibata, K | 1 |
| Wambebe, C | 2 |
| Diwan, PK | 1 |
| Alvarez, FM | 1 |
| Davanzo, EA | 1 |
| Nuutila, J | 1 |
| Männistö, PT | 1 |
| Calderon, SF | 1 |
| Oosterloo, SK | 1 |
| Pichler, L | 1 |
| Kobinger, W | 1 |
| Sakurai, Y | 1 |
| Kiyota, Y | 1 |
| Shimazoe, T | 1 |
| Ohta, H | 2 |
| Shibata, S | 1 |
| Ellenbroek, B | 1 |
| Schwarz, M | 2 |
| Jaspers, R | 1 |
| Cools, A | 1 |
| Oishi, R | 1 |
| Yamaguchi, K | 1 |
| Enslen, M | 1 |
| Decarli, B | 1 |
| Anantharaman, K | 1 |
| Sokomba, E | 1 |
| Sukul, NC | 1 |
| Bala, SK | 1 |
| Bhattacharyya, B | 1 |
| de Graaf, CJ | 1 |
| Kan, JP | 2 |
| Wermuth, CG | 1 |
| Roncucci, R | 2 |
| Bizière, K | 2 |
| Barnes, JC | 1 |
| Barnes, NJ | 1 |
| Barnes, NM | 1 |
| Domeney, AM | 1 |
| Hoffman, DC | 1 |
| Cremens, MC | 1 |
| Kazandjian, A | 1 |
| Spyraki, C | 2 |
| Papadopoulou, Z | 1 |
| Sfikakis, A | 1 |
| Varonos, DD | 1 |
| Joseph, JA | 1 |
| Kandasamy, SB | 1 |
| Hunt, WA | 1 |
| Dalton, TK | 1 |
| Stevens, S | 1 |
| Saito, R | 1 |
| Matsushita, Y | 1 |
| Klockgether, T | 1 |
| Ahmad, Q | 1 |
| Merali, Z | 1 |
| Shmygina, EG | 1 |
| Nowak, K | 1 |
| Welsch-Kunze, S | 1 |
| Avdelidis, D | 1 |
| Amir, S | 1 |
| O'Brien, DP | 1 |
| Morato, GS | 1 |
| Olgiati, VR | 1 |
| Algeri, S | 1 |
| Stramentinoli, G | 1 |
| Hillegaart, V | 2 |
| Fowler, CJ | 1 |
| Hruska, RE | 3 |
| Girault, JA | 1 |
| Danguir, J | 1 |
| Savaki, HE | 1 |
| Glowinski, J | 1 |
| Besson, MJ | 1 |
| Perel, JM | 1 |
| Stiller, R | 1 |
| Hassan, MN | 1 |
| Reches, A | 1 |
| Kuhn, C | 1 |
| Higgins, D | 1 |
| Fahn, S | 1 |
| Mandel, P | 1 |
| Aizenstein, ML | 1 |
| Scavone, C | 1 |
| Steinschreiber, S | 1 |
| de-Lucia, R | 1 |
| Wolgin, DL | 1 |
| Chesire, RM | 1 |
| Centore, JM | 1 |
| White, LK | 1 |
| Larson, DM | 1 |
| Borda, L | 1 |
| Holloway, HW | 1 |
| Yurek, DM | 1 |
| Randall, PK | 1 |
| Coyle, S | 1 |
| Napier, TC | 1 |
| Breese, GR | 1 |
| Autuono, PG | 1 |
| Baumann, GH | 1 |
| Bürki, HR | 2 |
| Marsden, CA | 1 |
| Guldberg, HC | 1 |
| Gumulka, W | 1 |
| Przegaliński, E | 1 |
| Villeneuve, A | 1 |
| Larousse, C | 1 |
| Dresse, A | 1 |
| Pinchard, A | 1 |
| Schaper, WK | 1 |
| van Nueten, JM | 1 |
| Verbruggen, FJ | 3 |
| Andén, NE | 1 |
| Bédard, P | 1 |
| Sayers, AC | 1 |
| Kleinlogel, H | 1 |
| Beecham, IJ | 1 |
| Sasajima, K | 1 |
| Ono, K | 1 |
| Kitagawa, S | 1 |
| Inaba, S | 1 |
| Yamamoto, H | 1 |
| Lauener, H | 2 |
| Olley, JE | 4 |
| Asper, H | 1 |
| Baggiolini, M | 1 |
| Ruch, W | 1 |
| Thörner, R | 1 |
| Moller Nielsen, I | 1 |
| Fjalland, B | 1 |
| Pedersen, V | 1 |
| Nymark, M | 1 |
| Sowińska, H | 1 |
| Baran, L | 1 |
| Sarnek, J | 1 |
| Tseng, LF | 1 |
| Loh, HH | 1 |
| Kojima, M | 1 |
| Nose, T | 1 |
| Yoneda, N | 1 |
| Cools, AR | 1 |
| Delini-Stula, A | 1 |
| György, L | 1 |
| Pfeifer, KA | 1 |
| Hajtman, B | 1 |
| Loew, DM | 1 |
| Fog, RL | 1 |
| Randrup, A | 1 |
| Pakkenberg, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety. Double Blind and Randomized Clinical Trial Controlled With Alprazolam[NCT03702803] | Phase 2 | 122 participants (Anticipated) | Interventional | 2016-03-16 | Recruiting | ||
| Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease[NCT01341431] | Phase 2 | 50 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women[NCT01573637] | Phase 3 | 78 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for haloperidol and Anochlesia
| Article | Year |
|---|---|
Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Topics: Animals; Catalepsy; Disease Models, Animal; Haloperidol; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
[Regulation of dopaminergic neuronal activity by heart-type fatty acid binding protein in the brain].
Topics: Acetylcholine; Animals; Basal Ganglia Diseases; Brain; Catalepsy; Dopamine; Dopamine Antagonists; Fa | 2011 |
An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats.
Topics: Animals; Benzoates; Catalepsy; Corpus Striatum; Enkephalins; Excitatory Amino Acid Antagonists; Glut | 2007 |
Catalepsy induced by body pinch: relation to stress-induced analgesia.
Topics: Analgesia; Animals; Apomorphine; Catalepsy; Endorphins; Haloperidol; Mice; Naloxone; Pain; Receptors | 1986 |
2 trials available for haloperidol and Anochlesia
| Article | Year |
|---|---|
Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Basal Ganglia; Catalepsy; Dopamine | 1995 |
Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal.
Topics: Adolescent; Adult; Antipsychotic Agents; Arousal; Catalepsy; Enzyme-Linked Immunosorbent Assay; Halo | 1997 |
799 other studies available for haloperidol and Anochlesia
| Article | Year |
|---|---|
Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Butaclamol; Catalepsy; Conditioning, Psychologica | 1978 |
Psychotropic agents. 3. 4-(4-Substituted piperidinyl)-1-(4-fluorophenyl)-1-butanones with potent neuroleptic activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Butanones; Catalepsy; Humans; Lethal Dose 50; Male; Meth | 1978 |
Synthesis of 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole derivatives and their central nervous system activities.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Hu | 1979 |
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Molecular Structure; Piperazines; Pyri | 1992 |
Synthesis and biological evaluation of a series of substituted N-alkoxyimides and -amides as potential atypical antipsychotic agents.
Topics: Amides; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Chemical Phenomen | 1991 |
5-Piperazinylalkyl-2(3H)-oxazolones with neuroleptic activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Dogs; Indicators and Reag | 1989 |
Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8- triazaspiro[4.5]decan-4-ones as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cebus; Chemical Phen | 1985 |
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Binding, Competitive; Catalepsy; Cerebral Cortex; | 1986 |
Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzim idazolone derivatives.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzimidazoles; Brain; Catalepsy; Catt | 1987 |
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Body Temperature; Catalepsy; Hum | 1980 |
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Body Temperature; Catalepsy; Hum | 1980 |
Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzamides; Catalepsy; Humans; Rats; Stereotyped | 1981 |
Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Catalepsy; Chemical Phenom | 1982 |
Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding, Competitive; Catalepsy; Corpu | 1994 |
3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Brain; Catalepsy; Cloza | 1996 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Biological Avail | 1996 |
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydro | 1998 |
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Cerebral Cortex; Co | 1998 |
Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Cattle; Corpus Striatum; Dopamine Agen | 1998 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).
Topics: Administration, Oral; Animals; Antipsychotic Agents; Brain; Catalepsy; Cell Line; Chromones; Drug Ev | 1998 |
New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain; Catalepsy; CHO Cells; Cricetinae; Dopamine Antag | 1999 |
Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical an
Topics: Animals; Antipsychotic Agents; Aorta, Thoracic; Brain; Catalepsy; Cattle; Dopamine Agents; In Vitro | 1999 |
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dioxanes; Dopamine Antagonists; Drug Evaluation, Pr | 1999 |
Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Butyrophenones; Catalepsy; Ca | 2000 |
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; C | 2002 |
Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation.
Topics: Amphetamine; Animals; Antipsychotic Agents; Binding, Competitive; Catalepsy; Central Nervous System | 2002 |
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Topics: Amines; Animals; Antidepressive Agents; Benzodiazepines; Catalepsy; Cell Line; Dopamine Agents; Fema | 2002 |
The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+.
Topics: Acetyl-CoA Carboxylase; Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Carrier | 2003 |
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzothiepins; Catalepsy; Cognition Disorders; Do | 2004 |
Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.
Topics: Animals; Azepines; Catalepsy; Clozapine; Drug Design; Haloperidol; Humans; In Vitro Techniques; Male | 2004 |
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
Topics: 3T3 Cells; Animals; Benzamides; Biological Availability; Brain; Caco-2 Cells; Catalepsy; Cell Membra | 2004 |
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzazepines; Binding Sites; Catalepsy; Catalysis | 2005 |
Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Brain; Catalepsy; Glutathione; Glutathione Pe | 2009 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
Further evaluation of the tropane analogs of haloperidol.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol | 2014 |
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
Topics: Animals; Brain; Catalepsy; Central Nervous System Stimulants; Cognition; Dextroamphetamine; Drug Des | 2016 |
Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Immunologic; Animals; Antioxidants; Antipar | 2022 |
The mGlu
Topics: Adenosine; Animals; Catalepsy; Dopamine; Haloperidol; HEK293 Cells; Humans; Mice; Parkinson Disease; | 2022 |
Conditioned catalepsy vs. Increase in locomotor activity induced by haloperidol.
Topics: Animals; Catalepsy; Dopamine Antagonists; Haloperidol; Locomotion; Rats; Rats, Wistar | 2023 |
Local field potential (LFP) power and phase-amplitude coupling (PAC) changes in the striatum and motor cortex reflect neural mechanisms associated with bradykinesia and rigidity during D2R suppression in an animal model.
Topics: Animals; Catalepsy; Corpus Striatum; Haloperidol; Hypokinesia; Male; Mice; Models, Animal; Motor Cor | 2023 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; | 2019 |
Calcium Salt of N-(5-Hydroxynicotinoyl)-L-Glutamic Acid Weakens Depressive-Like Behavior and Parkinsonian Syndrome in Experiment on Rodents.
Topics: Animals; Antidepressive Agents; Calcium; Catalepsy; Depression; Glutamic Acid; Haloperidol; Male; Mi | 2019 |
Conjugation of haloperidol to PEG allows peripheral localisation of haloperidol and eliminates CNS extrapyramidal effects.
Topics: Animals; Blood-Brain Barrier; Catalepsy; Haloperidol; Molecular Docking Simulation; Polyethylene Gly | 2020 |
Dual Target Ligands with 4-
Topics: Amines; Animals; Catalepsy; Cell Line, Tumor; Cell Proliferation; Haloperidol; HEK293 Cells; Histami | 2020 |
Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.
Topics: Animals; Brain; Catalepsy; Chalcones; Dopamine; Haloperidol; Mice; Monoamine Oxidase; Monoamine Oxid | 2020 |
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Catalepsy; Disease Models, Animal; Di | 2021 |
The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Antagonists; Haloperidol; Mice; TOR Serine-Threon | 2020 |
Low frequency deep brain stimulation in the inferior colliculus ameliorates haloperidol-induced catalepsy and reduces anxiety in rats.
Topics: Animals; Anxiety; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Male; Rats | 2020 |
Discovery and optimization of a novel CNS penetrant series of mGlu
Topics: Allosteric Regulation; Animals; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2021 |
Pharmacological assessments of potent A
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Antiparkinson Agents; | 2017 |
Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms.
Topics: Animals; Brain; Catalepsy; Cytochrome P450 Family 2; Haloperidol; Liver; Male; Microinjections; Nico | 2017 |
Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Dose-Response Relationship, Drug; Este | 2017 |
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Glutat | 2018 |
An ethanolic extract of Desmodium adscendens exhibits antipsychotic-like activity in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Ethanol; Fabaceae; Fe | 2017 |
Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Catalepsy; Chlorpromazine; | 2017 |
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
Role of vasopressin V1a receptor in ∆
Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoids; Catalepsy; Dose-Response Relationship, Drug; D | 2017 |
Awakenings in rats by ultrasounds: A new animal model for paradoxical kinesia.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2018 |
Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma.
Topics: Acetates; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Caesalpinia; Catalepsy; Cell Degranu | 2018 |
Haloperidol-induced catalepsy is ameliorated by deep brain stimulation of the inferior colliculus.
Topics: Animals; Antipsychotic Agents; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperido | 2018 |
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Topics: Administration, Oral; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Benzodiazepines; Catal | 2018 |
Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catalepsy; Cyclooxygenase Inhibitor | 2018 |
Paradoxical kinesia induced by appetitive 50-kHz ultrasonic vocalizations in rats depends on glutamatergic mechanisms in the inferior colliculus.
Topics: Animals; Appetitive Behavior; Catalepsy; Diazepam; Disease Models, Animal; GABA Modulators; Glutamic | 2018 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neu | 2018 |
Cross-tolerance between nitric oxide synthase inhibition and atypical antipsychotics modify nicotinamide-adenine-dinucleotide phosphate-diaphorase activity in mouse lateral striatum.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Enzyme Inhibitors; | 2019 |
Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Dose-Response Relati | 2018 |
Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Antagonists; Haloperidol; Immobilization; Injecti | 2018 |
Albizia zygia root extract exhibits antipsychotic-like properties in murine models of schizophrenia.
Topics: Albizzia; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Cognition; Disease Models, Ani | 2018 |
Influence of aversive stimulation on haloperidol-induced catalepsy in rats.
Topics: Affect; Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopam | 2019 |
Role of Aqueous Extract of the Wood Ear Mushroom, Auricularia polytricha (Agaricomycetes), in Avoidance of Haloperidol-lnduced Catalepsy via Oxidative Stress in Rats.
Topics: Animals; Antipsychotic Agents; Basidiomycota; Catalepsy; Disease Models, Animal; Fruiting Bodies, Fu | 2019 |
The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Catalepsy; Fluoxetine; Haloperidol; Male | 2019 |
Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice.
Topics: Action Potentials; Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Brain; Catalepsy; | 2013 |
Early life stress causes refractoriness to haloperidol-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Catecholamines; Cerebral Cortex; Dopamine Ago | 2013 |
Effect of rosiglitazone, a PPAR-γ ligand on haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Haloperidol; Hypoglycemic Agents; Ligands; Male; Mice; Oxidative Stress; PPAR ga | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia | 2013 |
Anticataleptic effects of 5-HT(1B) receptors in the globus pallidus.
Topics: Animals; Catalepsy; Globus Pallidus; Haloperidol; Locomotion; Male; Neurons; Pyridines; Pyrroles; Ra | 2013 |
Dopaminergic mechanisms underlying catalepsy, fear and anxiety: do they interact?
Topics: Analysis of Variance; Animals; Anxiety; Catalepsy; Conditioning, Classical; Dopamine; Dopamine Antag | 2013 |
Modulation of haloperidol-induced catalepsy in rats by GABAergic neural substrate in the inferior colliculus.
Topics: Animals; Catalepsy; Dopamine Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Halo | 2013 |
Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Buspirone; Catalepsy; Conditioning, Psychologica | 2014 |
Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.
Topics: Animals; Catalepsy; Cerebellum; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Dose-Respo | 2014 |
Distinct effects of haloperidol in the mediation of conditioned fear in the mesolimbic system and processing of unconditioned aversive information in the inferior colliculus.
Topics: Animals; Catalepsy; Conditioning, Classical; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Re | 2014 |
Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzhydryl Compounds; Brain; Catalepsy; Disease Mod | 2013 |
Evaluation of the antipsychotic potential of aqueous fraction of Securinega virosa root bark extract in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Dose-Response Relatio | 2014 |
The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Cholinergic Antagonists; Disease Mod | 2014 |
Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Topics: Administration, Intranasal; Animals; Catalepsy; Corpus Striatum; Drug Carriers; Drug Compounding; Dr | 2014 |
Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Catalepsy; Clozapine; Haloperidol; | 2014 |
Glutamatergic neurotransmission in the inferior colliculus influences intrastriatal haloperidol-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Aci | 2014 |
An adaptive role of TNFα in the regulation of striatal synapses.
Topics: Animals; Biotinylation; CA1 Region, Hippocampal; Catalepsy; Corpus Striatum; Dopamine Antagonists; D | 2014 |
Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Catalepsy; Dose-Response Re | 2014 |
Evaluating the effects and safety of intravenous lipid emulsion on haloperidol-induced neurotoxicity in rabbit.
Topics: Animals; Body Temperature; Catalepsy; Fat Emulsions, Intravenous; Haloperidol; In Situ Nick-End Labe | 2014 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response | 2015 |
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).
Topics: Allosteric Regulation; Animals; Catalepsy; Central Nervous System Agents; Drug Synergism; Exenatide; | 2014 |
Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients?
Topics: Animals; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Inferior Colliculi; | 2015 |
Developmental exposure to purity-controlled polychlorinated biphenyl congeners (PCB74 and PCB95) in rats: effects on brainstem auditory evoked potentials and catalepsy.
Topics: Animals; Brain Stem; Catalepsy; Evoked Potentials, Auditory; Female; Haloperidol; Male; Polychlorina | 2015 |
The local application of a flavonoid, (-)-epicatechin, increases the spiking of globus pallidus neurons in a dose-dependent manner and diminishes the catalepsy induced by haloperidol.
Topics: Animals; Antipsychotic Agents; Catalepsy; Catechin; Dose-Response Relationship, Drug; gamma-Aminobut | 2015 |
Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Catalepsy; Corpus Striatum; En | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Catalepsy; Cognition; Corpus Striatum; Cyclic GMP; El | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Int | 2015 |
The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.
Topics: Animals; Catalepsy; Corpus Striatum; Cytoskeletal Proteins; Dopamine Antagonists; Dose-Response Rela | 2015 |
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Cor | 2015 |
Contribution of the central histaminergic transmission in the cataleptic and neuroleptic effects of haloperidol.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Chlorpheniramine; Dose-Response Relati | 2015 |
2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Cell Survi | 2015 |
Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.
Topics: Action Potentials; Animals; Basal Ganglia; Bee Venoms; Catalepsy; Disease Models, Animal; Dopamine A | 2015 |
Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine.
Topics: Analgesics; Animals; Anticonvulsants; Antidepressive Agents; Antiparkinson Agents; Bridged-Ring Comp | 2015 |
Immunohistochemical evidence for the involvement of gonadotropin releasing hormone in neuroleptic and cataleptic effects of haloperidol in mice.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Brain; Catalepsy; Dopamine D2 Receptor Antagonist | 2016 |
EFFECTS OF VERAPAMIL ON DOPAMINE DEPENDENT BEHAVIOURS IN RATS.
Topics: Animals; Apomorphine; Avoidance Learning; Catalepsy; Dopamine; Haloperidol; Male; Rats; Receptors, D | 1999 |
Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.
Topics: Animals; Antipsychotic Agents; Cannabidiol; Catalepsy; Corpus Striatum; Dopamine Antagonists; Halope | 2016 |
Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized cata
Topics: Analysis of Variance; Animals; Apomorphine; Catalepsy; Conditioning, Classical; Disease Models, Anim | 2016 |
Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cata | 2016 |
CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Topics: Animals; Arachidonic Acids; Cannabinoids; Catalepsy; Dopamine Antagonists; Endocannabinoids; Haloper | 2016 |
Effect of L-pGlu-(1-benzyl)-l-His-l-Pro-NH
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Ischemia; Catalepsy; Cell Death; Diseas | 2016 |
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Catalepsy; Chick Embryo; Disease Models, | 2017 |
Anti-Psychotic Activity of Aqueous Root Extract of Hemidesmus indicus: A Time Bound Study in Rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Drug Delivery Systems; Haloperidol; Hemidesmus; Patents as | 2017 |
Short-term selective breeding for high and low prepulse inhibition of the acoustic startle response; pharmacological characterization and QTL mapping in the selected lines.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; C | 2008 |
Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Aminopyridines; Animals; Carbo | 2008 |
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Disea | 2008 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus | 2008 |
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Mode | 2008 |
High frequency stimulation of the posterior hypothalamic nucleus restores movement and reinstates hippocampal-striatal theta coherence following haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Corpus Striatum; Cortical Synchronization; Deep Brain Stimulation; Dopamine Anta | 2008 |
Behavioral and biochemical effects of amperozide and serotonin agents on nigrostriatal and mesolimbic dopamine systems.
Topics: Amphetamines; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine; Haloperidol; Limbic S | 2008 |
Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Catalep | 2008 |
Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; G | 2009 |
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Disease Models, Animal; Drug Design; Drug Eva | 2008 |
Dose-dependent response of central dopaminergic systems to buspirone in mice.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Catalepsy; Dopamine D2 Receptor Antagonists; Dose-Response | 2008 |
To breed or not to breed? Empirical evaluation of drug effects in adolescent rats.
Topics: Aging; Animals; Antipsychotic Agents; Breeding; Catalepsy; Clozapine; Dose-Response Relationship, Dr | 2009 |
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Azepines; Catalepsy; Clozapine; Dizo | 2009 |
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Catalepsy; Chemi | 2009 |
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.
Topics: Acetamides; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Behavior, | 2009 |
Study of bipathic effect of haloperidol.
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Dose-Response Relationship | 2008 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease M | 2009 |
A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal.
Topics: Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Computer Simulation; Dopamine Antagonists; Dopa | 2009 |
Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex.
Topics: Animals; Catalepsy; Dietary Supplements; Frontal Lobe; Haloperidol; Male; Rats; Rats, Wistar; Seroto | 2009 |
Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dose-Response Relati | 2009 |
In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Catalepsy; Chlorpromazine; Corpus St | 2009 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benser | 2009 |
A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Dose-Response Relationship, Drug; Gona | 2009 |
Caffeine withdrawal retains anticataleptic activity but Withania somnifera withdrawal potentiates haloperidol-induced catalepsy in mice.
Topics: Analysis of Variance; Animals; Caffeine; Catalepsy; Haloperidol; Mice; Nervous System; Plant Extract | 2009 |
Effects of 5-HT in globus pallidus on haloperidol-induced catalepsy in rats.
Topics: Animals; Catalepsy; Dopamine Antagonists; Globus Pallidus; Haloperidol; Male; Microinjections; Rats; | 2009 |
Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders.
Topics: Acridines; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Analysis of Varian | 2009 |
Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.
Topics: Animals; Antioxidants; Antipsychotic Agents; Brain; Catalepsy; Dose-Response Relationship, Drug; Dys | 2009 |
Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
Topics: Animals; Caffeine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Parkinson Disease | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Ben | 2009 |
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Behavior; Catalepsy; Cell Line; Disease Models, Anima | 2009 |
Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control.
Topics: Acoustic Stimulation; Animals; Catalepsy; Cues; Dopamine Antagonists; Dyskinesia, Drug-Induced; Halo | 2009 |
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2010 |
Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine.
Topics: Animals; Caffeine; Catalepsy; Central Nervous System Stimulants; Disease Susceptibility; Dopamine D2 | 2009 |
Central nervous system effects of the essential oil of the leaves of Alpinia zerumbet in mice.
Topics: Alpinia; Animals; Antipsychotic Agents; Anxiety; Apomorphine; Behavior, Animal; Catalepsy; Central N | 2009 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal | 2010 |
Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain.
Topics: Acetylcholine; Animals; Brain Chemistry; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Catalep | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
Prenatal lipopolysaccharide reduces motor activity after an immune challenge in adult male offspring.
Topics: Animals; Apomorphine; Brain; Catalepsy; Dopamine; Dopamine Agonists; Dopamine Antagonists; Explorato | 2010 |
Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Catalepsy; Cell Line; Cell Membran | 2010 |
Acoustic tone or medial geniculate stimulation cue training in the rat is associated with neocortical neuroplasticity and reduced akinesia under haloperidol challenge.
Topics: Acoustic Stimulation; Animals; Catalepsy; Conditioning, Operant; Cues; Dendrites; Evoked Potentials, | 2010 |
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Re | 2010 |
Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dizocilpine Maleate; Dose-Response Relationship, Dr | 2010 |
Protective effects of aqueous fruit extract from Sea Buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum.
Topics: Administration, Oral; Animals; Catalepsy; Dopamine; Exploratory Behavior; Fruit; Haloperidol; Hippop | 2010 |
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors.
Topics: Animals; Catalepsy; Cocaine; Corpus Striatum; Dopamine Agents; Dopamine and cAMP-Regulated Phosphopr | 2010 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagoni | 2011 |
Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes.
Topics: Animals; Basal Ganglia Diseases; Catalepsy; Cholinergic Antagonists; Drug Synergism; Drug Therapy, C | 2010 |
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Globus P | 2010 |
Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Topics: Animals; Apomorphine; Aripiprazole; Buffers; Catalepsy; Cell Membrane; Cerebral Cortex; Corpus Stria | 2011 |
The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Topics: Analysis of Variance; Animals; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Dopamine Antagonists | 2011 |
Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Ha | 2011 |
Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dyskinesia, Drug-Induced; | 2011 |
Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
Topics: Animals; Antipsychotic Agents; Breeding; Catalepsy; Haloperidol; Male; Mice; Motor Activity; Recepto | 2011 |
The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Central Nervous System Stimulants; Clo | 2011 |
Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.
Topics: Animals; Basal Ganglia Diseases; Carya; Catalepsy; Disease Models, Animal; Haloperidol; Male; Moveme | 2011 |
Persistent behavioral impairments and alterations of brain dopamine system after early postnatal administration of thimerosal in rats.
Topics: Animals; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2011 |
Effect of ethanolic extract of Rubia peregrina L. (Rubiaceae) on monoamine-mediated behaviour.
Topics: Adrenergic Agents; Animals; Catalepsy; Dopamine Agents; Dyskinesias; Haloperidol; Lithium Compounds; | 2011 |
Acute lithium administration selectively lowers tyrosine levels in serum and brain.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Catalepsy; Drug Interactions; Haloperido | 2011 |
Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (
Topics: Administration, Oral; Allosteric Regulation; Animals; Antiparkinson Agents; Biological Availability; | 2011 |
Gene networks and haloperidol-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Computational Biology; Corpus Striatum; Female; Gene Expre | 2012 |
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Avoidance L | 2012 |
Co-administration of haloperidol and drugs affecting the angiotensin pathway: effect on the extrapyramidal system.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antipsyc | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
Topics: Animals; Catalepsy; Conditioning, Psychological; Dopamine Antagonists; Dose-Response Relationship, D | 2012 |
Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine Plasma Membrane Transport Protei | 2012 |
Effects of sertraline on experimental mouse models of psychosis.
Topics: Animals; Antidepressive Agents; Apomorphine; Catalepsy; Dextroamphetamine; Disease Models, Animal; D | 2012 |
Ethanolic extract of Rubia peregrina L. (Rubiaceae) inhibits haloperidol-induced catalepsy and reserpine-induced orofacial dyskinesia.
Topics: Animals; Catalepsy; Ethanol; Haloperidol; Male; Movement Disorders; Plant Extracts; Rats; Reserpine; | 2012 |
Reversal of oxidative stress by histamine H₃ receptor-ligands in experimental models of schizophrenia.
Topics: Amphetamine; Animals; Antioxidants; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain Chemi | 2012 |
Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
Topics: Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine Anta | 2012 |
Sedative, antiepileptic and antipsychotic effects of Viscum album L. (Loranthaceae) in mice and rats.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Apomorphine; Catalepsy; Disease Models, Animal; Epil | 2012 |
Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Dipeptides; | 2011 |
Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Biological Availability; Calciu | 2012 |
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzodiazepines; Brain; Catalepsy; Cel | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Di | 2013 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Rel | 2012 |
Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Behavior, Animal; Catalepsy; | 2012 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Antihistaminic and antiallergic actions of extracts of Solanum nigrum berries: possible role in the treatment of asthma.
Topics: Animals; Anti-Allergic Agents; Asthma; Catalepsy; Clonidine; Eosinophilia; Fruit; Guinea Pigs; Halop | 2012 |
Structure-based design, synthesis and molecular modeling studies of thiazolyl urea derivatives as novel anti-parkinsonian agents.
Topics: Animals; Antiparkinson Agents; Catalepsy; Chemistry Techniques, Synthetic; Drug Design; Haloperidol; | 2012 |
Blood-brain barrier unlocked.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Blood-Brain Barrier; Catalepsy; | 2012 |
[Stress effect on haloperidol-induced catalepsy and its circadian rhythm in intact and ovariectomized female rats].
Topics: Animals; Antipsychotic Agents; Catalepsy; Circadian Rhythm; Female; Haloperidol; Ovariectomy; Rats; | 2012 |
Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.
Topics: 5-alpha Reductase Inhibitors; Animals; Apomorphine; Benzazepines; Catalepsy; Dopamine Agonists; Dopa | 2013 |
Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Drug Synergism; En | 2013 |
Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat.
Topics: Aging; Animals; Antipsychotic Agents; Catalepsy; Drug Synergism; Haloperidol; Male; Rats; Rats, Wist | 2012 |
Somatostatin antagonist induces catalepsy in the aged rat.
Topics: Age Factors; Aging; Animals; Brain; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Inject | 2013 |
Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats.
Topics: Animals; Caffeine; Catalepsy; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Dru | 2013 |
Peptide hormone ghrelin enhances neuronal excitability by inhibition of Kv7/KCNQ channels.
Topics: Action Potentials; Animals; CA1 Region, Hippocampal; Catalepsy; Cyclic AMP-Dependent Protein Kinases | 2013 |
[On filo- and ontogenetic development of dopaminergic regylation of wakefulness-sleep cycle in vertabrates].
Topics: Animals; Apomorphine; Benzazepines; Brain Mapping; Catalepsy; Dopamine; Dopamine Agonists; Dopamine | 2012 |
Nootropic activity of Albizzia lebbeck in mice.
Topics: Albizzia; Animals; Avoidance Learning; Behavior, Animal; Brain Chemistry; Catalepsy; Clonidine; Depr | 2002 |
Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Catalepsy; Dopamine Agoni | 2002 |
Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.
Topics: Animals; Autoradiography; Behavior, Animal; Brain Chemistry; Catalepsy; Corpus Striatum; Dose-Respon | 2002 |
Discrimination of morphine- and haloperidol-induced muscular rigidity and akinesia/catalepsy in simple tests in rats.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Haloperidol; | 2002 |
Cyclooxygenase inhibitor modulation of dopamine-related behaviours.
Topics: Amphetamine; Animals; Behavior, Animal; Benzazepines; Brain; Catalepsy; Cyclooxygenase 2; Cyclooxyge | 2002 |
The differential effect of haloperidol and repetitive induction on four immobility responses in mouse and guinea pig.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Dopamine Antagonists; Guinea Pigs; Halop | 2002 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonist | 2002 |
In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Blood Pressure; Catalepsy; Do | 2002 |
Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2002 |
Effects of dopamine receptor blockade on cerebral blood flow response to somatosensory stimulation in the unanesthetized rat.
Topics: Animals; Behavior, Animal; Catalepsy; Cerebrovascular Circulation; Dopamine Antagonists; Dose-Respon | 2002 |
5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Dose-Response Relationship, Drug; Halope | 2002 |
Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Cocaine; Cocaine-Related Disorders; Conditioning, Opera | 2002 |
Gender-related differences in the effects of nitric oxide donors on neuroleptic-induced catalepsy in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Female; Haloperidol; Isosorbide Dini | 2003 |
Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Haloper | 2003 |
The alpha 2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: role of serotonergic mechanisms.
Topics: Adrenergic alpha-2 Receptor Antagonists; Catalepsy; Corpus Striatum; Dopamine; Dose-Response Relatio | 2003 |
A role for presynaptic mechanisms in the actions of nomifensine and haloperidol.
Topics: Animals; Autoreceptors; Brain; Catalepsy; Dopamine; Dopamine Antagonists; Dopamine Plasma Membrane T | 2003 |
Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4.
Topics: Animals; Behavior, Animal; Blotting, Northern; Catalepsy; Haloperidol; Mice; Mice, Knockout; Muscari | 2003 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Di | 2003 |
The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals.
Topics: Animals; Ataxia; Behavior, Animal; Catalepsy; Diamines; Disease Models, Animal; Dizocilpine Maleate; | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat.
Topics: Adrenergic Uptake Inhibitors; Alkaloids; Animals; Catalepsy; Central Nervous System; Central Nervous | 2003 |
SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum.
Topics: Analysis of Variance; Animals; Brain Mapping; Catalepsy; Corpus Striatum; Dopamine Antagonists; Dose | 2003 |
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Corpus Striatum; Dopam | 2003 |
Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy.
Topics: Animals; Caffeine; Catalepsy; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Male; M | 2003 |
High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Apomorphine; Catalepsy; Ch | 2003 |
Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications.
Topics: Animals; Catalepsy; Clozapine; Dose-Response Relationship, Drug; Dronabinol; Drug Synergism; Haloper | 2003 |
[EXPERIMENTAL EQUIVALENTS OF THE NEUROLOGIC SYNDROME OF NEUROLEPTICS].
Topics: Antipsychotic Agents; Catalepsy; Catatonia; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Neuro | 1964 |
Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier.
Topics: Amphetamine; Animals; Behavior, Animal; Blood Glucose; Blood-Brain Barrier; Body Temperature; Brain; | 2003 |
Effect of undernutrition on morphine analgesia, haloperidol catalepsy and pentobarbitone sodium hypnosis in developing new born rats.
Topics: Analgesia; Analgesics, Opioid; Animals; Animals, Newborn; Behavior, Animal; Catalepsy; Central Nervo | 2003 |
Burst activity of spiny projection neurons in the striatum encodes superimposed muscle tetani in cataleptic rats.
Topics: Action Potentials; Animals; Catalepsy; Corpus Striatum; Haloperidol; Male; Muscle Contraction; Neura | 2003 |
Pharmacological actions of a novel and selective dopamine D3 receptor antagonist, KCH-1110.
Topics: Animals; Antipsychotic Agents; Benzamides; Binding, Competitive; Body Temperature; Catalepsy; Cell L | 2003 |
Brain tyrosine depletion attenuates haloperidol-induced striatal dopamine release in vivo and augments haloperidol-induced catalepsy in the rat.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Dopamine Antagonists; Haloperidol; Male; Microdialysi | 2004 |
The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression.
Topics: Alitretinoin; Animals; Antineoplastic Agents; Antipsychotic Agents; Autoradiography; Basal Ganglia D | 2004 |
Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Dopamine; Dopamine Anta | 2004 |
Increase of spiny I activity in striatum after development of context-dependent sensitization of catalepsy in rats.
Topics: Action Potentials; Animals; Catalepsy; Corpus Striatum; Dopamine Antagonists; Electrophysiology; Hal | 2004 |
Neuroleptic-like effects of gamma-hydroxybutyrate: interactions with haloperidol and dizocilpine.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dizocilpine Maleate; Dose-Response Relationship, Drug; Hal | 2004 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Decreased brain docosahexaenoic acid during development alters dopamine-related behaviors in adult rats that are differentially affected by dietary remediation.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain; | 2004 |
Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Topics: Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Catalepsy; Cell Count; Corpus Striatum; Diz | 2004 |
Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice.
Topics: Adamantane; Analysis of Variance; Animals; Catalepsy; Dopamine Antagonists; Haloperidol; Imidazoles; | 2004 |
Atypical antipsychotic profile of flunarizine in animal models.
Topics: Administration, Oral; Animals; Catalepsy; Dextroamphetamine; Disease Models, Animal; Dizocilpine Mal | 2005 |
Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; | 2004 |
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Behavior, Animal; Ca | 2005 |
Effect of M2 muscarinic receptor blockade in rats with haloperidol-produced catatonic syndrome.
Topics: Animals; Catalepsy; Cyclopentanes; Diamines; Dopamine; Haloperidol; Male; Mandelic Acids; Muscarinic | 2004 |
Synthesis of 61-bis(1-adamantylcarbamoyl)-1,2-methano[60]fullerene and its antagonistic effect on haloperidol-induced catalepsy in mice.
Topics: Adamantane; Animals; Catalepsy; Fullerenes; Haloperidol; Injections, Intraperitoneal; Male; Mice; Mi | 2004 |
Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain Chemistry; Buspirone; Catal | 2004 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.
Topics: alpha-Tocopherol; Animals; Ascorbic Acid; Catalepsy; Disease Models, Animal; Dopamine Antagonists; D | 2005 |
Passiflora actinia Hooker extracts and fractions induce catalepsy in mice.
Topics: Animals; Antipsychotic Agents; Catalepsy; Haloperidol; Male; Mice; Passiflora; Plant Extracts; Plant | 2005 |
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2005 |
Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
Topics: Animals; Catalepsy; Diabetes Mellitus, Experimental; Dizocilpine Maleate; Dopamine Antagonists; Dose | 2005 |
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium Channel Blockers; Catalepsy; Central Nervous Sys | 2005 |
Modulating role of NO in haloperidol-induced catalepsy.
Topics: Animals; Arginine; Catalepsy; Cerebral Cortex; Electron Spin Resonance Spectroscopy; Haloperidol; Ni | 2005 |
Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Topics: Animals; Antipsychotic Agents; Area Under Curve; Arginine; Biological Availability; Catalepsy; Centr | 2005 |
Ginkgo biloba leaf extract (EGb 761) enhances catalepsy induced by haloperidol and L-nitroarginine in mice.
Topics: Animals; Catalepsy; Dopamine Antagonists; Drug Interactions; Enzyme Inhibitors; Ginkgo biloba; Halop | 2005 |
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Disease Models, Animal; Female; Fluoxetine; Haloperidol; | 2005 |
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Catalepsy; Dopamine Antagonists; Do | 2006 |
Fyn is required for haloperidol-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Blotting, Western; Calcium; Catalepsy; Cells, | 2006 |
Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.
Topics: Animals; Catalepsy; Female; Haloperidol; Male; Medicine, Ayurvedic; Mice; Parkinsonian Disorders; Ph | 2006 |
Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Drug Administration Schedule; Drug Inter | 2005 |
The effect of nitric oxide on fentanyl and haloperidol-induced catalepsy in mice.
Topics: Animals; Catalepsy; Enzyme Inhibitors; Fentanyl; Haloperidol; Male; Mice; Nitric Oxide; Nitric Oxide | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Avoidance Lea | 2006 |
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents | 2007 |
Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Central Nervous System Stimulants; Cor | 2006 |
Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug | 2006 |
Identification of a new functional target of haloperidol metabolite: implications for a receptor-independent role of 3-(4-fluorobenzoyl) propionic acid.
Topics: Animals; Brain; Catalepsy; Cell Line, Transformed; Disease Models, Animal; Dopamine Antagonists; Enz | 2006 |
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, | 2007 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; | 2007 |
Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Ataxia; Buspirone; Catalepsy; Dyskinesia, Drug-I | 2007 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalep | 2007 |
Synthesis and biological evaluation of 1-amino-2-phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists.
Topics: Amino Acids; Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Cell Line; Haloperidol; Humans | 2007 |
Some behavioural effects of carbamazepine - comparison with haloperidol.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; Carbamazepine; Catalepsy; Haloperid | 2007 |
The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats.
Topics: Animals; Benzopyrans; Catalepsy; Haloperidol; Male; Nitriles; Pyrroles; Rats; Rats, Wistar; Receptor | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazol | 2007 |
Characterization of the quantitative trait locus for haloperidol-induced catalepsy on distal mouse chromosome 1.
Topics: Animals; Catalepsy; Chromosome Mapping; Corpus Striatum; Crosses, Genetic; DNA; Female; Haloperidol; | 2008 |
Effects of dextromethorphan on dopamine dependent behaviours in rats.
Topics: Animals; Antitussive Agents; Apomorphine; Behavior, Animal; Catalepsy; Dextroamphetamine; Dextrometh | 2007 |
Effect of Withania somnifera root extract on haloperidol-induced catalepsy in albino mice.
Topics: Animals; Brain; Catalepsy; Haloperidol; Male; Mice; Oxidative Stress; Phytotherapy; Plant Extracts; | 2008 |
L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum.
Topics: Animals; Antipsychotic Agents; Benzazepines; Blotting, Western; Calcium Channel Blockers; Calcium Ch | 2007 |
Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Central Nervous System Stimulan | 2008 |
Effect of NR-ANX-C (a polyherbal formulation) on haloperidol induced catalepsy in albino mice.
Topics: Animals; Antipsychotic Agents; Camellia sinensis; Catalepsy; Cholinergic Antagonists; Drugs, Chinese | 2007 |
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
Topics: Acetamides; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Catalepsy; Cell Line; | 2008 |
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.
Topics: Administration, Oral; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Benzodi | 2008 |
Epinephrine potentiates antipsychotic, but not cataleptogenic effect of haloperidol in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dizocilpine Maleate; Drug Synergism; Epinephrine; Haloperi | 2007 |
Dysregulation of the mesolimbic dopamine system and reward in MCH-/- mice.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Catalepsy; Dopamine; Dopamine Antagoni | 2008 |
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Catalepsy; C | 2008 |
Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments.
Topics: Amphetamine; Animals; Apomorphine; Catalepsy; Excitatory Amino Acid Antagonists; Haloperidol; Ketami | 2008 |
Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
Topics: Animals; Behavior, Animal; Binding, Competitive; Catalepsy; Cerebral Cortex; Dizocilpine Maleate; Do | 2008 |
[Arousal inhibiting and catalepsy in neuroleptic drugs].
Topics: Animals; Arousal; Catalepsy; Chlorpromazine; Chlorprothixene; Fluphenazine; Haloperidol; Humans; Met | 1966 |
Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dialysis; | 1984 |
Central effects of angiotensin II, its fragment and analogues.
Topics: Angiotensin II; Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; Catecholamines; Haloperido | 1984 |
Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide.
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ceruletide; Clonidine; Drug Antagonism; Haloperidol | 1984 |
Gamma-aminobutyric acid and basal ganglia outflow pathways.
Topics: Animals; Basal Ganglia; Catalepsy; Disease Models, Animal; gamma-Aminobutyric Acid; Haloperidol; Hum | 1984 |
[Psychopharmacologic spectrum of melanostatin].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats | 1980 |
Sustained gamma-aminobutyric acid receptor stimulation and chronic neuroleptic effects.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dendrites; Dopamine; Drug Tolerance; gamma-Aminobutyric Ac | 1980 |
Pimozide: delayed onset of action at rat striatal pre- and postsynaptic dopamine receptors.
Topics: Animals; Apomorphine; Catalepsy; Drug Synergism; Female; Haloperidol; Humans; Mixed Function Oxygena | 1980 |
[The neuroleptic efficiency of some butyrophenone and fluorinated phenothiazine derivatives (author's transl)].
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Catalepsy; Haloperidol; Humans; Phenot | 1980 |
Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Topics: Animals; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Kinetics; Ma | 1981 |
Differential sensitivity to neuroleptic drugs of cerebral dopamine receptors following chronic treatment of rats with trifluoperazine.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Female; Haloperidol; Humans; Radioligand Assay; Rat | 1981 |
The effects of a hypothalamic peptide factor, MIF and its cyclic analog on tolerance to haloperidol in the rat.
Topics: Animals; Body Temperature; Catalepsy; Dipeptides; Drug Tolerance; Haloperidol; Humans; Male; MSH Rel | 1981 |
Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Flupenthixol; Haloperidol; Humans; | 1981 |
Hypokinesia in mice and catalepsy in rats elicited by morphine associated with antidopaminergic agents, including atypical neuroleptics.
Topics: alpha-Methyltyrosine; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Clozapine; Haloperidol; | 1981 |
Behavioral pharmacologic studies in the monkey with DD-3480.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Butyrophenones; Catalepsy; Haloperidol | 1982 |
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Cholecystokinin; Extincti | 1982 |
Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Conditioning, Operant; Flupenthixol; H | 1982 |
Notes on buspirone's mechanisms of action.
Topics: Acetylcholine; Animals; Anti-Anxiety Agents; Behavior, Animal; Brain Chemistry; Buspirone; Catalepsy | 1982 |
Enhanced effect of haloperidol and apomorphine after hypophysectomy: pharmacokinetic considerations.
Topics: Animals; Apomorphine; Brain; Catalepsy; Haloperidol; Humans; Hypophysectomy; Kinetics; Male; Rats; R | 1983 |
Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Anxiety Agents; Buspirone; Catalepsy; Cerebral Cortex; | 1983 |
Aminoalkylindoles: atypical dopamine antagonists.
Topics: Amphetamine; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine Antagonists; Halope | 1983 |
Cataleptogenic potency of the antipsychotic drugs is inversely correlated with neuronal activity in the amygdaloid complex of the rat.
Topics: Action Potentials; Amygdala; Animals; Antipsychotic Agents; Catalepsy; Chlorpromazine; Clozapine; Do | 1983 |
The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol.
Topics: Analgesics; Analgesics, Opioid; Animals; Catalepsy; Cimetidine; Diphenhydramine; Drug Interactions; | 1983 |
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Binding | 1984 |
Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Topics: Animals; Antipsychotic Agents; Brain; Butaclamol; Catalepsy; Dopamine; Fluphenazine; Haloperidol; Hu | 1981 |
[Effect of an imidazobenzodiazepine (RO 15-1788) on aggressive behavior in mice].
Topics: Aggression; Animals; Apomorphine; Benzodiazepinones; Brain; Catalepsy; Dose-Response Relationship, D | 1984 |
Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol.
Topics: Animals; Anticonvulsants; Catalepsy; Central Nervous System Depressants; Ceruletide; Cholecystokinin | 1981 |
[Effect of functional changes in the dopamine system of the brain on enkephalinamide-induced catalepsy in the rat].
Topics: Animals; Behavior, Animal; Catalepsy; Dioxanes; Dopamine; Electric Stimulation; Enkephalins; Ergonov | 1983 |
[Neuroendocrine modulation of haloperidol-induced catalepsy].
Topics: Androgens; Animals; Catalepsy; Dopamine; Endocrine Glands; Estrogens; Extrapyramidal Tracts; Haloper | 1983 |
The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Binding Sites; Catalepsy; Corpus Striatum; Di | 1983 |
Cholinergic-dopaminergic interactions in experimental catalepsy.
Topics: Animals; Apomorphine; Catalepsy; Dopamine; Drug Interactions; Haloperidol; Humans; Male; Mice; Paras | 1983 |
Modification of the behavioural effects of haloperidol and of dopamine receptor regulation by altered thyroid status.
Topics: Animals; Behavior, Animal; Body Temperature; Catalepsy; Haloperidol; Humans; Hyperthyroidism; Hypoth | 1984 |
Effects of naloxone on methamphetamine and apomorphine stereotypy and on haloperidol catalepsy in rats.
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Humans; Male; Methamphetamine; Naloxone; Rats; Stereot | 1984 |
Parametric influences on catalepsy.
Topics: Animals; Behavior, Animal; Catalepsy; Haloperidol; Humans; Male; Rats; Rats, Inbred Strains | 1984 |
On some central effects of elymoclavine.
Topics: Animals; Bromocriptine; Catalepsy; Central Nervous System; Corpus Striatum; Ergolines; Exploratory B | 1984 |
[Differentiation between catalepsies induced by l-tetrahydropalmatine and by haloperidol and morphine (author's transl)].
Topics: Animals; Berberine Alkaloids; Brain Chemistry; Catalepsy; Dopamine; Female; Haloperidol; Homovanilli | 1981 |
[Relevance of dopaminergic system to the catalepsy induced by tetrahydroberberine (author's transl)].
Topics: Animals; Apomorphine; Berberine; Berberine Alkaloids; Catalepsy; Female; Haloperidol; Humans; Male; | 1981 |
[Various methods of overcoming secondary resistance to treatment developing in relation to adaptation to psychotropic drugs during long-term treatment (clinico-experimental study)].
Topics: Adult; Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Drug | 1984 |
Haloperidol and cerebral metabolism in the conscious rat: relation to pharmacokinetics.
Topics: Animals; Blood Pressure; Body Temperature; Brain; Catalepsy; Consciousness; Glucose; Haloperidol; He | 1984 |
Role of mesencephalic reticular formation in cholinergic-induced catalepsy and anticholinergic reversal of neuroleptic-induced catalepsy.
Topics: Acetylcholine; Animals; Atropine; Catalepsy; Caudate Nucleus; Cholinergic Fibers; Haloperidol; Human | 1984 |
Decreased catalepsy response to haloperidol in the genetically dystonic (dt) rat.
Topics: 4-Butyrolactone; Aging; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Dystonia; Golgi Appara | 1984 |
[Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Topics: Animals; Apomorphine; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; | 1984 |
[Catalepsy in the rat after haloperidol and some new GABA-ergic agents].
Topics: Animals; Catalepsy; Corpus Striatum; Drug Synergism; gamma-Aminobutyric Acid; Haloperidol; Humans; R | 1984 |
The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent.
Topics: 5,8,11,14-Eicosatetraynoic Acid; 8,11,14-Eicosatrienoic Acid; Animals; Apomorphine; Aspirin; Catalep | 1984 |
Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Body Temperature; Brain; Catalepsy; Ch | 1983 |
Morphine versus haloperidol catalepsy in the rat: an electromyographic analysis of postural support mechanisms.
Topics: Animals; Biomechanical Phenomena; Catalepsy; Electrodes, Implanted; Electromyography; Extremities; H | 1983 |
Effects of parathyroid hormone or haloperidol-induced catalepsy and nigral GAD activity.
Topics: Animals; Carboxy-Lyases; Catalepsy; Glutamate Decarboxylase; Haloperidol; Humans; Male; Parathyroid | 1983 |
Antidyskinetic properties of estrogens.
Topics: Animals; Apomorphine; Catalepsy; Estradiol; Estrogens; Glutamate Decarboxylase; Haloperidol; Humans; | 1983 |
Morphine may not produce true catalepsy.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Morphine; Rats; Rat | 1983 |
Is the brain histamine involved in cataleptogenic action of analgesics and haloperidol?
Topics: Analgesics; Animals; Brain; Catalepsy; Haloperidol; Histamine; Histidine; Humans; Male; Rats; Rats, | 1983 |
Effects of calcitonin on the brain of aged rats.
Topics: Age Factors; Animals; Apomorphine; Calcitonin; Catalepsy; Drug Synergism; Extrapyramidal Tracts; Hal | 1983 |
[High dosage haloperidol reduces cataleptic response with increased noradrenaline metabolism in the rat brain areas].
Topics: Animals; Brain; Catalepsy; Dopamine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; | 1983 |
Effect of intraperitoneally administered GABA on haloperidol-induced catalepsy in the rat.
Topics: Animals; Catalepsy; Drug Interactions; gamma-Aminobutyric Acid; Haloperidol; Humans; Injections, Int | 1980 |
Chronic administration of haloperidol during development: behavioral and psychopharmacological effects.
Topics: Animals; Behavior, Animal; Birth Weight; Body Weight; Brain Chemistry; Catalepsy; Female; Fertility; | 1980 |
Circadian changes in behavioral effects of haloperidol in rats.
Topics: Animals; Behavior, Animal; Blepharoptosis; Catalepsy; Circadian Rhythm; Dose-Response Relationship, | 1982 |
Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride.
Topics: Adult; Animals; Apomorphine; Behavior, Animal; Body Temperature; Catalepsy; Ergolines; Female; Halop | 1983 |
Alterations in apomorphine concentration in spinal cord and brain follow the time course of catalepsies induced by different treatments.
Topics: Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; gamma-Aminobutyric Acid; Haloperidol; Huma | 1983 |
Bilateral injection of kainic acid into the rat striatum potentiates morphine, arecoline and pilocarpine but not haloperidol catalepsy.
Topics: Animals; Arecoline; Catalepsy; Corpus Striatum; Drug Interactions; Haloperidol; Humans; Injections; | 1982 |
Circadian changes in the destruction and effects of haloperidol in the rat.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Circadian Rhythm; Dose-Response Relationship, Drug; Hal | 1982 |
Pavlovian conditional tolerance to haloperidol catalepsy: evidence of dynamic adaptation in the dopaminergic system.
Topics: Animals; Catalepsy; Conditioning, Classical; Dopamine; Drug Tolerance; Haloperidol; Humans; Rats; Re | 1982 |
Changes in blood-brain barrier permeability to drugs in decompressed rats.
Topics: Animals; Atropine; Atropine Derivatives; Blood-Brain Barrier; Catalepsy; Decompression Sickness; Dom | 1982 |
Biphasic dose-response effect of baclofen on haloperidol catalepsy in the rat.
Topics: Animals; Baclofen; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Rats; Rat | 1982 |
Tolerance and reverse tolerance to haloperidol catalepsy induced by the difference of administration interval in mice.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; | 1982 |
[Preliminary pharmacological studies on the central action of phenyl- and piperidinemethyl derivatives of benzoxazolone-2].
Topics: Animals; Benzoxazoles; Body Temperature; Brain; Catalepsy; Drug Synergism; Female; Haloperidol; Hexo | 1981 |
Role of substantia nigra pars reticulata neurons in the expression of neuroleptic-induced catalepsy.
Topics: Animals; Catalepsy; Dopamine; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Haloperidol | 1981 |
Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors.
Topics: Animals; Catalepsy; Cerebral Cortex; Corpus Striatum; Haloperidol; Humans; Kainic Acid; Male; Neural | 1980 |
Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy.
Topics: Allylglycine; Animals; Apomorphine; Behavior, Animal; Catalepsy; Drug Interactions; GABA Antagonists | 1980 |
Reticuline: a dopamine receptor blocker.
Topics: Alkaloids; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzylisoquinolines; Catalepsy; Dopa | 1980 |
Tonic immobility in domestic fowl: anticataleptic effects of quipazine.
Topics: Animals; Catalepsy; Chickens; Haloperidol; Humans; Motor Activity; Quinolines; Quipazine; Stereotype | 1980 |
Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat.
Topics: Animals; Brain Chemistry; Catalepsy; Cattle; Dose-Response Relationship, Drug; Haloperidol; Humans; | 1980 |
Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Morphine; Motor Act | 1980 |
Antidopaminergic properties of yohimbine.
Topics: Acetylcholine; Animals; Catalepsy; Corpus Striatum; Dopamine; Dopamine Antagonists; Dose-Response Re | 1980 |
Chronic administration of haloperidol during development: later psychopharmacological responses to apomorphine and arecoline.
Topics: Animals; Apomorphine; Arecoline; Behavior, Animal; Catalepsy; Female; Haloperidol; Humans; Male; Pre | 1980 |
Involvement of caudate nucleus, amygdala or reticular formation in neuroleptic and narcotic catalepsy.
Topics: Amygdala; Animals; Catalepsy; Caudate Nucleus; Haloperidol; Humans; Male; Methyltyrosines; Morphine; | 1981 |
Increased amphetamine stereotypy and longer haloperidol catalepsy in spontaneously hypertensive rats.
Topics: Amphetamines; Animals; Brain; Catalepsy; Catecholamines; Female; Haloperidol; Humans; Hypertension; | 1981 |
Tonic immobility in domestic fowl: possible interaction of serotonergic and dopaminergic mechanisms.
Topics: Animals; Apomorphine; Catalepsy; Chickens; Fenfluramine; Haloperidol; Humans; Immobilization; Recept | 1981 |
Postictal behavioral arrest in the rat: "catalepsy" or "catatonia"?
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Catatonia; Electric Stimulation; Female; Haloperi | 1981 |
Differential cataleptogenic and antistereotypic effects of caerulein and haloperidol.
Topics: Animals; Catalepsy; Ceruletide; Drug Interactions; Haloperidol; Humans; Male; Methylphenidate; Mice; | 1981 |
Alteration in dopaminergic and muscarinic cholinergic receptors after subchronic treatment with haloperidol in the developing rat brain.
Topics: Animals; Animals, Newborn; Brain; Catalepsy; Corpus Striatum; Female; Haloperidol; Humans; Male; Mot | 1981 |
Tolerance to behavioral effects of haloperidol.
Topics: Animals; Behavior, Animal; Blepharoptosis; Body Weight; Catalepsy; Drug Tolerance; Growth; Haloperid | 1981 |
Kainic acid injections in the striatum alter the cataleptic and locomotor effects of drugs influencing dopaminergic and cholinergic systems.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Haloperidol; Humans; Injections; Kainic Acid; Male; M | 1981 |
[Hyperprolactinemia and catalepsy induced by haloperidol].
Topics: Animals; Catalepsy; Haloperidol; Humans; Injections, Intraperitoneal; Male; Pituitary Gland; Prolact | 1981 |
Biphasic locomotor response to intra-accumbens dopamine in a nonhuman primate.
Topics: Animals; Catalepsy; Dopamine; Haloperidol; Humans; Injections; Male; Motor Activity; Nucleus Accumbe | 1981 |
Effect of chronic estradiol and haloperidol treatment on striatal dopamine receptors.
Topics: Animals; Catalepsy; Corpus Striatum; Estradiol; Female; Haloperidol; Humans; Rats; Rats, Inbred Stra | 1981 |
Glucose potentiates haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Drug Synergism; Glucose; Haloperidol; Humans; Male; Rats; Rats, Inbred Strains; | 1981 |
[Pharmacological studies on the functional development of the central nervous system in first generation rats born to phenytoin-treated mothers (author's transl)].
Topics: Animals; Animals, Newborn; Ataxia; Birth Rate; Brain; Catalepsy; Diazepam; Eye; Feeding Behavior; Fe | 1982 |
Intrastriatal injection of kainic acid prevents the development of postsynaptic dopamine receptor hypersensitivity after chronic haloperidol treatment.
Topics: Animals; Apomorphine; Catalepsy; Corpus Striatum; Haloperidol; Humans; Injections; Kainic Acid; Male | 1982 |
Haloperidol, catalepsy, and equilibrating functions in the rat: antagonistic interaction of clinging and labyrinthine righting reactions.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Ear, Inner; Haloperidol; Humans; Kinesthesis; | 1981 |
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
Topics: Aminooxyacetic Acid; Animals; Antiparkinson Agents; Catalepsy; Delayed-Action Preparations; Drug Syn | 1982 |
Dopamine metabolites and catalepsy after lithium and haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Dopamine; Haloperidol; Homovanillic Acid; | 1982 |
Alterations in drug induced catalepsy and post-decapitation convulsions following brain and spinal cord depletion of norepinephrine by the neurotoxin DSP-4.
Topics: Amines; Animals; Arecoline; Benzylamines; Brain; Catalepsy; Drug Interactions; Haloperidol; Humans; | 1982 |
Sex difference in the development of hypersensitivity or tolerance to haloperidol in the rat.
Topics: Animals; Castration; Catalepsy; Drug Hypersensitivity; Drug Tolerance; Female; Haloperidol; Humans; | 1982 |
The striatal dopaminergic catalepsy mechanism is not necessary for the expression of pontine catalepsy produced by carbachol injections into the pontine reticular formation.
Topics: Animals; Basal Ganglia; Carbachol; Catalepsy; Dopamine; Dopamine Antagonists; Excitatory Amino Acid | 1995 |
N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Catalepsy; Dizocilpine Maleate; Haloperido | 1995 |
Striatal dopamine-mediated motor behavior is altered following occlusion of the middle cerebral artery.
Topics: Animals; Catalepsy; Cerebral Arteries; Dextroamphetamine; Dopamine; Dopamine Agents; Dopamine Antago | 1995 |
Evidence for an action of araboascorbic acid on dopaminergic pathways of the corpus striatum.
Topics: Animals; Ascorbic Acid; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; | 1995 |
Changes in dopamine, serotonin and their metabolites in discrete brain areas of rat offspring after in utero exposure to cocaine or related drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Amitriptyline; Amygdala; Analysis of Variance; Animals; Brain | 1993 |
[The strio-hypothalamic functional connections in pharmacologically evoked catalepsy in Wistar rats].
Topics: Animals; Catalepsy; Corpus Striatum; Electroencephalography; Haloperidol; Hypothalamus, Anterior; Mo | 1994 |
[Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy].
Topics: Animals; Catalepsy; Glycine; Haloperidol; Male; Mice; Palmitic Acids; Rats; Reserpine | 1995 |
Effect of manipulation of the GABA system on dopamine-related behaviors.
Topics: 3-Mercaptopropionic Acid; Animals; Apomorphine; Baclofen; Catalepsy; Dopamine Agonists; GABA Agents; | 1995 |
Taurine prevents haloperidol-induced changes in striatal neurochemistry and behavior.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Drug Administration Schedule; Evaluation | 1995 |
[Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Dopamine Agonists; Dose-Response Relationship, Dr | 1995 |
Behavioral and biochemical changes after bilateral electrolytic lesions of the red nucleus of rat.
Topics: Animals; Apomorphine; Azepines; Behavior, Animal; Body Temperature; Brain Chemistry; Catalepsy; Dopa | 1995 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperi | 1995 |
Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice.
Topics: Animals; Catalepsy; Granisetron; Haloperidol; Mice; Serotonin Antagonists; Time Factors; Tropanes | 1995 |
Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments.
Topics: Animals; Behavior, Animal; Catalepsy; Clozapine; Drug Interactions; Gene Expression Regulation, Enzy | 1995 |
K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys.
Topics: 4-Aminopyridine; Amodiaquine; Animals; Apamin; Behavior, Animal; Catalepsy; Dopamine Agonists; Dose- | 1995 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Ca | 1993 |
[Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Iso | 1993 |
Pharmacodynamic interactions of omeprazole with CNS active drugs in rats.
Topics: Administration, Oral; Analgesia; Animals; Catalepsy; Drug Interactions; Haloperidol; Hypnosis; Male; | 1995 |
Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment.
Topics: Animals; Body Weight; Catalepsy; Clozapine; Haloperidol; Immunohistochemistry; Male; Prosencephalon; | 1995 |
Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment.
Topics: Animals; Benzazepines; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; Mal | 1995 |
The influence of antineoplaston A5 on the central dopaminergic structures.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; Dopamine; Haloperidol; Male; | 1994 |
Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Benzazepines; Catalepsy; Dopamine D2 Receptor Antago | 1994 |
The relationship between motor effects in rats following acute and chronic haloperidol treatment.
Topics: Acute Disease; Animals; Catalepsy; Chronic Disease; Disease Models, Animal; Dyskinesia, Drug-Induced | 1994 |
Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats.
Topics: Animals; Benzazepines; Catalepsy; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; | 1994 |
Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: Acetylcholine; Animals; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dronabinol | 1994 |
[Neuroleptic catalepsy in rats is accompanied by activation of brain prolyl endopeptidase and is eliminated by inhibitors of this enzyme].
Topics: Animals; Brain; Catalepsy; Enzyme Activation; Haloperidol; Leucine; Prolyl Oligopeptidases; Rats; Se | 1994 |
Effects of carbaryl on some dopaminergic behaviors in rats.
Topics: Administration, Oral; Animals; Apomorphine; Behavior, Animal; Carbaryl; Catalepsy; Cholinesterases; | 1994 |
On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzazepines; Brain; Catalepsy; Corpus Striatum; Hal | 1993 |
Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Dopamine Agents; Drug Synergism; Haloperidol; Mal | 1993 |
Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
Topics: Animals; Animals, Newborn; Apomorphine; Basal Ganglia; Catalepsy; Corpus Striatum; Dopamine; Dopamin | 1993 |
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; | 1994 |
Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release.
Topics: Acetylcholine; Animals; Basal Metabolism; Catalepsy; Corpus Striatum; Dopamine; gamma-Aminobutyric A | 1994 |
Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Catalepsy; Caudate Nucleus; Dopamine; Glutam | 1994 |
The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Catalep | 1994 |
Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Caudate Nucleus; Chromatography, High Pressure L | 1994 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransf | 1994 |
Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antipsychotic Agents; Benzazepines; Blood Pressure | 1994 |
Further studies on the relationship between dopamine cell density and haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Cell Count; Dopamine; Haloperidol; Hybridization, Genetic; Male; Mice; Mice, Inb | 1994 |
The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
Topics: Animals; Binding, Competitive; Brain; Catalepsy; Corpus Striatum; Dextroamphetamine; Dose-Response R | 1994 |
Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: 2-Amino-5-phosphonovalerate; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amantadine; | 1994 |
Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Behavior, | 1994 |
KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Topics: Adenosine; Administration, Oral; Animals; Antihypertensive Agents; Benserazide; Catalepsy; Dose-Resp | 1994 |
Injection of apomorphine into the medial prefrontal cortex of the rat increases haloperidol-induced catalepsy.
Topics: Animals; Apomorphine; Catalepsy; Dopamine; Haloperidol; Injections; Male; Prefrontal Cortex; Rats; R | 1994 |
Pharmacological properties of beta-amyrin palmitate, a novel centrally acting compound, isolated from Lobelia inflata leaves.
Topics: Animals; Antidepressive Agents; Apomorphine; Blepharoptosis; Catalepsy; Central Nervous System; Dose | 1993 |
Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats.
Topics: Animals; Catalepsy; Caudate Nucleus; Haloperidol; Male; Motor Activity; Neostriatum; Putamen; Quinol | 1993 |
The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Excitatory Amino Acid | 1993 |
Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile.
Topics: Animals; Basal Ganglia Diseases; Brain; Catalepsy; Chromatography, High Pressure Liquid; Circadian R | 1993 |
3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Topics: Animals; Benserazide; Catalepsy; Drug Combinations; Haloperidol; Levodopa; Male; Mice; Motor Activit | 1994 |
Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Catalepsy; Catech | 1993 |
Effects of a single administration of buspirone on catalepsy, yawning and stereotypy in rats.
Topics: Analysis of Variance; Animals; Apomorphine; Buspirone; Catalepsy; Haloperidol; Male; Rats; Rats, Wis | 1993 |
Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1993 |
Effects of the 5-HT receptor antagonists cyanopindolol, ICI 169,369, cisapride and granisetron on neuroleptic-induced catalepsy in mice.
Topics: Animals; Buspirone; Catalepsy; Cisapride; Female; Granisetron; Haloperidol; Male; Mice; Pindolol; Pi | 1993 |
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Topics: Animals; Benzamides; Benzazepines; Catalepsy; Chlordiazepoxide; Dizocilpine Maleate; Dopamine D2 Rec | 1993 |
[Epiphyseal interrelations with the striatum in the haloperidol-induced catalepsy model].
Topics: Animals; Catalepsy; Corpus Striatum; Disease Models, Animal; Haloperidol; Male; Pineal Gland; Rats; | 1993 |
Serotonergic involvement in haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, S | 1993 |
Frontal cortex lesions modify the cataleptogenic properties of haloperidol but not of clozapine.
Topics: Animals; Catalepsy; Cerebral Cortex; Clozapine; Corpus Striatum; Dopamine; Frontal Lobe; Haloperidol | 1993 |
Intracerebral haloperidol potentiates the dorsal immobility response in the rat.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Female; Haloperidol; Microinjections; Ovariectomy; Rats | 1993 |
Partial 6-hydroxydopamine-induced lesions and haloperidol-induced catalepsy.
Topics: Aging; Animals; Apomorphine; Brain Chemistry; Catalepsy; Corpus Striatum; Dose-Response Relationship | 1993 |
D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Catalepsy; Dopamine D2 Receptor Antagonists; H | 1993 |
The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.
Topics: Animals; Antiparkinson Agents; Catalepsy; Dopamine Agonists; Dopamine Antagonists; Drug Interactions | 1995 |
Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dyskinesia, Drug-Induced; Grooming; Haloperidol; Male; N | 1995 |
Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery.
Topics: Acetylcholinesterase; Amphetamine; Animals; Avoidance Learning; Brain; Catalepsy; Central Nervous Sy | 1995 |
Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Central Nervous System Depressants; Dopa | 1995 |
Mapping the genes for haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Chromosome Mapping; Crossing Over, Genetic; Genotype; Haloperidol; Male; Mice; M | 1996 |
Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; C | 1996 |
Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.
Topics: Adrenalectomy; Animals; Catalepsy; Catecholamines; Glucocorticoids; Haloperidol; Male; Parkinson Dis | 1995 |
Effects of chronic methamphetamine on SCH23390- or haloperidol-induced catalepsy, and effects of coadministration of SCH23390 or haloperidol in mice.
Topics: Animals; Benzazepines; Catalepsy; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antago | 1996 |
[Substances that increase the extracellular level of dopamine in the striatum prevent development of haloperidol catalepsy in rats].
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Extracellular | 1996 |
Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice.
Topics: Animals; Benzazepines; Catalepsy; Cocaine; Dopamine Antagonists; Dose-Response Relationship, Drug; H | 1995 |
The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dizocilpine Maleate; Dopamine; gamma-Aminobutyric A | 1996 |
Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat.
Topics: Animals; Antipsychotic Agents; Arginine; Aspartic Acid; Catalepsy; Corpus Striatum; Dihydroxyphenyla | 1996 |
Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; Drug Administration Schedule; Extrapyrami | 1996 |
The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Biphenyl Compounds; Catalepsy; Dizocilpine Male | 1996 |
[The effect of the blinding of rats on the dynamics of short-period rhythmic processes with removal of the epiphysis].
Topics: Animals; Blindness; Catalepsy; Eye Enucleation; Haloperidol; Periodicity; Pineal Gland; Rats; Swimmi | 1996 |
Injection of a GABA antagonist into the mesopontine reticular formation abolishes haloperidol-induced catalepsy in rats.
Topics: Animals; Basal Ganglia; Catalepsy; Haloperidol; Male; Picrotoxin; Rats; Rats, Wistar; Reticular Form | 1996 |
Solcoseryl stimulates behavioural activity of rats.
Topics: Actihaemyl; Animals; Behavior, Animal; Catalepsy; Dopamine Antagonists; Exploratory Behavior; Halope | 1996 |
5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Catalepsy; Clozapine; Haloper | 1996 |
[The effect on central dopaminergic structures of various hydrazides of phosphorylated carbonic acids and diaziridines].
Topics: Acetates; Animals; Apomorphine; Body Temperature; Catalepsy; Dopamine Agents; Drug Interactions; Hal | 1996 |
SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties.
Topics: Acetylcholine; Aminoacridines; Animals; Avoidance Learning; Brain Chemistry; Catalepsy; Cholinergic | 1997 |
Effect of pre-treatment of some calcium channel blockers on catalepsy and stereotypic behaviour in rats.
Topics: Animals; Calcium Channel Blockers; Catalepsy; Central Nervous System Depressants; Central Nervous Sy | 1996 |
The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats.
Topics: 2-Naphthylamine; Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Dopamine D2 Receptor | 1997 |
The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Topics: Animals; Antiparkinson Agents; Benzazepines; Benzothiazoles; Body Temperature; Catalepsy; Clozapine; | 1997 |
Effect of aspartate and glutamate on nociception, catalepsy and core temperature in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesia; Analgesics, Opioid; Animals; Aspartic Acid; Body Temperatur | 1997 |
Single restraint stress sensitizes acute chewing movements induced by haloperidol, but not if the 5-HT1A agonist 8-OH-DPAT is given prior to stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Catalepsy; | 1997 |
8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Dopamine; Haloperidol; Male; Rats; Rats, | 1997 |
The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.
Topics: Adrenergic beta-Antagonists; Animals; Antipsychotic Agents; Carteolol; Catalepsy; Haloperidol; Locom | 1997 |
Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats.
Topics: 2-Chloroadenosine; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Catalepsy; Dopamine Antago | 1997 |
Dopaminergic and cholinergic interaction in cataleptic responses in mice.
Topics: Animals; Apomorphine; Benzazepines; Catalepsy; Cholinergic Antagonists; Dopamine; Dopamine Agonists; | 1997 |
MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dizocilpine Maleate; Dopamine Antagonists | 1997 |
Synthesis and cataleptic effects of optically active dihydrohaloperidols and dihydrobromoperidols.
Topics: Animals; Catalepsy; Haloperidol; Male; Mice; Mice, Inbred Strains; Molecular Structure; Motor Activi | 1997 |
Undernutrition during suckling changes the sensitivity to haloperidol and chlorpromazine in two behavioural measures in weaning rats.
Topics: Analysis of Variance; Animals; Animals, Suckling; Catalepsy; Chlorpromazine; Dopamine Antagonists; D | 1997 |
The effects of beta-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia.
Topics: Adrenergic beta-Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Arousal; Catale | 1997 |
Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Corpus Striatum; Cyclic AMP-Dependent Pr | 1997 |
MK-801 potentiates antidystonic effects of clozapine but not of haloperidol in mutant dystonic hamsters.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Clozapine; Cricetinae; Dizocilpine Maleate; Drug Synergi | 1997 |
Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Catalepsy; Genotype; Haloperidol; Mice; Mice, I | 1997 |
Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
Topics: Animals; Bromocriptine; Carbidopa; Catalepsy; Dopamine Agents; Dopamine Agonists; Dopamine Antagonis | 1997 |
Behavioral activity of 1S,3R-ACPD, an agonist of metabotropic glutamate receptors.
Topics: Animals; Apomorphine; Avoidance Learning; Catalepsy; Cycloleucine; Haloperidol; Injections, Intraven | 1997 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S | 1997 |
[Corticostriatal relations in the waking-sleep cycle of normal rats and in pathology].
Topics: Acoustic Stimulation; Animals; Catalepsy; Caudate Nucleus; Cerebral Cortex; Disease Susceptibility; | 1997 |
Mirtazapine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Ag | 1998 |
Tolerance to catalepsy following chronic haloperidol is not associated with changes in GABA release in the globus pallidus.
Topics: Animals; Antipsychotic Agents; Catalepsy; Drug Tolerance; gamma-Aminobutyric Acid; Globus Pallidus; | 1998 |
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.
Topics: Aging; alpha-Methyltyrosine; Animals; Avoidance Learning; Catalepsy; Cognition; Cognition Disorders; | 1998 |
Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson's disease.
Topics: Animals; Antidepressive Agents; Catalepsy; Depressive Disorder; Drug Evaluation, Preclinical; Halope | 1997 |
Expression of Fos protein in the limbic regions of the rat following haloperidol decanoate.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Haloperidol; Immunohistochemistry; L | 1998 |
Antipsychotic-like profile of alstonine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Catalepsy; Drug Evaluatio | 1998 |
D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1998 |
Modification of cataleptic responses to dopamine receptor antagonists after withdrawal from chronic cocaine or cocaine plus dopamine antagonist administration.
Topics: Animals; Antipsychotic Agents; Catalepsy; Cocaine; Dopamine Agonists; Dopamine Uptake Inhibitors; Ha | 1998 |
Riluzole, a glutamate release inhibitor, and motor behavior.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Behavior, Animal; Benzazepines; Benzodiazepines; | 1998 |
The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
Topics: Animals; Antipsychotic Agents; Benzamides; Catalepsy; Dopamine Antagonists; Dose-Response Relationsh | 1998 |
Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not.
Topics: Animals; Antipsychotic Agents; Benzazepines; Catalepsy; Clozapine; Conditioning, Operant; Haloperido | 1998 |
Involvement of 5-HT6 receptors in nigro-striatal function in rodents.
Topics: Adrenergic Agents; Animals; Basal Ganglia Diseases; Benzazepines; Catalepsy; Clozapine; Corpus Stria | 1998 |
Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Catalepsy; Clozapine; Drug Interactions; Halo | 1999 |
Synergistic interactions between ampakines and antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; Dioxoles; Drug Synergis | 1999 |
Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.
Topics: Animals; Binding, Competitive; Catalepsy; Cell Line; Dopamine Antagonists; Fluorobenzenes; Haloperid | 1999 |
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Catalepsy; Cyclopentanes; Drug Evaluation, Prec | 1999 |
Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat.
Topics: Animals; Catalepsy; Dopamine; Dopamine Antagonists; Haloperidol; Injections, Subcutaneous; Male; Mon | 1999 |
Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
Topics: Adenosine; Animals; Antipsychotic Agents; Behavior, Animal; Caffeine; Catalepsy; Clozapine; Corpus S | 1999 |
Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats.
Topics: Animals; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; | 1999 |
Behavioral changes as a result of dotarizine or flunarizine influence on dopaminergic neurotransmission in the striatum.
Topics: Administration, Oral; Animals; Area Under Curve; Benzhydryl Compounds; Calcium Channel Blockers; Cat | 1998 |
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dopamine Antagonists; Electromyography; Excitatory Amino | 1999 |
Evidence of sex related differences in the effects of calcium channel blockers on neuroleptic-induced catalepsy in mice.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Calcium Channel Blockers; Catalepsy; Dose-Res | 1999 |
Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation.
Topics: Animals; Catalepsy; Clozapine; Drug Interactions; Haloperidol; Immunoblotting; Immunohistochemistry; | 1999 |
[The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative--in experiments on mice].
Topics: Animals; Antipsychotic Agents; Catalepsy; Dose-Response Relationship, Drug; Female; Haloperidol; Inj | 1999 |
Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14.
Topics: Animals; Antipsychotic Agents; Catalepsy; Chromosome Mapping; Female; Genome; Genotype; Haloperidol; | 1999 |
Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Molecular Mimicry; MSH Rele | 1999 |
Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Free Radical | 1999 |
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats.
Topics: Animals; Anti-Ulcer Agents; Antipsychotic Agents; Catalepsy; Clozapine; Dopamine Antagonists; Dose-R | 1999 |
Effects of haloperidol on the expression of lymphocyte dopamine receptor mRNAs in the rat.
Topics: Animals; Antipsychotic Agents; Catalepsy; DNA Primers; Haloperidol; Lymphocytes; Male; Rats; Rats, S | 1999 |
State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801.
Topics: Animals; Antipsychotic Agents; Catalepsy; Central Nervous System Stimulants; Dizocilpine Maleate; Do | 1999 |
Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding, Competitive; Brain Chemistry; | 1999 |
Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzazepines; | 1999 |
Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy.
Topics: Animals; Autoradiography; Catalepsy; Dizocilpine Maleate; Dopamine Antagonists; Drug Interactions; G | 1999 |
Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment.
Topics: Animals; Apomorphine; Binding, Competitive; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agonists; | 1999 |
Inhibition of haloperidol-induced catalepsy in rats by root extracts from Piper methysticum F.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Haloperidol; Kava; Male; Plant Ext | 1999 |
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dextroamphetamine; Dopamine Agents; Dopam | 1999 |
Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.
Topics: Animals; Catalepsy; Cell Count; Dopamine; Dopamine Antagonists; Enzyme Inhibitors; Haloperidol; Hist | 2000 |
Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.
Topics: Animals; Apomorphine; Behavior, Animal; Body Temperature; Catalepsy; Clozapine; Haloperidol; Injecti | 2000 |
Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
Topics: Animals; Autoradiography; Behavior, Animal; Benzazepines; Catalepsy; Dopamine Antagonists; Dopamine | 2000 |
[The effect of lithium chloride on the rat behavior after short-term oligemic hypoxia].
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Catalepsy; Drug Synergism; Haloperidol; Ischemic Atta | 1998 |
Central action of some cytostatics--methotrexate (MTX) and doxorubicin (DXR). I. Long-term influence on the pain sensitivity and activity of brain dopaminergic system in mice.
Topics: Analgesics; Animals; Behavior, Animal; Body Weight; Brain; Catalepsy; Doxorubicin; Drug Interactions | 1998 |
Sex differences in catalepsy: evidence for hormone-dependent postural mechanisms in haloperidol-treated rats.
Topics: Animals; Biomechanical Phenomena; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Female; G | 2000 |
Detection and mapping of quantitative trait loci for haloperidol-induced catalepsy in a C57BL/6J x DBA/2J F2 intercross.
Topics: Animals; Catalepsy; Chromosome Mapping; Chromosomes, Human, Pair 14; Crosses, Genetic; Female; Halop | 1999 |
Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.
Topics: Animals; Bridged Bicyclo Compounds; Catalepsy; Dopamine Antagonists; Excitatory Amino Acid Agonists; | 2000 |
Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Conditioning, Operant; Haloperidol; Male | 1999 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catal | 2000 |
Relationship between structure and drug-induced parkinsonism.
Topics: Antipsychotic Agents; Catalepsy; Cinnarizine; Drug Design; Flunarizine; Haloperidol; Humans; Parkins | 2000 |
The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.
Topics: Animals; Antidepressive Agents; Apomorphine; Carbamazepine; Catalepsy; Disease Models, Animal; Dopam | 2000 |
Haloperidol catalepsy consolidation in the rat as a model of neuromodulatory integration.
Topics: Animals; Catalepsy; Dopamine; Dopamine Antagonists; Haloperidol; Learning; Long-Term Potentiation; M | 2000 |
[Glutamate receptor antagonists attenuate experimental catalepsy in rats].
Topics: Adamantane; Animals; Antipsychotic Agents; Ataxia; Catalepsy; Diamines; Dizocilpine Maleate; Dose-Re | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions.
Topics: Animals; Anxiety; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine Agonists; Dopamine Antagoni | 2000 |
Distinct functions of the two isoforms of dopamine D2 receptors.
Topics: Animals; Apomorphine; Benzazepines; Catalepsy; Chimera; Dopamine; Dopamine Agonists; Dopamine Antago | 2000 |
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.
Topics: Animals; Catalepsy; Chlorisondamine; Cotinine; Dopamine Antagonists; Drug Synergism; Haloperidol; Ma | 2000 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behav | 2000 |
Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Basal Ganglia Diseases; Catalepsy; Clozapine; Con | 2000 |
Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Brain; Catalepsy; Cocaine; Dopamine Uptake Inhibitors; F | 2001 |
Effects of pertussis toxin on behavioral responses during different withdrawal periods from chronic cocaine treatment.
Topics: Adenosine Diphosphate Ribose; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Catalep | 2000 |
Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs.
Topics: Animals; Catalepsy; Central Nervous System Depressants; Crosses, Genetic; Dopamine Antagonists; Etha | 2000 |
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
Topics: Adenosine; Amphetamines; Animals; Caffeine; Catalepsy; Corpus Striatum; Dopamine Antagonists; Enkeph | 2001 |
Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy.
Topics: Animals; Benzazepines; Catalepsy; Dopamine Antagonists; Haloperidol; Male; Mice; Mice, Knockout; Mus | 2001 |
Nitric oxide synthase inhibitors cause motor deficits in mice.
Topics: Animals; Brain Chemistry; Catalepsy; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enzym | 2001 |
Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
Topics: Animals; Avoidance Learning; Catalepsy; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug | 2001 |
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Rel | 2001 |
Neurotensin-deficient mice show altered responses to antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Catalepsy; Gene Deletion; Gene Targeting; Haloperidol; Mice; Molecula | 2001 |
Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
Topics: Animals; Antipsychotic Agents; Catalepsy; Circadian Rhythm; Dopamine Antagonists; Dose-Response Rela | 2001 |
Haloperiodol-induced microcatalepsy differs in CD-1, BALB/c, and C57BL/6 mice.
Topics: Animals; Antipsychotic Agents; Catalepsy; Conditioning, Operant; Dose-Response Relationship, Drug; H | 2001 |
Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Catalepsy; Dyskinesia, Drug-Induced; Electromyo | 2001 |
Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP).
Topics: Animals; Base Sequence; Brain; Catalepsy; DNA Primers; Haloperidol; Hydroxyindoleacetic Acid; Mice; | 2001 |
Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties.
Topics: Analgesics; Animals; Antipsychotic Agents; Blood-Brain Barrier; Body Temperature; Catalepsy; Corpus | 2001 |
Mecamylamine effects on haloperidol-induced catalepsy and defecation.
Topics: Animals; Antipsychotic Agents; Catalepsy; Defecation; Drug Synergism; Haloperidol; Male; Mecamylamin | 2001 |
Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats.
Topics: Animals; Behavior, Animal; Catalepsy; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; D | 2001 |
[Ability of novel non-competitive glutamate receptor blocking agents to weaken motor disorders in animals].
Topics: Animals; Anticonvulsants; Ataxia; Benzene Derivatives; Catalepsy; Cations; Cyclohexanes; Excitatory | 2001 |
Neurobehavioural study of subchronic administration of oxydemeton-methyl (insecticide and acaricide) in rats.
Topics: Animals; Antipsychotic Agents; Barbital; Behavior, Animal; Catalepsy; Convulsants; Electroshock; Exp | 2001 |
Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Catalepsy; Central Nervous System; Dop | 2002 |
Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Clozapine; Dopamine; Dopamine Agents; Dose-Response | 2002 |
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.
Topics: Animals; Antipsychotic Agents; Apomorphine; Atropine; Benztropine; Catalepsy; Drug Interactions; Hal | 1976 |
Acetylcholine turnover rate in n. accumbens, n. caudatus, globus pallidus, and substantia nigra: action of cataleptogenic and non-cataleptogenic antipsychotics.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Catalepsy; Caudate Nucleus; Chlorpromazine; Clozapine; | 1977 |
Chronic neuroleptic therapy: tolerance and GABA systems.
Topics: Adenylyl Cyclases; Aminobutyrates; Animals; Antipsychotic Agents; Brain; Brain Chemistry; Catalepsy; | 1977 |
A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzamides; Binding, Competitive; Catalepsy; Corpus Striatu | 1978 |
On the central noradrenergic mechanism involved in haloperidol-induced catalepsy in the rat.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain Chemistry; Catalepsy; Drug Inte | 1978 |
Influence of GABA-agonists and antagonists on neuroleptic-induced catalepsy in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Drug Interactions; GABA Antagonists; gamma-Aminobutyric Ac | 1978 |
Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines.
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Anxiety Agents; Benzodiazepines; Catalepsy; Corpus Stria | 1978 |
[Lithium modifications of the cataleptogenic properties of various neuroleptic drugs in the rat].
Topics: Animals; Antipsychotic Agents; Catalepsy; Drug Synergism; Female; Haloperidol; Humans; Lithium; Phen | 1978 |
Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050).
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzamides; Catalepsy; Chlorpromazine; Dogs; Dopamine; D | 1979 |
Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic Des-Tyr1-gamma-endorphin.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Blepharoptosis; Brain; Butyrophenones; Catalepsy; E | 1979 |
Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat.
Topics: Animals; Avoidance Learning; Behavior, Animal; Catalepsy; Clozapine; Dextroamphetamine; Fluphenazine | 1978 |
A study of the changes in motor behaviour caused by TRH on intracerebral injection.
Topics: Animals; Brain; Catalepsy; Chloral Hydrate; Dextroamphetamine; Dopamine; Dose-Response Relationship, | 1979 |
Is morphine-induced catalepsy related to activation of dopaminergic neurones?
Topics: Animals; Apomorphine; Catalepsy; Dopamine; Haloperidol; Humans; Male; Methyltyrosines; Morphine; Nal | 1978 |
Noradrenergic influences on catalepsy.
Topics: Animals; Animals, Newborn; Arecoline; Catalepsy; Haloperidol; Humans; Hydroxydopamines; Male; Morphi | 1978 |
Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Central Nervous System; Clomipramine; Drug Interactions; Haloperidol; Humans; Ma | 1979 |
Cataleptic action of nitrazepam and brain dopamine function in mice.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Catalepsy; Chlorpromazine; Dop | 1977 |
[Effect of pharmacological agents and coagulation of the n. raphe dorsalis on morphine effects].
Topics: Animals; Brain Stem; Catalepsy; Cyproheptadine; Dimenhydrinate; Electrocoagulation; Female; Fencloni | 1979 |
The effects of agents acting at pre- and postsynaptic alpha-adrenoceptors on haloperidol catalepsy [proceedings].
Topics: Animals; Catalepsy; Drug Interactions; Haloperidol; Humans; Male; Mice; Receptors, Adrenergic; Recep | 1979 |
A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
Topics: Aggression; Amphetamine; Analgesics, Opioid; Animals; Apomorphine; Behavior, Animal; Brain; Cataleps | 1975 |
Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD.
Topics: 5,7-Dihydroxytryptamine; Animals; Apomorphine; Behavior, Animal; Brain Injuries; Catalepsy; Ergoline | 1978 |
Movement induced in cataleptic rats: differential effects produced by electrical stimulation of the lateral hypothalamus, substantia nigra, and reticular formation.
Topics: Animals; Catalepsy; Electric Stimulation; Electroencephalography; Haloperidol; Humans; Hypothalamus; | 1978 |
Tolerance of haloperidol catalepsy.
Topics: Administration, Oral; Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Haloperi | 1977 |
Amphetamine-haloperidol interactions in rat striatum: failure to correlate behavioral effects with dopaminergic and cholinergic dynamics.
Topics: Amphetamine; Animals; Behavior, Animal; Catalepsy; Choline; Corpus Striatum; Dopamine; Drug Interact | 1977 |
The interaction of clonidine with dopamine-dependent behaviour in rodents.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Clonidine; Corpus Striatum; Dextroamphetamine; Do | 1977 |
Involvement of striatal dopamine, homovanillic acid and 3,4-dihydroxyphenylacetic acid in the hypothermia and catalepsy induced by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Body Temperature; Catalepsy; Corpus Stria | 1977 |
The demonstration in vivo of specific binding sites for neuroleptic drugs in mouse brain.
Topics: Animals; Apomorphine; Brain; Catalepsy; Chlorpromazine; Dibenzocycloheptenes; Dopamine; Haloperidol; | 1977 |
Noradrenergic involvement in dopamine-dependent stereotyped and cataleptic responses in the rat.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Brain Chemistry; Brain Stem; Catalepsy; Cerebellum; Cer | 1977 |
Haloperidol-induced tolerance to morphine catalepsy.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; Humans; Male; Mor | 1977 |
Dopamine receptor blocking activity of sulpiride in the central nervous system.
Topics: Administration, Oral; Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; Cerebral Ventricles; | 1977 |
Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Drug Interactions; Haloperidol; Homovanillic Acid; Hu | 1978 |
Potentiation by haloperidol of the catalepsy produced by lesions in the parafascicular nucleus of the rat.
Topics: Afferent Pathways; Animals; Catalepsy; Caudate Nucleus; Dose-Response Relationship, Drug; Haloperido | 1978 |
Dopaminergic mediation of beta-endorphin-induced catalepsy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain Chemistry; Catalepsy; Corpus Striatum; D | 1978 |
Correlation between multitest and single test catalepsy assessment.
Topics: Animals; Catalepsy; Fluphenazine; Haloperidol; Humans; Male; Rats; Time Factors | 1978 |
[Effect of phosphodiesterase inhibitors on neuroleptic-induced catalepsy and apomorphine-induced stereotypic movements in rats].
Topics: Animals; Apomorphine; Atropine; Catalepsy; Haloperidol; Humans; Movement Disorders; Papaverine; Phos | 1978 |
The pharmacological investigations of the central action of benzydamine.
Topics: Animals; Benzydamine; Brain; Catalepsy; Chlorpromazine; Dopamine; Haloperidol; Humans; Male; Norepin | 1978 |
Evidence that a nigral gabaergic--cholinergic balance controls posture.
Topics: Animals; Apomorphine; Arecoline; Behavior, Animal; Carbachol; Catalepsy; Choline O-Acetyltransferase | 1979 |
Dopaminergic antagonism and catalepsy in the developing rat.
Topics: Aging; Animals; Catalepsy; Dopamine; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Rats; | 1979 |
Altered response to apomorphine and haloperidol after nine days of cocaine injections.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Cocaine; Drug Interactions; Haloperidol; Humans; | 1979 |
Electroconvulsive shock reduces the cataleptogenic effect of both haloperidol and arecoline in rats.
Topics: Anesthesia; Animals; Arecoline; Catalepsy; Electroshock; Haloperidol; Halothane; Humans; Male; Rats; | 1979 |
Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors.
Topics: Animals; Apomorphine; Binding, Competitive; Brain; Butyrophenones; Catalepsy; Haloperidol; Humans; M | 1979 |
Potentiation of haloperidol-induced catalepsy by dopamine agonists: possible involvement of central 5-hydroxytryptamine.
Topics: Animals; Apomorphine; Brain; Catalepsy; Dextroamphetamine; Dopamine; Drug Interactions; Haloperidol; | 1979 |
[Relationship of the homovanillic acid content in the rat brain after the administration of a neuroleptic and the degree of dopamine receptor sensitivity to an agonist].
Topics: Animals; Apomorphine; Brain; Catalepsy; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates | 1979 |
Serotonin--dopamine interactions in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Catalepsy; Corpus Striatum; Dopamine; Drug Int | 1979 |
Biphasic effect of direct GABA mimetic drugs on haloperidol-induced catalepsy [proceedings].
Topics: Animals; Catalepsy; Drug Interactions; gamma-Aminobutyric Acid; Haloperidol; Humans; Male; Rats | 1979 |
Effect of haloperidol on reflex activation of rat alpha-motoneurones. A possible explanation for akinesia and catalepsy?
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Humans; In Vitro Techniques; Male; Motor Neurons; Move | 1979 |
Accumulation of apomorphine in caudate nucleus and hippocampus of the rabbit.
Topics: Animals; Apomorphine; Catalepsy; Caudate Nucleus; Cerebellum; Dose-Response Relationship, Drug; Halo | 1979 |
[Methods for detecting "cataleptic states" in the rat].
Topics: Animals; Behavior, Animal; Catalepsy; Haloperidol; Humans; Methods; Oxotremorine; Rats | 1978 |
[Pharmacological studies of an antipschotic agent, penfluridol. (1). The central pharmacological actions].
Topics: Agonistic Behavior; Animals; Apomorphine; Avoidance Learning; Blepharoptosis; Body Temperature; Cata | 1976 |
AMT catalepsy and hypokinesia: interaction with morphine and cocaine.
Topics: Animals; Body Temperature; Brain Chemistry; Catalepsy; Catecholamines; Cocaine; Drug Interactions; D | 1976 |
[Facilitation of the effects of L-DOPA by alpha-methyldopa].
Topics: Animals; Blood Pressure; Catalepsy; Cats; Dopamine; Drug Interactions; Drug Therapy, Combination; Ha | 1976 |
Effects of fentanyl and droperidol on the dopamine metabolism of the rat striatum.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Droperidol; Fentany | 1976 |
Differential attenuation of some effects of haloperidol in rats given scopolamine.
Topics: Amphetamine; Animals; Avoidance Learning; Catalepsy; Corpus Striatum; Dose-Response Relationship, Dr | 1976 |
Interaction of drug effects with testing procedures in the measurement of catalepsy.
Topics: Animals; Catalepsy; Female; Haloperidol; Humans; Rats; Time Factors | 1976 |
Effects of aminooxyacetic acid and baclofen on the catalepsy and on the increase of mesolimbic and striatal dopamine turnover induced by haloperidol in rats.
Topics: Acetates; Aminobutyrates; Aminooxyacetic Acid; Animals; Baclofen; Brain Chemistry; Catalepsy; Corpus | 1976 |
Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics.
Topics: Animals; Butyrophenones; Catalepsy; Chlorpromazine; Clozapine; Corpus Striatum; Dopamine; Dose-Respo | 1976 |
Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat.
Topics: Animals; Apomorphine; Behavior; Biogenic Amines; Brain; Brain Chemistry; Catalepsy; Dopamine; Halope | 1976 |
On a prime role for newly synthesized dopamine in striatal function.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Drug Synergism; Female; Haloperidol; Homovanillic Aci | 1975 |
Effect of sensory stimulation on the potency of cataleptogens.
Topics: Acoustic Stimulation; Animals; Arecoline; Catalepsy; Female; Haloperidol; Humans; Mice; Mice, Inbred | 1975 |
Detection of the nueroleptic properties of clozapine, sulpiride and thioridazine.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Clozapine; Dextroamphetamine; Dibenzazepines; Dos | 1975 |
[Farnesol and neuroleptics. I. Reinforcement by farnesol of the experimental cataleptigenic effect of neuroleptics].
Topics: Animals; Catalepsy; Chlorpromazine; Drug Synergism; Farnesol; Haloperidol; Humans; Rats; Reserpine; | 1975 |
[Behavior pharmacology of maprotiline, a new antidepressant].
Topics: Aggression; Amitriptyline; Animals; Anthracenes; Apomorphine; Behavior, Animal; Body Temperature; Ca | 1975 |
Haloperidol catalepsy in grouped and isolated mice.
Topics: Animals; Behavior, Animal; Catalepsy; Drug Interactions; Haloperidol; Humans; Injections, Subcutaneo | 1975 |
Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Tem | 1975 |
Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat.
Topics: Animals; Catalepsy; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Hal | 1992 |
Effects of age and isolation on the evolution of catalepsy during chronic haloperidol treatment.
Topics: Aging; Animals; Catalepsy; Drug Tolerance; Haloperidol; Housing, Animal; Male; Rats; Social Isolatio | 1992 |
The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding Sites; Catalepsy; Cycloserine; Dizoc | 1992 |
Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Catalepsy; Dopamine; Haloperidol; Male; Mice; Mice, | 1992 |
Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Caudate Nucleus; Corpus Striatum; Dialysis; Dopamine; Fema | 1992 |
D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Topics: Animals; Benzazepines; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Drug Intera | 1992 |
Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Corpus Striatum; Cyclic AMP; Dopamine; Haloperid | 1992 |
Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspirin; Catalepsy; Corpus Striatum; Cyclooxygenase Inhibit | 1992 |
Similarities between the akinesia induced by carbachol microinjections into the pontine reticular formation and neuroleptic catalepsy.
Topics: Analysis of Variance; Animals; Carbachol; Catalepsy; Haloperidol; Male; Microinjections; Morphine; M | 1992 |
Upregulation of postsynaptic dopamine receptors in the striatum does not influence haloperidol-induced catalepsy in mice.
Topics: Animals; Biogenic Monoamines; Catalepsy; Corpus Striatum; Haloperidol; Kinetics; Male; Mice; Mice, I | 1992 |
Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Catalepsy; Cholinesterase Inhibitors; Corpus Stri | 1992 |
One brief exposure to a psychological stressor induces long-lasting, time-dependent sensitization of both the cataleptic and neurochemical responses to haloperidol.
Topics: Animals; Catalepsy; Corticosterone; Dopamine; Haloperidol; Housing, Animal; Male; Nucleus Accumbens; | 1992 |
Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.
Topics: 2-Amino-5-phosphonovalerate; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; | 1991 |
Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Cerebral Cortex; Corpus Striatum; Excitatory Amino Acid Antagonists; Glutamates; | 1991 |
An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia.
Topics: Age Factors; Animals; Apomorphine; Catalepsy; Estradiol; Female; Haloperidol; Male; Rats; Receptors, | 1991 |
Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist.
Topics: Animals; Anticonvulsants; Benzocycloheptenes; Catalepsy; Dose-Response Relationship, Drug; Haloperid | 1991 |
Nicotine potentiates the behavioral effects of haloperidol.
Topics: Animals; Behavior, Animal; Catalepsy; Drug Synergism; Haloperidol; Male; Nicotine; Rats; Rats, Inbre | 1991 |
[Neuropharmacological activity of cerucal and haloperidol by intraperitoneal and intrastriatal administration in rats].
Topics: Animals; Avoidance Learning; Catalepsy; Corpus Striatum; Haloperidol; Injections; Injections, Intrap | 1991 |
Prolactin response to morphine in intact and adrenalectomized lactating rats.
Topics: Adrenalectomy; Animals; Catalepsy; Corticosterone; Female; Haloperidol; Lactation; Morphine; Prolact | 1991 |
One experience with 'lower' or 'higher' intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Catalepsy; Corticosterone; Deoxygluco | 1991 |
Dissociation of haloperidol-induced "anhedonia" and catalepsy by lesions of the dorsal raphe nucleus.
Topics: Animals; Catalepsy; Dopamine Antagonists; Drinking; Haloperidol; Male; Philosophy; Raphe Nuclei; Rat | 1991 |
[Comparison of central stimulating effects between ephedrine and apomorphine].
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ephedrine; Haloperidol; Male; Mice; Motor Activity; | 1991 |
Dorsal raphe nucleus lesions have no effect on neuroleptic-induced catalepsy and on the anticataleptic activity of buspirone.
Topics: Animals; Buspirone; Catalepsy; Haloperidol; Male; Raphe Nuclei; Rats; Rats, Inbred Strains; Receptor | 1991 |
On the selection of mice for haloperidol response and non-response.
Topics: Animals; Autoradiography; Catalepsy; Haloperidol; Mice; Mice, Inbred Strains; Receptors, Dopamine; R | 1991 |
[Pharmacological effects of the novel dopamine uptake inhibitor 1-[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on the central nervous system].
Topics: Animals; Barbiturates; Body Temperature; Catalepsy; Dogs; Dopamine; Dose-Response Relationship, Drug | 1991 |
The effect of theophylline and immobilization stress on haloperidol-induced catalepsy and on metabolism in the striatum and hippocampus, studied with lactography.
Topics: Adrenalectomy; Animals; Catalepsy; Corpus Striatum; Haloperidol; Hippocampus; Immobilization; Lactat | 1991 |
Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hal | 1991 |
Chronic cocaine-induced supersensitivity id blocked by co-treatment with the peptide cyclo-(Leu-Gly).
Topics: Animals; Body Temperature; Catalepsy; Cocaine; Haloperidol; Motor Activity; Neuropeptides; Peptides, | 1990 |
Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Cau | 1991 |
Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catalepsy; | 1991 |
Further studies on the neuroleptic profile of manassantin A.
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Binding, | 1990 |
Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Chlorpromazine; Cloz | 1990 |
The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Dextroamphetamine; D | 1990 |
Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy.
Topics: Animals; Antipsychotic Agents; Benzazepines; Catalepsy; Corpus Striatum; Dose-Response Relationship, | 1990 |
Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation.
Topics: Animals; Apomorphine; Brain Stem; Carbachol; Catalepsy; Dopamine Agents; Haloperidol; Injections; In | 1990 |
Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotonergic function.
Topics: Amphetamine; Animals; Brain Chemistry; Catalepsy; Dopamine; Down-Regulation; Drug Interactions; Halo | 1991 |
[Behavioral effects of a new antidepressant, setiptiline].
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Antidepressive Agents; Body Temperature; Catalepsy; Dru | 1991 |
The enhancement of the hypomotility induced by small doses of haloperidol in the phase of dopaminergic supersensitivity in mice.
Topics: Animals; Apomorphine; Catalepsy; Cerebral Cortex; Corpus Striatum; Dopamine; Haloperidol; Homovanill | 1991 |
Influences of diterpene sclareol glycol on some dopamine related behavior.
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Diterpenes; Dopamine; Haloperidol; Male; Mice; Mo | 1991 |
Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice.
Topics: Animals; Buspirone; Catalepsy; Chlorpromazine; Clomipramine; Female; Haloperidol; Male; Mice; Pindol | 1990 |
Differential effect of bupropion on haloperidol and morphine catalepsy in the rat.
Topics: Animals; Antidepressive Agents; Bupropion; Catalepsy; Female; Haloperidol; Male; Morphine; Propiophe | 1990 |
Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats.
Topics: Animals; Aspartic Acid; Baclofen; Bromocriptine; Catalepsy; Dibenzocycloheptenes; Dizocilpine Maleat | 1990 |
Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants.
Topics: Animals; Behavior, Animal; Catalepsy; Dose-Response Relationship, Drug; Drug Tolerance; Haloperidol; | 1990 |
The effect of serotonergic agents on haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Dopamine; Haloperidol; Male; Rats; Rats, Inbred Strains; Receptors, Serotonin; S | 1990 |
Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Catalepsy; Dopamine; Haloperidol; Male; | 1990 |
Influences of estrogen and/or progesterone on some dopamine related behavior in rats.
Topics: Animals; Behavior, Animal; Benzyl Alcohols; Catalepsy; Dopamine; Estrogens; Female; Haloperidol; Mot | 1990 |
Effects of a Palicourea marcgravii leaf extract on some dopamine-related behaviors of rats.
Topics: Animals; Apomorphine; Catalepsy; Drug Synergism; Haloperidol; Male; Motor Activity; Plant Extracts; | 1990 |
Is experimental catalepsy properly measured?
Topics: Adrenal Glands; Animals; Apomorphine; Catalepsy; Disease Models, Animal; Drug Interactions; Haloperi | 1990 |
Effects of dihydroergotoxine on some dopamine-related behaviors in rats.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catalepsy; Catecholamines; Dihydroergotoxin | 1990 |
Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Haloperidol; Male; Rats; Rats, Inbred F344; R | 1989 |
A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Binding, Competitive; Catalepsy; Dihydroxyphe | 1989 |
Relative importance of the dopaminergic system in haloperidol-catalepsy and the anticataleptic effect of antidepressants and methamphetamine in rats.
Topics: Animals; Antidepressive Agents; Catalepsy; Dopamine; Haloperidol; Imipramine; Male; Methamphetamine; | 1989 |
Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
Topics: Animals; Brain Diseases; Catalepsy; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; G(M1) Gangl | 1989 |
Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats.
Topics: Animals; Catalepsy; Dibenzocycloheptenes; Dizocilpine Maleate; Dose-Response Relationship, Drug; Hal | 1989 |
Significance of the cerebral dopaminergic neurotransmission for the individual differences in learning and memory (experiments on rats).
Topics: Animals; Apomorphine; Catalepsy; Dopamine; Ergolines; Haloperidol; Learning; Male; Memory; Rats; Rat | 1989 |
Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
Topics: Animals; Antipsychotic Agents; Benzazepines; Catalepsy; Drug Tolerance; Haloperidol; Male; Rats; Rat | 1989 |
Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice.
Topics: Animals; Catalepsy; Haloperidol; Male; Mice; Time Factors | 1989 |
Seemingly paradoxical jumping in cataleptic haloperidol-treated rats is triggered by postural instability.
Topics: Animals; Behavior, Animal; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Posture; | 1989 |
Relation between dopaminergic control of pituitary lactotroph function and deceleration of age-related changes in serum prolactin of diet-restricted rats.
Topics: Aging; Animals; Bromocriptine; Catalepsy; Diet; Dopamine; Female; Haloperidol; Male; Pituitary Gland | 1989 |
Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome.
Topics: Adolescent; Animals; Behavior, Animal; Catalepsy; Chewing Gum; Child; Child, Preschool; Drug Interac | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobut | 1989 |
[Comparison between the catalepsies induced by delta 9-tetrahydro-cannabinol and haloperidol in rats].
Topics: Animals; Catalepsy; Dronabinol; Female; Haloperidol; Male; Rats | 1987 |
Study of the participation of the dopaminergic transmission system in the effects of two newly synthesized barbiturates.
Topics: Animals; Apomorphine; Barbiturates; Catalepsy; Haloperidol; Male; Pentobarbital; Phenytoin; Rats; Re | 1988 |
1-[3-(Diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Catalepsy; Corpus Stria | 1985 |
Inhibition of haloperidol-induced catalepsy by cholecystokinin octapeptides after central administration to rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Haloperidol; Humans; Injections, Intraventricular; Male; R | 1985 |
Effect of H2 receptor blockade upon hypothermic, cataleptogenic and antinociceptive action of prostacyclin (PGI)2 administered into the lateral rat brain ventricle.
Topics: Analgesics; Animals; Body Temperature; Catalepsy; Cimetidine; Drug Interactions; Epoprostenol; Halop | 1985 |
The effect of different types of cortical lesions on drug-induced catalepsy in rats: a pharmacological analysis.
Topics: Animals; Antipsychotic Agents; Catalepsy; Cerebral Cortex; Dopamine; Haloperidol; Morphine; Rats; Ra | 1985 |
Catalepsy induced by SCH 23390 in rats.
Topics: Animals; Antipsychotic Agents; Benzazepines; Catalepsy; Dose-Response Relationship, Drug; Drug Inter | 1985 |
Neuroleptic-induced catalepsy: a D2 blockade phenomenon?
Topics: Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Drug Intera | 1985 |
Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; MSH Release-Inhibiting Horm | 1986 |
Bandage backfall: labyrinthine and non-labyrinthine components.
Topics: Animals; Aporphines; Catalepsy; Ear, Inner; Haloperidol; Kinesthesis; Male; Muscles; Neck Muscles; P | 1986 |
[Seasonal changes in the behavioral effects of neuroleptics on white rats].
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Female; Haloperidol; Methotrimeprazine; | 1986 |
Potentiation of haloperidol-induced catalepsy by beta-adrenoceptor antagonists in mice.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Catalepsy; Chlordiazepoxide; Dose-Response Relations | 1986 |
Transient supression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla.
Topics: Adrenal Medulla; Animals; Catalepsy; Epinephrine; Haloperidol; Male; Rats; Rats, Inbred Strains; Str | 1987 |
Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice.
Topics: Animals; Catalepsy; Drug Interactions; Haloperidol; Histamine H1 Antagonists; Histamine H2 Antagonis | 1987 |
Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats.
Topics: Aging; Animals; Antipsychotic Agents; Benzamides; Catalepsy; Chickens; Dextroamphetamine; Fenclonine | 1987 |
Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus.
Topics: Amphetamine; Animals; Antipsychotic Agents; Blepharoptosis; Body Temperature; Catalepsy; Furans; Hal | 1987 |
Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Catalepsy; Drug Interactions; Haloperidol; Male; | 1988 |
Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
Topics: Animals; Behavior, Animal; Catalepsy; Catechol O-Methyltransferase Inhibitors; Central Nervous Syste | 1987 |
8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Haloperidol; Ma | 1988 |
Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy.
Topics: Animals; Benzazepines; Catalepsy; Corpus Striatum; Haloperidol; Male; Pyridines; Quinolinic Acid; Qu | 1988 |
Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Catalepsy; Drug Interactions; Fenfluramine; Haloper | 1988 |
Possible function of alpha 1-adrenoceptors in the CNS in anaesthetized and conscious animals.
Topics: Anesthesia; Animals; Blood Pressure; Brain; Catalepsy; Cats; Clonidine; Dogs; Exploratory Behavior; | 1985 |
[Behavioral pharmacology of amantadine with special references to the effect on abnormal behavior in mice and rats].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Catalepsy; Central Nervous System; Dronabinol; Ha | 1985 |
Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats.
Topics: Animals; Brain Mapping; Catalepsy; Corpus Striatum; Dopamine; Electromyography; Haloperidol; Male; M | 1985 |
Thalamus as a relay station for catalepsy and rigidity.
Topics: Animals; Brain Mapping; Catalepsy; Escape Reaction; Haloperidol; Male; Morphine; Muscimol; Muscle Ri | 1985 |
Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.
Topics: Animals; Brain; Catalepsy; Desipramine; Dopamine; Dronabinol; Haloperidol; Hydroxydopamines; Locus C | 1987 |
Role of dopaminergic and GABAergic mechanisms in discrete brain areas in phencyclidine-induced locomotor stimulation and turning behavior.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Caudate Nucleus; Dopamine; Globus Pallidus; Haloperidol | 1986 |
Behavioural responses of rats on high- and low-protein diets, as a function of period of weaning.
Topics: Animals; Behavior, Animal; Body Temperature; Catalepsy; Dietary Proteins; Eating; Female; Growth; Ha | 1986 |
Some behavioural and EEG effects of ascorbic acid in rats.
Topics: Animals; Ascorbic Acid; Behavior, Animal; Catalepsy; Dextroamphetamine; Dose-Response Relationship, | 1986 |
Prolonged cataleptogenic effects of potentized homoeopathic drugs.
Topics: Agaricales; Agaricus; Animals; Cannabis; Carbon; Catalepsy; Graphite; Haloperidol; Homeopathy; Male; | 1986 |
Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Catalepsy; Corpus Striatum; Drug Tolerance; | 1986 |
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Bod | 1987 |
Ketotifen can antagonise changes in sensitivity of cerebral dopamine receptors: behavioural correlates in rodent and primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Callitrichinae; Cata | 1987 |
Conditional tolerance to haloperidol-induced catalepsy: striatal dopamine receptor supersensitivity is a possible explanation.
Topics: Animals; Catalepsy; Corpus Striatum; Drug Tolerance; Haloperidol; Models, Neurological; Receptors, D | 1988 |
Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacological treatment of psychosis.
Topics: Animals; Brain; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Rats; Rats, Inbred S | 1988 |
Evidence for the independent role of GABA synapses of the zona incerta-lateral hypothalamic region in haloperidol-induced catalepsy.
Topics: Animals; Bicuculline; Catalepsy; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Haloperi | 1988 |
Dose-catalepsy response to haloperidol in rat: effects of strain and sex.
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Female; Haloperidol; Male; Rats; Rats, Inbred | 1988 |
[Effect of destruction of the hypothalamic suprachiasmatic nuclei on the dynamics of swimming and haloperidol-induced catalepsy in rats].
Topics: Animals; Catalepsy; Circadian Rhythm; Electrolysis; Female; Haloperidol; Motor Activity; Physical Ex | 1988 |
Behavioural and biochemical effects of haloperidol during the oestrous cycle of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catalepsy; Dopamine; Estrus; Female; Halop | 1988 |
Radiation-induced increases in sensitivity of cataleptic behavior to haloperidol: possible involvement of prostaglandins.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine; Gamma Rays; Haloperidol; In Vitro T | 1988 |
Effect of aspirin on haloperidol-induced cataleptic behavior in mice.
Topics: Animals; Aspirin; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Mice, Inbred | 1988 |
Catalepsy after microinjection of haloperidol into the rat medial prefrontal cortex.
Topics: Animals; Catalepsy; Dopamine; Frontal Lobe; Haloperidol; Male; Microinjections; Rats; Rats, Inbred S | 1988 |
The spontaneously diabetic Wistar-BB rat manifests altered grooming and catalepsy responses: implications of impaired dopamine function.
Topics: Animals; Catalepsy; Diabetes Mellitus, Experimental; Dopamine; Grooming; Haloperidol; Male; Rats; Ra | 1988 |
[Dynamics of minute rhythms of catalepsy and role of a regimen of daily administration of haloperidol on the formation of tolerance].
Topics: Animals; Catalepsy; Drug Tolerance; Haloperidol; Male; Rats; Time Factors | 1988 |
Conditioned tolerance to haloperidol- and droperidol-induced catalepsy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Catalepsy; Conditioning, Psychological; | 1988 |
Morphine subtracts subcomponents of haloperidol-isolated postural support reflexes to reveal gradients of their integration.
Topics: Animals; Body Temperature; Catalepsy; Drug Interactions; Female; Haloperidol; Male; Morphine; Postur | 1986 |
Dopamine dependent behaviours in rats with bilateral ibotenic acid-induced lesions of the globus pallidus.
Topics: Amphetamines; Animals; Apomorphine; Behavior, Animal; Catalepsy; Dopamine; Functional Laterality; Gl | 1986 |
Pharmacological subtraction of the sensory controls over grasping in rats.
Topics: Animals; Catalepsy; Diazepam; Drug Combinations; Foot; Haloperidol; Male; Morphine; Rats; Rats, Inbr | 1987 |
Lack of the effect of ketamine on some dopaminergic behaviors in rats.
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Ketamine; Male; Rats; Rats, Inbred Strains; Stereotype | 1986 |
Biochemical and behavioural indices of striatal dopaminergic activity after 6-methyltetrahydropterin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1987 |
Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol.
Topics: Animals; Avoidance Learning; Behavior, Animal; Catalepsy; Exploratory Behavior; Haloperidol; Male; M | 1987 |
Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Avoidance Learning; Catalepsy; Conditioning, Classical; Cor | 1987 |
Influence of hypophysectomy on dopamine receptors and dopaminergic behaviors.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Female; Haloperidol; Hypophysectomy; Male; Pi | 1987 |
Apomorphine and haloperidol effects on striatal 3H-dopamine release in anesthetized, awake restrained and freely moving rats.
Topics: Anesthesia, General; Animals; Apomorphine; Catalepsy; Corpus Striatum; Dopamine; Gallamine Triethiod | 1986 |
Potentiation of haloperidol-induced catalepsy by ascorbic acid in rats and nonhuman primates.
Topics: Animals; Ascorbic Acid; Catalepsy; Drug Synergism; Female; Haloperidol; Male; Rats; Rats, Inbred Str | 1986 |
Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Domperidone; Haloperidol; Male; Prolactin; Ra | 1986 |
Behavioral effects of a single neuroleptic treatment grow with the passage of time.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Fluphenazine; | 1986 |
[Effect of glycine linoleamide on haloperidol and reserpine catalepsy in the rat].
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; | 1986 |
[Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
Topics: Animals; Catalepsy; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Mastication; Psy | 1986 |
Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide.
Topics: Animals; Behavior, Animal; Catalepsy; Dopamine; Haloperidol; Male; Metoclopramide; Motor Activity; P | 1986 |
Minaprine, a new drug with antidepressant properties.
Topics: Acetylcholine; Animals; Antidepressive Agents; Biogenic Amines; Catalepsy; Haloperidol; Mice; Pyrida | 1985 |
Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Catalepsy; Drug Therapy, Combination; Haloperido | 1985 |
Forelimb placing and hopping reflexes in haloperidol- and morphine-treated cataleptic rats.
Topics: Animals; Catalepsy; Haloperidol; Locomotion; Male; Morphine; Orientation; Posture; Rats; Reaction Ti | 1985 |
Evidence for a cholinergic role in haloperidol-induced catalepsy.
Topics: Animals; Atropine; Brain; Catalepsy; Cholinergic Fibers; Drug Synergism; Haloperidol; Hemicholinium | 1985 |
Experimental catalepsy is both enhanced and disrupted by apomorphine.
Topics: Animals; Apomorphine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Motor Ac | 1985 |
Head displacement and bracing in haloperidol-treated rats compared to rats with lateral hypothalamic damage.
Topics: Animals; Brain Diseases; Catalepsy; Disease Models, Animal; Haloperidol; Hydroxydopamines; Hypothala | 1985 |
[Minute rhythms of haloperidol catalepsy in rats].
Topics: Animals; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Rats; Time Factors | 1986 |
Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs.
Topics: Animals; Ascorbic Acid; Behavior, Animal; Catalepsy; Dextroamphetamine; Drug Synergism; Haloperidol; | 1985 |
Haloperidol in large doses reduces the cataleptic response and increases noradrenaline metabolism in the brain of the rat.
Topics: Animals; Brain; Catalepsy; Cerebral Cortex; Chromatography, High Pressure Liquid; Corpus Striatum; D | 1985 |
Reduced metabolic response of the rat brain to haloperidol after chronic treatment.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Catalepsy; Deoxyglucose; Drug Tolerance; Haloperid | 1985 |
Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice.
Topics: Animals; Catalepsy; Drug Interactions; Haloperidol; Humans; Injections, Intraventricular; Injections | 1985 |
Fractionation of the cataleptic bracing response in rats.
Topics: Animals; Catalepsy; Ear, Inner; Forelimb; Haloperidol; Hindlimb; Humans; Male; Posture; Propriocepti | 1985 |
[Adaptation to neuroleptic preparations and several ways of combatting it (experimental study)].
Topics: Animals; Apomorphine; Catalepsy; Drug Therapy, Combination; Drug Tolerance; Haloperidol; Male; Mice; | 1985 |
Reduced metabolic response of the aged rat brain to haloperidol.
Topics: Aging; Animals; Autoradiography; Brain; Catalepsy; Deoxyglucose; Glucose; Haloperidol; Male; Rats; R | 1985 |
Simultaneous catalepsy and apomorphine-induced stereotypic behavior in mice.
Topics: Animals; Apomorphine; Catalepsy; Chlorpromazine; Domperidone; Drug Interactions; Haloperidol; Inject | 1985 |
Ontogeny of tolerance to haloperidol: behavioral and biochemical measures.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Chemistry; Catalepsy; Corpus Striatum; D | 1985 |
Fetal methylazoxymethanol acetate-induced lesions cause reductions in dopamine receptor-mediated catalepsy and stereotypy.
Topics: Animals; Azo Compounds; Brain; Brain Chemistry; Catalepsy; Choline O-Acetyltransferase; Depression, | 1985 |
Possible dissociation of central dopamine receptor antagonism and cataleptic behavior.
Topics: Animals; Apomorphine; Catalepsy; Haloperidol; Male; Prolactin; Rats; Rats, Inbred Strains; Receptors | 1985 |
Pharmacokinetics and effects of haloperidol in the isolated mouse.
Topics: Aggression; Animals; Brain; Catalepsy; Haloperidol; Kinetics; Male; Methylphenidate; Mice; Social Is | 1985 |
[Metabolism of dopamine and norepinephrine in rat brain after acute and chronic administration of haloperidol, loxapine and clozapine].
Topics: Animals; Apomorphine; Azepines; Brain; Catalepsy; Chlorides; Corpus Striatum; Dopamine; Drug Evaluat | 1974 |
Drug-induced catalepsy as influenced by convulsant and anticonvulsant drugs.
Topics: Animals; Anticonvulsants; Arecoline; Bemegride; Caffeine; Catalepsy; Central Nervous System Stimulan | 1973 |
The nucleus amygdaloideus centralis and neuroleptic activity in the rat.
Topics: Amygdala; Animals; Behavior; Benzoates; Butyrophenones; Catalepsy; Dextroamphetamine; Dibenzazepines | 1974 |
Anticataleptic actions of amantadine hydrochloride.
Topics: Amantadine; Animals; Aporphines; Body Temperature; Catalepsy; Central Nervous System; Drug Antagonis | 1970 |
The role of monoamines in rotation induced or potentiated by amphetamine after nigral, raphe and mesencephalic reticular lesions in the rat brain.
Topics: Amines; Amphetamine; Animals; Behavior, Animal; Brain; Brain Injuries; Catalepsy; Cerebral Cortex; C | 1973 |
Role of 5-HT in the action of some drugs affecting extrapyramidal system.
Topics: Amphetamine; Animals; Brain; Catalepsy; Chlorpromazine; Electrodes; Extrapyramidal Tracts; Female; F | 1973 |
Tolerance to the behavioral and neurochemical effects of haloperidol and morphine in rats chronically treated with morphine or haloperidol.
Topics: Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine; Drug Tolerance; Haloperidol; Humans | 1974 |
Disulfiram and the effect of catecholamines on neuroleptic-induced catalepsy in mice and rats.
Topics: Animals; Brain; Catalepsy; Chlorpromazine; Dihydroxyphenylalanine; Disulfiram; Drug Antagonism; Halo | 1967 |
Flurothyl in mice: seizure, post-convulsive behavior, and interactions with psychotropic drugs.
Topics: Amphetamine; Animals; Atropine; Behavior, Animal; Biperiden; Caffeine; Catalepsy; Central Nervous Sy | 1968 |
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. I. The comparative pharmacology of pimozide, haloperidol, and chlorpromazine.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzimidazoles; Blepharoptosis; Body Temperatur | 1968 |
Influences of cholinergic mechanisms on the function and turnover of brain dopamine.
Topics: Animals; Apomorphine; Atropine; Basal Ganglia; Brain; Catalepsy; Cyclopentanes; Dopamine; Hallucinog | 1971 |
Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Bleph | 1974 |
[Neuropharmacological findings after chronic administration of haloperidol, loxapine and clozapine].
Topics: Animals; Catalepsy; Cauda Equina; Dibenzazepines; Dibenzoxazepines; Dose-Response Relationship, Drug | 1974 |
Potentiation of catalepsy induced by narcotic agents during Haffner's test for analgesia.
Topics: Analgesia; Animals; Atropine; Catalepsy; Codeine; Dose-Response Relationship, Drug; Drug Synergism; | 1974 |
Synthesis and preliminary pharmacology of a novel butyrophenone derivative, ID-4708.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Butyrophenones; Catalepsy; Cats; Chlorpr | 1974 |
[Effect of neuroleptic agents in the chronic pharmacological experiment].
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Corpus Striatum; Dibenzoxazepines; Drug Tolerance | 1974 |
On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity.
Topics: Amygdala; Animals; Atropine; Catalepsy; Catatonia; Caudate Nucleus; Corpus Striatum; Dose-Response R | 1974 |
Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain.
Topics: Animals; Arecoline; Atropine; Behavior, Animal; Catalepsy; Caudate Nucleus; Corpus Striatum; Diffusi | 1972 |
Mesolimbic involvement with behavioural effects indicating antipsychotic activity.
Topics: Animals; Behavior, Animal; Catalepsy; Dextroamphetamine; Dibenzothiazepines; Dose-Response Relations | 1974 |
Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.
Topics: Animals; Apomorphine; Basal Ganglia; Catalepsy; Corpus Striatum; Dibenzoxazepines; Dopamine; Drug To | 1973 |
Drug-induced catalepsy as influenced by psychostimulants, apomorphine, L-dopa, and yohimbine.
Topics: Amphetamine; Animals; Apomorphine; Catalepsy; Dihydroxyphenylalanine; Hallucinogens; Haloperidol; Hu | 1973 |
The activity of some neuroleptic drugs and amphetamine in normal and isolated rats.
Topics: Aggression; Amphetamine; Animals; Brain; Catalepsy; Chlorpromazine; Dopamine; Haloperidol; Humans; M | 1973 |
Pharmacology of neuroleptics upon repeated administration.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Catalepsy; Cross Reactions; Dose-Response Rel | 1974 |
Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
Topics: Amantadine; Animals; Apomorphine; Blood Pressure; Body Temperature; Brain Chemistry; Catalepsy; Chlo | 1974 |
Significance of dopamine receptor activity in dl-p-methoxyamphetamine- and d-amphetamine-induced locomotor activity.
Topics: Amphetamine; Animals; Apomorphine; Aporphines; Catalepsy; Dextroamphetamine; Dopamine; Haloperidol; | 1974 |
Differential antagonism by naloxone of inhibitory effects of haloperidol and morphine on brain self-stimulation.
Topics: Animals; Behavior, Animal; Blepharoptosis; Brain; Catalepsy; Catatonia; Electric Stimulation; Electr | 1974 |
Pharmacology of a new anti-parkinsonian drug: KAO-264.
Topics: Animals; Atropine; Catalepsy; Haloperidol; Haplorhini; Humans; Mydriatics; Parasympatholytics; Thiop | 1971 |
Modification of the behavioural changes induced by haloperidol in the ray by lesions in the caudate nucleus, the caudate-putamen and globus pallidus.
Topics: Analysis of Variance; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Electrocoagulation; Globus | 1972 |
Stereotypic and anticataleptic activities of amphetamine after intracerebral injections.
Topics: Amphetamine; Animals; Atropine; Behavior, Animal; Catalepsy; Caudate Nucleus; Drug Interactions; Glo | 1972 |
Neurochemical correlates of the waltzing-shaker syndrome in the Varitint-waddler mouse.
Topics: Animals; Autoradiography; Behavior, Animal; Carbon Isotopes; Catalepsy; Dextroamphetamine; Dihydroxy | 1972 |
Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.
Topics: Animals; Catalepsy; Central Nervous System; Central Nervous System Diseases; Chlorpromazine; Drug Hy | 1972 |
Cholinergic and neuroleptic induced catalepsy: modification by lesions in the globus pallidus and substantia nigra.
Topics: Animals; Behavior, Animal; Catalepsy; Drug Synergism; Globus Pallidus; Haloperidol; Humans; Nicotini | 1971 |
The influence of various neuroleptic drugs on shock avoidance responding in rats. II. Nondiscriminated Sidman avoidance procedure with alternate reinforcement and extinction periods and analysis of the interresponse times (IRT's).
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1969 |
Modification of certain central nervous effects of haloperidol during long-term treatment in the mouse and rat.
Topics: Amphetamine; Animals; Brain; Catalepsy; Central Nervous System; Dopamine; Drug Synergism; Female; Ha | 1969 |
The prediction of sedative potency of neuroleptics.
Topics: Animals; Ataxia; Avoidance Learning; Catalepsy; Chlorpromazine; Haloperidol; Humans; Hypnotics and S | 1970 |
The influence of various neuroleptic drugs on noise escape response in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1970 |
Neuroleptic action of quaternary chlorpromazine and related drugs injected into various brain areas in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cerebral Ventricles; Chlorpromazine; Dopamine; | 1968 |